Saponin conjugate and vaccine or pharmaceutical composition containing the same
The new saponin conjugate developed through structural modification solves the toxicity and stability of saponin adjuvant in clinical applications, improves its adjuvant activity and safety, is suitable for the development of therapeutic vaccines, and achieves more effective cellular immune response.
Patent Information
- Application Number
- CN202080041297.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-06-03
- Filing Date
- 2020-06-01
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2040-06-01
AI Technical Summary
In clinical applications, the existing saponin adjuvants have problems such as dose-limiting toxicity, poor stability, unclear molecular mechanism of action and limited supply of high-quality products, making it difficult to effectively induce cellular immunity and have high safety.
A novel saponin conjugate was developed to enhance the stability and toxicity of saponins through structural modification while enhancing their adjuvant activity as an adjuvant for vaccines to enhance cellular immune response.
The new saponin adjuvant enhances cellular immune response while reducing toxicity, providing safer and more effective vaccine adjuvant options suitable for the development of therapeutic vaccines.
Smart Images

Figure CN114040918B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to saponin conjugates, their synthesis and intermediates thereof. The present invention also provides a pharmaceutical composition comprising the saponin conjugates of the present invention, and a method of using the saponin conjugates or compositions to treat infectious diseases, cancer and immune disorders. Background Art
[0002] In current vaccine formulations, the efficacy of adjuvants has been proven. The current challenge is that for therapeutic vaccines, the combination of antigens and adjuvants must effectively stimulate both humoral and cellular immunity in order to treat complex diseases such as AIDS, malaria, tuberculosis and cancer. The basis for developing novel vaccine antigens is that without the assistance of adjuvants, antigens can only slightly stimulate pathogen-specific T cell responses and cannot effectively provide immune protection. The development of vaccine adjuvants is a major research focus of the current vaccine formulation industry. However, there are still no approved adjuvants that can effectively induce cellular immunity and have high safety in clinical use.
[0003] Quillaja saponins (Q. saponins) are triterpene glycosides extracted from the bark of the Chilean soap tree (Quillaja saponaria Molina). Quillaja saponins are strong irritants to airway mucus production and can cause inflammation of the digestive tract. Four major triterpene glycosides have been isolated from Quillaja extracts and identified as QS-7, QS-17, QS-18, and QS-21 (Quillaja saponin fractions 7, 17, 18, and 21). These saponins have the same triterpene backbone quillaic acid and are all linked to the trisaccharide β-D-Gal-(1→2)-[β-D-Xyl-(1→3)]-β-D-GlcA at the 3-O position. QS-21 contains a linear tetrasaccharide β-D-Apif / Xylp-(1→3)-β-D-Xyl-(1→4)-α-L-Rha-(1→2)-β-D-Fuc at the 28-O position and has a stereochemically rich fatty acyl chain 1 bonded via the fucose 4-O position. The structures of QS-21 and its purified analogs are shown in the following table:
[0004]
[0005]
[0006] Apif: apiofuranose; Xylp: xylopyranose;
[0007] Glcp: glucopyranose; Rhap: rhamnopyranose.
[0008] The QS-21 molecule has been used in hundreds of recent and ongoing vaccine clinical trials (malaria, herpes, Alzheimer's disease, human immunodeficiency virus-1 (HIV-1), melanoma, breast cancer, small cell lung cancer, prostate cancer, etc.), and has been established as a prospective adjuvant for enhancing immune response and saving doses. However, there are still four major problems in the clinical use of QS-21: QS-21 has dose-limiting toxicity, poor stability, insufficient understanding of the molecular mechanism of action, and limited supply of high-quality products.
[0009] GPI-0100 is a semi-synthetic saponin mixture derived from the bark extract of the soap tree. The crude bark extract is treated under mild alkaline hydrolysis conditions, and then a straight C12 fatty carbon chain (analiphatic dodeacyl chain) is connected through a hydrolytically stable amide bond to obtain GPI-0100. This modification makes the molecular structure of the soap tree saponin more stable at high temperatures (more tolerance at higher temperature), and also greatly reduces the intrinsic toxicity of the soap tree extract. However, its adjuvant activity is reduced as a result. Therefore, the development of saponin adjuvants that can induce potent cellular immunity and have low toxicity remains a focus of vaccine research and development. The present invention has developed a new generation of saponin-based adjuvants, which have improved efficacy in enhancing cellular immunity and are more suitable for combination with therapeutic vaccines compared to existing adjuvants. Summary of the invention
[0010] The present invention relates to novel compounds, referred to herein as saponin conjugates, wherein
[0011] In one aspect, the present invention provides a saponin conjugate of formula (I) or a pharmaceutically acceptable salt thereof:
[0012]
[0013] in:
[0014] ● is a single bond or a double bond;
[0015] ●W is methyl (Me), -CHO, —CH2OR 1 ,—C(O)R x or CH2OR x ;
[0016] ●V is hydrogen or -OR 1 ;
[0017] ●Y is CH2, —O—, —S—, —NR— or —NH—;
[0018] ●Q is CH2, C=O, C=N-OH or C=N-OMe;
[0019] ●X is CH2, —O—, —NH—, —NH—(C═O)—, —S— or O—(C═O)—;
[0020] R is an optionally substituted cyclic or non-cyclic moiety selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, aryl-aliphatic, cycloaliphatic, heterocyclo-aliphatic, heteroaryl-aliphatic, alkoxy-aliphatic, and aryloxy-aliphatic; or selected from the group consisting of: C1-C 18 aliphatic, 5-10 membered aryl-aliphatic, 5-10 membered heteroaryl-aliphatic having 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur, 4-7 membered heterocyclic-aliphatic having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;
[0021] ●R 1 independently hydrogen or an oxygen protecting group selected from the group consisting of alkyl ethers, allyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates and carbonates; or a carbohydrate having a monosaccharide structure, such as glucose, mannose, galactose, N-acetylglucosamine, N-acetylgalactosamine, altrose, allose, fucose, rhamnose, etc.;
[0022]
[0023] in:
[0024] ■a, b and c are independently 0 or 1 each time they appear;
[0025] ■R 0 are independently hydrogen or an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates, and carbonates;
[0026] ■R a , R b , R c and R d Each occurrence is independently hydrogen, halogen, OH, OR, OR x ; R x each occurrence is independently hydrogen or an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates, and carbonates;
[0027] Z is hydrogen; or an optionally substituted cyclic or acyclic moiety selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, aralkyl, heterocyclyl, and heteroaryl; or a carbohydrate having the structure:
[0028]
[0029] ◆Among which:
[0030] ◆R 2 Each occurrence is either hydrogen or a carbohydrate domain with the following structure:
[0031]
[0032] in:
[0033] ■a, b and c are independently 0, 1 or 2 each time they appear;
[0034] ■d is an integer from 1 to 5, wherein the structures in each bracket d may be the same or different; provided that the structure in bracket d represents a furanose or pyranose moiety, and the sum of b and c is 1 or 2;
[0035] ■R 0 is hydrogen or an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates and carbonates;
[0036] ■R a , R b , R c and R d Each occurrence is independently hydrogen, halogen, OH, OR, OR x , NR2, NHCOR or an optionally substituted group selected from: acyl, C1-C 10 aliphatic, C1-C6 heteroaliphatic, 6-10 membered aryl, aryl-aliphatic; or 5-10 membered heteroaryl having 1-4 heteroatoms selected from the group consisting of nitrogen, oxygen or sulfur; or 4-7 membered heterocyclyl having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur;
[0037] ◆R 3 For hydrogen, halogen, OH, OR x ,
[0038] ◆R 4 For hydrogen, halogen, CH2OR x or selected from acyl, C1-C 10 An optionally substituted group of the aliphatic group;
[0039] ◆R xeach occurrence is independently hydrogen or an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates, and carbonates;
[0040] The present invention encompasses the recognition that the clinical use of GPI-0100 as an adjuvant mixture is limited due to its complex structure and difficulty in isolating it in pure form. The present invention provides compounds similar to GPI-0100.
[0041] On the other hand, the compounds of the invention have been shown to be useful as adjuvants. Therefore, in certain embodiments, a vaccine is provided comprising one or more bacterial antigens, viral antigens, protozoan antigens or tumor-associated antigens and one or more compounds of the invention. In certain embodiments, one or more antigens are non-covalently bound to a pharmaceutically acceptable excipient. In certain embodiments, one or more antigens are covalently bound to a pharmaceutically acceptable excipient.
[0042] In another aspect, the present invention provides a method of enhancing an immune response to an antigen, comprising administering a provided vaccine to an individual in an effective amount to enhance the individual's immune response to the antigen.
[0043] In another embodiment, the present invention provides a saponin substance that induces immune responses to humoral immunity and cellular immunity.
[0044] In another embodiment, the present invention provides a method for stimulating or enhancing cytokine production in a subject, the method comprising, inter alia, administering to the subject any one of the compounds of the present invention, such that immune cells secrete cytokines.
[0045] On the other hand, the present invention provides a method for vaccinating an individual, comprising administering a provided vaccine to the individual. In some embodiments, the individual is a human. In some embodiments, the vaccine is administered orally. In other embodiments, the vaccine is administered intramuscularly. In other embodiments, the vaccine is administered subcutaneously. In certain embodiments, the adjuvant compound is administered in an amount of 10-1000 μg. In certain embodiments, the adjuvant compound is administered in an amount of 500-1000 μg. In certain embodiments, the adjuvant compound is administered in an amount of 100-500 μg. In certain embodiments, the adjuvant compound is administered in an amount of 50-250 μg. In certain embodiments, the adjuvant compound is administered in an amount of 50-500 μg. In certain embodiments, the adjuvant compound is administered in an amount of 250-500 μg. The antigen for vaccinating the individual can be a cancer antigen, a bacterial antigen, a viral antigen, a protozoan antigen, or a self-antigen.
[0046] In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical composition is a vaccine comprising an antigen and an adjuvant of the present invention.
[0047] On the other hand, the present invention provides a kit comprising a pharmaceutical composition of a compound of the present invention. In some embodiments, the kit comprises prescription information. In some embodiments, the kit comprises a combination of an adjuvant compound of the present invention and another immunotherapeutic agent (e.g., a vaccine, an antibody). These preparations may be packaged separately or packaged together. The kit optionally includes instructions for prescribing a drug. In certain embodiments, the kit includes various doses of each reagent. The kit may include sufficient amounts of each component to treat an individual for one week, two weeks, three weeks, four weeks, or several months. In certain embodiments, the kit includes an immunotherapy cycle. In certain embodiments, the kit includes sufficient amounts of a pharmaceutical composition to immunize an individual against an antigen for a long period of time.
[0048] In one embodiment, the present invention provides a method for preparing a compound represented by the structure of formula (II) or a pharmaceutically acceptable salt thereof:
[0049]
[0050] in:
[0051] ● is a single bond or a double bond;
[0052] ●W is Me, —CHO, —CH2OR 1 ,—C(O)R x or CH2OR x ;
[0053] ●V is hydrogen or -OR x ;
[0054] ●Y is CH3, -OH, -SH, -NHR 5 , -NH2 or an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates and carbonates, wherein R 5 selected from the group consisting of alkyl ethers, allyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates and carbonates;
[0055] ●Q is CH2, C=O, C=N-OH or C=N-OMe;
[0056] ●X is CH2, —O—, —NH—, —NH—(C═O)—, —S— or O—(C═O)—;
[0057] ●R1 is independently hydrogen, an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates, and carbonates; or a carbohydrate having the structure:
[0058]
[0059] in:
[0060] ■a, b and c are independently 0 or 1 each time they appear;
[0061] ■ R0 is independently hydrogen or an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates and carbonates;
[0062] ■R a , R b , R c and R d Each occurrence is independently hydrogen, halogen, OH, OR, OR x ; R x Each occurrence is independently hydrogen or an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates, and carbonates; and
[0063] R is a cyclic or non-cyclic moiety selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, aryl-aliphatic, cycloaliphatic, heterocyclo-aliphatic, heteroaryl-aliphatic, alkoxy-aliphatic, and aryloxy-aliphatic; or an optionally substituted group selected from the group consisting of: C1-C 18 aliphatic, 5-10 membered arylaliphatic, 5-10 membered heteroaryl-aliphatic having 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen or sulfur, 4-7 membered heterocyclic-aliphatic having 1-2 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur.
[0064] In one embodiment of the present invention, the compound of formula (II) can be obtained by a method comprising the following steps:
[0065] The compound represented by the structure of formula (III) is reacted with the compound represented by the structure of formula (IV) or a pharmaceutically acceptable salt thereof.
[0066]
[0067] In formula (III):
[0068] ●R 1 are independently hydrogen, an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates and carbonates; or a carbohydrate having the structure
[0069]
[0070] in:
[0071] ■a, b and c are independently 0 or 1 each time they appear;
[0072] ■ R0 is independently hydrogen or an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates and carbonates;
[0073] ■R a , R b , R c and R d Each occurrence is independently hydrogen, halogen, OH, OR, OR x ; R x each occurrence is independently hydrogen or an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates, and carbonates;
[0074] ■LG is a leaving group, in particular, it can be
[0075]
[0076] In formula (IV):
[0077] ● is a single bond or a double bond;
[0078] ●W is Me, —CHO, —CH2OR x or—C(O)R x ;
[0079] ●V is hydrogen or -OR x ;
[0080] ●Y is CH3, -OH, -SH, -NHR 5 , -NH2 or an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates and carbonates; and
[0081] ●R 2 , R x or R 5 is independently hydrogen or an oxygen protecting group selected from the group consisting of alkyl ethers, allyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates and carbonates.
[0082] In one embodiment of the present invention, a compound of formula (I) can be obtained by a method comprising the following steps:
[0083] Reacting the compound of formula (II) with the compound of formula (V) or a pharmaceutically acceptable salt thereof:
[0084]
[0085] in:
[0086] PG and PG1 are oxygen protecting groups selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates and carbonates;
[0087] R1 is independently hydrogen, an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates, and carbonates; or a carbohydrate having the following structure:
[0088]
[0089] in:
[0090] ■a, b and c are independently 0 or 1 each time they appear;
[0091] ■ R0 is independently hydrogen or an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates and carbonates;
[0092] ■R a , R b , R c and R d Each occurrence is independently hydrogen, halogen, OH, OR, OR x ; R x each occurrence is independently hydrogen or an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates, and carbonates;
[0093] ● R2 is independently hydrogen, halogen, CH2OH or an optionally substituted group selected from lower alkyl; and
[0094] ●LG is a leaving group, in particular, it can be
[0095]
[0096] definition
[0097] As used herein, the following definitions shall apply unless otherwise indicated.
[0098] "Stereoisomers" refer to compounds that have different chirality at one or more stereocenters. Stereoisomers include enantiomers and diastereomers.
[0099] "Subject" refers to mammals, including humans and non-human mammals.
[0100] As used herein, the term "aliphatic" or "aliphatic group" or "aliphatic moiety" refers to a straight chain (i.e., non-branched) or branched substituted or unsubstituted hydrocarbon chain that is completely saturated or contains one or more unsaturated units, or to a monocyclic or bicyclic hydrocarbon that is completely saturated or contains one or more unsaturated units, but is not aromatic (also referred to herein as "carbocycle", "alicyclic" or "cycloalkyl") with a single point of attachment to the rest of the molecule. Unless otherwise specified, an aliphatic group comprises aliphatic carbon atoms. In some embodiments, an aliphatic group comprises 1-12 aliphatic carbon atoms. In some embodiments, an aliphatic group comprises 1-11 aliphatic carbon atoms. In other embodiments, an aliphatic group comprises 1-10 aliphatic carbon atoms. In other embodiments, an aliphatic group comprises 1-9 aliphatic carbon atoms, and in other embodiments, an aliphatic group comprises 1-8 aliphatic carbon atoms. In other embodiments, an aliphatic group comprises 1-7 aliphatic carbon atoms. In other embodiments, an aliphatic group comprises 1-6 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms.
[0101] In some embodiments, alicyclic (or "carbocycle" or "cycloalkyl") refers to a monocyclic CC hydrocarbon that is fully saturated or contains one or more unsaturated units, but is not aromatic with a single point of attachment to the rest of the molecule. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl, and mixtures thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl, or (cycloalkyl)alkenyl.
[0102] The term (heteroatom) refers to one or more of oxygen, sulfur, nitrogen, phosphorus or silicon (including any oxidized form of nitrogen, sulfur, phosphorus or silicon; any basic nitrogen in quaternized form or a substitutable nitrogen in a heterocyclic ring, such as N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR" (as in N-substituted pyrrolidinyl)).
[0103] As used herein, the term "unsaturated" refers to a moiety having one or more double bonds.
[0104] The term "halogen" refers to fluorine, chlorine, bromine or iodine.
[0105] The term "acyl" used alone or as part of a larger moiety refers to the radical formed by removing the hydroxy group from a carboxylic acid.
[0106] The terms "aralkyl" and "arylaliphatic" are used interchangeably and mean an aliphatic group in which a hydrogen atom is replaced by an aryl group. The aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, cinnamyl, and dihydrocinnamyl.
[0107] The term "aryl" is used alone or as part of a larger moiety, for example, in "aryl-aliphatic," "heteroaryl-aliphatic."
[0108] The term "aryloxy-aliphatic" (or "aralkoxy or arylkoxy" or "aryloxyalkyl") refers to a monocyclic or bicyclic ring system having a total of 5-14 ring members, wherein at least one ring in the system is aromatic and each ring in the system contains 3-7 ring members. The term "aryl" is used interchangeably with the term "aromatic ring".
[0109] In certain embodiments of the present invention, "aryl" refers to an aromatic ring system, including but not limited to benzyl, phenyl, biphenyl, naphthyl, anthracenyl, etc., which may have one or more substituents. As used herein, groups formed by fusion of an aromatic ring with zero or one or more non-aromatic rings are also included in the scope of the term "aryl", such as dihydroindanyl, phthalimide, naphthalimide, phenanthracenyl or tetrahydronaphthyl, etc.
[0110] The term "heteroaryl", used alone or as part of a larger moiety, such as "heteroaryloxy" or "heteroaryl-aliphatic" or "heteroarylalkyl", refers to a group having the following structural features: 5-10 ring atoms, preferably 5, 6 or 9 ring atoms; having a ring array that shares 6, 10 or 14 electrons; and having 1-5 heteroatoms other than carbon atoms. The term "heteroatom" refers to nitrogen, oxygen or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of basic nitrogen. Heteroaryl includes, but is not limited to, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl and pteridinyl.
[0111] As used herein, the terms "heteroaryl" and "heteroaryl-" also include groups formed by the fusion of a heteroaryl ring with one or more aryl, alicyclic or heterocyclic rings, with the point of attachment being on the heteroaryl ring. Non-limiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzothiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenathiazinyl, phenoxazinyl, tetrahydroquinolyl, tetrahydroisoquinolyl and 2H-pyrido[2,3-b]-1,4-oxazin-3(4H)-one. The heteroaryl group may be monocyclic or bicyclic. The term "heteroaryl" is used interchangeably with the terms "heteroaryl ring," "heteroaryl group," or "heteroaromatic," and any of the above terms include optionally substituted rings. The terms "heteroaryl-aliphatic" and "heteroaryl-alkyl" refer to an aliphatic substituted with a heteroaryl moiety, wherein the aliphatic and heteroaryl moieties independently are optionally substituted.
[0112] As used herein, the term "heteroaliphatic" refers to an aliphatic group in which one or two carbon atoms are independently substituted with one or more of oxygen, sulfur, nitrogen or phosphorus. Heteroaliphatic groups can be substituted or unsubstituted, branched or unbranched, cyclic or acyclic, and include "heterocycle", "heterocyclyl", "heterocycloaliphatic" or "heterocyclic" groups.
[0113] As used herein, the terms "heterocycle", "heterocyclyl" and "heterocyclic" are used interchangeably and refer to a saturated or partially unsaturated stable 5-7 membered monocyclic or 7-10 membered bicyclic heterocyclic moiety and, in addition to carbon atoms, have one or more (preferably 1-4) heteroatoms as defined above. When referring to the ring atoms of the heterocycle, the term "nitrogen" includes substituted nitrogen, for example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen can be N (for example in 3,4-dihydro-2H-pyrrolyl), NH (for example in pyrrolidinyl) or + NR (for example in N-substituted pyrrolidinyl).
[0114] The heterocyclyl ring may be attached to its side group at any heteroatom or carbon atom to form a stable structure, and any ring atom may be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic residues include, but are not limited to, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepanyl, oxazepanyl, thiazepanyl, morpholinyl, and quinuclidinyl.
[0115] The terms "heterocycle", "heterocyclyl", "heterocyclyl ring", "heterocyclic group" and "heterocyclic moiety" are used interchangeably herein and also include groups in which the heterocyclyl ring is fused to one or more aryl, heteroaryl or alicyclic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl or tetrahydroquinolinyl. The heterocyclyl group can be monocyclic or bicyclic.
[0116] The term "heterocycloaliphatic" refers to an alkyl group substituted with a heterocyclic group, wherein the aliphatic and heterocyclic portions independently are optionally substituted.
[0117] As used herein, the term "partially unsaturated" refers to a ring moiety that includes at least one double or triple bond. The term "partially unsaturated" is intended to encompass rings having multiple sites of unsaturation, but does not include aryl or heteroaryl moieties as defined herein.
[0118] On the other hand, the present invention provides "pharmaceutically acceptable" compositions comprising a therapeutically effective amount of one or more compounds described herein, formulated with one or more pharmaceutically acceptable carriers (additives) and / or diluents. As detailed, the pharmaceutical compositions of the present invention can be specifically formulated for administration in solid or liquid form, including forms suitable for: oral administration, such as drenches (aqueous or non-aqueous solutions or suspensions), tablets (e.g., tablets targeted for buccal, sublingual and systemic absorption), boluses, powders, granules, pastes for administration to the tongue; parenteral administration, such as intramuscular, subcutaneous, intravenous or epidural injection in the form of sterile solutions or suspensions or sustained-release preparations; topical administration, such as in the form of creams, ointments or controlled-release sprays or patches for administration to the lungs, skin or oral cavity; intravaginal or intrarectal, such as pessaries, creams or foams; sublingual; ocular; transdermal; or nasal, pulmonary and other mucosal surfaces.
[0119] The phrase "pharmaceutically acceptable" as used herein means that the compounds, compositions, materials and / or dosage forms are, within the scope of sound medical judgment, suitable for contact with the tissues of humans and animals without excessive toxicity, irritation, allergic response or other problems or complications, and have a reasonable benefit / risk ratio.
[0120] As used herein, the phrase "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition or vehicle. Encapsulating materials such as liquid or solid fillers, excipients, diluents or solvents are involved in transporting or carrying the subject compound from one part of the body to another part of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the patient. Some examples of materials that can be used as pharmaceutically acceptable carriers include: sugars, such as glucose, lactose, sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as carboxymethyl cellulose, ethyl cellulose and cellulose acetate; tragacanth powder; malt; gelatin; talc; excipients, such as cocoa butter and suppositories; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols. For example, glycerol, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffers, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethanol; pH buffered solutions; polyesters, polycarbonates and / or polyanhydrides; and other non-toxic compatible substances used in pharmaceutical formulations.
[0121] As used herein, the term "pharmaceutically acceptable salts" refers to salts that are suitable for contact with human and lower animal tissues without excessive toxicity, irritation, allergic reaction, etc., and have a reasonable benefit / risk ratio within the scope of reasonable medical judgment. Pharmaceutically acceptable salts are well known in the art. For example, SM Berge et al. describe pharmaceutically acceptable salts in detail in the Journal of Pharmaceutical Sciences (J. Pharmaceutical Sciences, 1977, 66, 1-19), which is incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of the present invention include salts derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are salts formed of amine groups with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid) or with organic acids (e.g., acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid), or salts of amino groups formed using other methods in the art (e.g., ion exchange). Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxyethanesulfonate, lactobionate, lactate, laurate, dodecylsulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like.
[0122] In other cases, the compounds of the invention may contain one or more acidic functional groups and are therefore capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases. In these cases, the term "pharmaceutically acceptable salts" refers to relatively non-toxic inorganic and organic base addition salts of the compounds of the invention. These salts can also be prepared in situ during the manufacture of the administration vehicle or dosage form, or by reacting the purified compound in free acid form with a suitable base (e.g., a pharmaceutically acceptable metal cation hydroxide, carbonate or bicarbonate), with ammonia or with a pharmaceutically acceptable organic primary, secondary, tertiary or quaternary amine. Salts derived from appropriate bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N(C 1-4alkyl) salts. Representative alkali metal salts or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Other pharmaceutically acceptable salts include non-toxic ammonium, quaternary ammonium, and amine cations formed using counterions (e.g., halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates, and aryl sulfonates) when appropriate. Representative organic amines that can be used to form base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like.
[0123] Unless otherwise stated, the structures described herein are also intended to include all isomeric (e.g., mirror image isomers, diastereomers, and geometric configuration) forms of the structures; for example, R and S configurations for each stereocenter, Z and E double bond isomers, and Z and E configuration isomers. Therefore, single stereochemical isomers as well as mirror image isomers, diastereomers, and geometric (or configuration) mixtures of the compounds of the present invention are within the scope of the present invention. Unless otherwise stated, all tautomers of the compounds of the present invention are within the scope of the present invention.
[0124] The compounds provided may contain one or more sugar moieties. Unless otherwise indicated, D- and L- configurations and mixtures thereof are within the scope of the present invention. Unless otherwise indicated, the present invention contemplates C- and S- connected instances and mixtures thereof.
[0125] Additionally, unless otherwise stated, structures depicted herein are also intended to include compounds that differ only in the presence of one or more isotopically enriched atoms. 13 C- or 14 Compounds of the present structure in which the carbon is replaced by a C-enriched carbon are within the scope of the present invention. Such compounds can be used, for example, as analytical tools, probes in biological assays, or therapeutic agents according to the present invention.
[0126] According to embodiments of the present invention, the phrase "protecting group" as used herein refers to a potentially reactive functional group that is temporarily modified to protect it from undesirable chemical transformations. Examples of such protecting groups include esters of carboxylic acids, silyl ethers of alcohols, and acetals and ketals of aldehydes and ketones, respectively. Of course, other suitable protecting groups may be used. In addition, Greene and Wuts describe a variety of protecting groups (as above).
[0127] In one embodiment of the invention, the protecting group can be a hydroxy protecting group in particular. In one embodiment of the invention, the hydroxy protecting group can be an alkyl, aryl, aralkyl, silyl or acyl group in particular. In another embodiment, the protecting group can be a trimethylsilyl, triethylsilyl, tert-butyldimethylsilyl (tert-butyldimethylsilyl, TBS), triisopropylsilyl (triisopropylsilyl, TIPS) or tert-butyldiphenylsilyl in particular. Of course, any other suitable protecting group can be used.
[0128] In one embodiment, the aralkyl group may be substituted or unsubstituted. In another embodiment, the aralkyl group may be, in particular, an arylmethyl group. In another embodiment, the protecting group may be, in particular, a benzyl group. In another embodiment, the protecting group may be, in particular, a methoxybenzyl group. In another embodiment, the methoxybenzyl group may be, in particular, a p-methoxybenzyl group.
[0129] In one embodiment of the present invention, the protecting group may be, in particular, an amino protecting group. In one embodiment of the present invention, the amino protecting group may be, in particular, a carbamate, an amide or an N-sulfonylamine. In another embodiment, the amino protecting group may be, in particular, carbobenzyloxy (Cbz), 9-fluorenylmethyloxycarbonyl (Fmoc), t-butyloxycarbonyl (tBoc), biphenylisopropyloxycarbonyl, t-amyloxycarbonylisobornyloxycarbonyl, alpha-dimethyl-3,5-dimethoxybenzyloxycarbonyl or 2-cyano-t-butyloxycarbonyl.
[0130] In addition, in one embodiment, the present invention provides a method for stimulating, suppressing, inhibiting or modulating an immune response in a subject, the method comprising, inter alia, administering to the subject any one or any combination of the compounds of the present invention.
[0131] In addition, in one embodiment, the present invention provides a method for stimulating, suppressing, inhibiting or regulating an immune response in an individual, the method particularly comprising administering to the individual a pharmaceutical composition, wherein the pharmaceutical composition particularly comprises any one of the compounds of the present invention or any combination thereof and one or more pharmaceutically acceptable excipients.
[0132] In addition, in one embodiment, a "pharmaceutical composition" may refer to a therapeutically effective amount of one or more compounds of the present invention and suitable excipients and / or carriers suitable for stimulating, suppressing, inhibiting or regulating immune responses in a subject.
[0133] In one embodiment, a "therapeutically effective amount" may refer to an amount that provides a therapeutic effect for a particular condition and dosing regimen. In one embodiment, such compositions may be administered by any method known in the art.
[0134] As described herein, the compounds of the present invention may contain "optionally substituted" moieties. In general, the term "substituted", whether or not preceded by the term "optionally", means that one or more hydrogens of the designated moiety are replaced by suitable substituents. Unless otherwise specified, an "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and when more than one position in any particular structure may be substituted by more than one substituent selected from a particular group, the substituents at each position may be the same or different. Combinations of substituents contemplated by the present invention are preferably those that result in the formation of stable or chemically feasible compounds.
[0135] As used herein, the phrase "parenteral administration" refers to modes of administration other than enteral and topical administration, usually injection, and includes, but is not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
[0136] As used herein, the phrases "systemic administration" or "administered systemically" and "peripheral administration" refer to the administration of a compound, drug or other substance other than directly into the central nervous system so that it enters the patient's system and undergoes metabolism and other similar processes, such as subcutaneous administration.
[0137] The term "pure" refers to a compound that is substantially free of related non-target structural compounds or chemical precursors (when chemically synthesized). This property can be quantified or expressed as "purity". In some embodiments, the target compound has less than about 30%, 20%, 10%, 5%, 2%, 1%, 0.5%, and 0.1% of non-target structures or chemical precursors.
[0138] The term "carbohydrate" refers to a sugar or a polymer of sugars. The terms "sugar," "polysaccharide," "carbohydrate," and "oligosaccharide" are used interchangeably. Most carbohydrates are aldehydes or ketones with many hydroxyl groups, usually one on each carbon atom of the molecule. Carbohydrates generally have the molecular formula Cn H 2n O n . Carbohydrates can be monosaccharides, disaccharides, trisaccharides, oligosaccharides or polysaccharides. The most basic carbohydrates are monosaccharides, such as glucose, galactose, sucrose, ribose, mannose, arabinose, xylose and fructose. Disaccharides are two linked monosaccharides. Exemplary disaccharides include sucrose, lactose, cellobiose and maltose. Typically, oligosaccharides include three to six monosaccharide units (e.g., raffinose, stachyose), while polysaccharides include six or more monosaccharide units. Exemplary polysaccharides include starch, glycogen and cellulose. Carbohydrates may contain modified sugar units, such as 2'-deoxyribose (wherein the hydroxyl group is removed), 2'-fluororibose (wherein the hydroxyl group is replaced by fluorine) or N-acetylglucosamine (a nitrogen-containing form of glucose). (e.g., 2'-fluororibose, deoxyribose and hexose). Carbohydrates can exist in many different forms, such as configurational isomers, cyclic forms, non-cyclic forms, stereoisomers, tautomers, anomers and isomers. BRIEF DESCRIPTION OF THE DRAWINGS
[0139] Figure 1 Graph showing the number of IFNγ (left 2 groups) and IL-2 (right 2 groups) secreting cells obtained with saponin and PEK antigen or without PEK antigen, as detected by ELISpot one week after the third administration.
[0140] Figure 2 The results show that one week after the third administration of saponin, the activation of T cells in the whole spleen CD3 + In T cells, IFNγ + (y-axis) for CD4 + or CD8 + (x-axis) Percentage of cells.
[0141] Figure 3 The results show that one week after the third administration of saponin, the activation of T cells in the whole spleen CD3 + In T cells, IL-2 + (y-axis) for CD4 + or CD8 + (x-axis) Percentage of cells.
[0142] Figure 4 The results show that one week after the third administration of saponin, the activation of T cells in the whole spleen CD3 + In T cells, TNFα + (y-axis) for CD4 + or CD8 + (x-axis) Percentage of cells.
[0143] Figure 5Flow cytometry analysis of T cell populations is shown, showing spleen CD62L in the total T cell population one week after the third administration of the saponin of the present invention. + (x-axis) CD44 + Representative scatter plots of (y axis). The cell population with low CD62L and high CD44 was classified as memory T cells, and live CD8 + Frequency of splenocytes expressing IFN-γ, TNF-α, or IL-2. When the frequency of positive events exceeded the mean ± standard error of the mean of the control group, it was considered cytokine positive.
[0144] Figure 6 The activation of T cells one week after the third administration of saponins 46-49, 53-56, 56α, 57-62, 64, 66, 77α, 77β, 78, 79, 83, 92, 95 is shown, in which the PEK-specific IFNγ formed in the spots of the four replicate reaction wells of the combined spleen cells + Or the mean of IL-2 or TNFα cells. When the frequency of positive events exceeded the mean ± standard error of the mean of the control group, it was judged as cytokine positive.
[0145] Figure 7 E7-specific IgG antibodies are shown. Serum was collected after each immunization of C57BL / 6 mice immunized with PEK / saponin, and E7 protein-specific IgG antibodies in the serum were measured by ELISA. The OD of each group of serum after 10,000-fold dilution was recorded. 450 Values are expressed as mean ± standard error of the mean (n = 3).
[0146] Figure 8 (A) is the percentage change of the median weight of mice within 5 days. The values are expressed as mean ± standard error of the mean (n = 5). (B) is the liver somatic cell index and (C) is the spleen somatic cell index, and the values are expressed as mean ± standard error of the mean (n = 5). The median change percentage of the body weight of mice receiving increasing doses of saponin adjuvant 56 was less than 5%. Compared with the control group, there was no change in the spleen somatic cell index and liver somatic cell index in all experimental groups. These data indicate that saponin 56 is an effective and safe candidate drug as a vaccine adjuvant.
[0147] Fig. 9 Shown is the effect of a signal dose of OVA vaccine with saponin conjugate 56 on E.G7-OVA tumors in female C57BL / 6 mice.
[0148] Fig.10 . The survival rate of mice under the threat of mouse influenza (PR8) after subcutaneous and intranasal administration of influenza vaccine combined with compound 56.
[0149] Fig.11.Antibody titers in mice administered subcutaneously with SARS-CoV-2 (2ug or 10ug) and adjuvants (alum and compound 56). DETAILED DESCRIPTION
[0150] Saponin conjugate
[0151] The present invention relates to saponin conjugates of formula (I) as defined above, their synthesis and intermediates thereof.
[0152] The saponin conjugate of formula (I) can be synthesized by the following synthesis steps.
[0153] Step 1-1: Synthesis of trisaccharide donor
[0154] The synthesis of the trisaccharide started with the glycosylation of xylosyl imidate 1 and rhamnose acceptor 2, which was catalyzed by BF3·OEt2 Lewis acid to give disaccharide 3 in 58% yield (Scheme 1). Afterwards, thio-disaccharide 3 was coupled with fucose 4α to provide the desired trisaccharide 5 in 58% yield. In addition, these two glycosylation steps can also be performed by a one-pot method, first conjugating disaccharide 3, and then adding fucose 4α and NIS to the reaction mixture in sequence to give trisaccharide 5. Trisaccharide 5 was selectively deprotected using morpholine at room temperature and then acetylated by acetic anhydride. The resulting pentaacetylated trisaccharide 6 was subjected to hydrogenolysis and imidoester formation to provide trisaccharide donor 10. The method for optimizing the trisaccharide first couples xylose 1 and rhamnose 7 to give disaccharide 8, which is then hydrolyzed and acetylated to give disaccharide 9. Trisaccharide 6 was obtained by glycosylation of disaccharide 9 and fucose 4α with an excellent yield of 96%. Imidoester derivatives of trisaccharides 12 and 13 were also synthesized by glycosylation of disaccharide 9 and arabinose 11α followed by hydrogenolysis and imidization reactions.
[0155] Scheme 1 - describes the synthesis of trisaccharides and their analogs.
[0156]
[0157] Step 1-2: Synthesis of tetrasaccharide donor
[0158] The synthesis of the tetrasaccharide was carried out by treating the glucosyl imidate 15 and the rhamnoside 14 with TMSOTf to give the disaccharide 16 with the correct β-(1→3) linkage in 51% yield (Scheme 2). The disaccharide imidate donor 17 was obtained after sulfhydryl hydrolysis and imidate formation, and then reacted with fucose 4α to give the trisaccharide 18, which was then treated with DDQ to remove the PMB protecting group. The obtained trisaccharide acceptor 19 was further conjugated with the xylosyl donor 1 to obtain the tetrasaccharide 20. After the structure was confirmed by NMR mass spectroscopy, the tetrasaccharide 20 was subjected to hydrogenolysis and imidate formation to provide the tetrasaccharide imidates 21 and 22.
[0159] Scheme 2 - describes the synthesis of tetrasaccharides and their analogs.
[0160]
[0161] Step 2: Synthesis of triterpene building blocks
[0162] First, an allyl group was introduced into the C-28 carboxylic acid to give quillaic ester 20 and echinocystic ester 21 (Scheme 3). To improve the selectivity of 3-O glycosylation, the 16-OH group on diol 20 was further protected with a triethylsilyl (TES) group via a three-step synthesis: selective 3-O acetylation, addition of TES to 16-OH, and then deacetylation, yielding 60% quillaic ester 25 through these three steps.
[0163] Scheme 3 - describes the synthesis of triterpene building blocks and their analogs.
[0164]
[0165] Step 3: Synthesis of protected bisdesmosidic saponins
[0166] For the glucuronic acid building blocks, glucuronides with benzoyl (Bz), isobutyryl (iPrCO), and pivaloyl (Piv) groups were synthesized. (Scheme 4). The glucoronate bromide 26 was reacted with thiotoluene to form thio-glucuronide 27. Thereafter, compound 27 was deacetylated and acylated with benzoyl chloride, isobutyryl chloride, and pivaloyl chloride to give 28-30. Following oxidation to remove the sulfhydryl group and then form the trichloroacetimidate, the glucuronate imidates 31-33 can be easily coupled with sapogenin. The coupling of benzoylated donor 31 with sapogenin 23 mainly formed orthoesters. The formation of orthoesters can be attributed to the lack of steric hindrance of the planar 2-O-benzoyl group. Therefore, isobutyrylated glucuronide 32 was introduced to establish a barrier near the carbonyl position. The product was successfully obtained in 21% yield, but the orthoester product still accounted for 47%, even so, this result encouraged us to use the trimethylacetyl group with greater steric hindrance. Finally, the use of trimethylacetylated donor 33 successfully obtained the conjugated product 34 in 48% yield, and 29% of the saccharide ester 23 was recovered. In addition, the reaction of saccharide ester 24 with benzoylated glucuronide 31 successfully obtained the product 36 in 72% yield.
[0167] To deprotect the C-28 carboxylic acid, the benzoyl, trimethylacetyl and methoxy groups were first hydrolyzed by heating under alkaline conditions. The resulting intermediate was then subjected to carboxylic acid benzylation and hydroxy triethylsilylation to obtain fully protected saponin ester 37 and echinocystin ester 38. 1 From the H NMR coupling constant analysis, we noticed that the glucuronide 4 The C1 configuration flips to 1 C4. The original coupling constant between H-1'-H-2' of glucuronide 34 was obtained from J H-1’-H-2’ = 7.8 Hz down to the J of TES-protected compound 37 H-1’-H-2’=4.2Hz, and the phenomenon of decreased coupling constants of other hydrogens on the glucuronide was also observed. In order to further obtain the glucuronide acceptor, the O-allyl ester was hydrolyzed by Pd(OAc)2 under a mild acidic environment to obtain compounds 39 and 40. At -75°C, oligosaccharide 13 and glucuronide 39 were combined under the promotion of BF3·OEt2 to obtain 41β in an excellent yield of 94%. The coupling of arabinose-containing trisaccharide 13 with saponin 39 produced 42β and 42α with yields of 75% and 16%, respectively. Similarly, by glycosylation of imidoester 10 with echinocystic acid 40, echinocystic acid ester 43(β) was also obtained in an excellent yield of 96%. The tetrasaccharide donor 21 was coupled with saponin 39 to obtain product 44 with an anomeric ratio of β / α to 1 / 1 under TLC analysis. N-phenyltrifluoroacetimidate 22 was then used; as a result, the major product saponin 44β was successfully obtained with a yield of 46%.
[0168] Scheme 4 - Demonstration of the preparation of compounds 41-44.
[0169]
[0170] Step 4: Synthesis of amide-bound and fully deprotected saponin
[0171] After hydrogenolysis of 41β, amide bond formation was performed continuously using the HBTU / DIPEA coupling system to obtain a series of conjugated amides. Afterwards, the product was subjected to acid hydrolysis and methanolysis to provide our target saponins. The representative saponins in Scheme 5 contain aliphatic carbon chains of different lengths from methyl to octadecyl, various aromatic aliphatics, heteroaromatic aliphatics, and heterocyclic aliphatics.
[0172] Scheme 5 - demonstrates the preparation of formula (I) according to an example of the present invention.
[0173]
[0174] R = alkyl, such as dodecyl (46), methyl (47), hexyl (48), octadecyl (49), ethyl (50), propyl (51), pentyl (52), etc.
[0175]
[0176] Step 5: Synthesis of saponin analogs
[0177] The synthesis of saponins contains a trisaccharide moiety in the α-direction (compound 56α, Scheme 6). Substituting L-arabinose for D-fucose gave the α / β anomer of saponin 77. Synthesis of echinocystoate 78 and the derivation of β-linked tetrasaccharide ester 79.
[0178] Scheme 6 - Demonstrates the preparation of saponin analogs according to embodiments of the present invention.
[0179]
[0180] Vaccine composition
[0181] On the other hand, the present application relates to a vaccine composition, which comprises an antigen and a saponin analog of the present application as an adjuvant. In some embodiments, the vaccine composition further comprises other adjuvants.
[0182] The vaccine composition of the present application can be used as a vaccine for inducing active immunity against an antigen in an individual. Any animal that may experience the beneficial effects of the composition of the present invention is within the scope of the treatable individual. In some embodiments, the individual is a mammal. In some embodiments, the individual is a human.
[0183] Administration of a vaccine (or the antisera elicited therefrom) may be for "prophylactic" or "therapeutic" purposes. Prophylactic administration of a vaccine is used to prevent or mitigate any subsequent manifestations of the disease. Vaccines are given prophylactically, before any symptoms of the disease occur. Vaccines are given therapeutically, upon or after symptoms are detected that indicate an animal may be infected with a pathogen or have a certain type of cancer. Therapeutic administration of a vaccine may slow down any actual manifestations of the disease. Thus, a vaccine may be given before the disease begins to spread or after it actually begins to spread.
[0184] Therefore, in one aspect, the present invention provides a vaccine comprising one or more bacteria, viruses, protozoa or tumor-associated antigens and one or more compounds of the present invention. In some embodiments, the vaccine comprises a single bacteria, protozoa, virus or tumor-associated antigen in combination with a compound of the present invention. In some embodiments, the vaccine comprises two or more bacteria, viruses, protozoa or tumor-associated antigens in combination with a compound of the present invention. In some embodiments, the vaccine comprises a single bacteria, virus, protozoa or tumor-associated antigen in combination with two or more compounds of the present invention.
[0185] In some embodiments, one or more antigens in provided vaccines are bacterial antigens. In certain embodiments, the bacterial antigen is an antigen associated with a bacterium selected from Bordetella pertussis, Bordetella parapertussis, Bordetella bronchiseptica, Borrelia burgdorferi, Borrelia spp., Chlamydia trachomatis, Helicobacter pylori, Chlamydia pneumoniae, Ureaplasma urealyticum, Mycoplasma pneumoniae, Staphylococcus spp., Staphylococcus aureus, Streptococcus pyogenes, Streptococcus spp., Streptococcus pneumoniae. pneumoniae), Streptococcus viridans, Enterococcus faecalis, Neisseria meningitidis, Neisseria gonorrhoeae, Bacillus anthracis, Salmonella spp., Salmonella typhi, Vibrio cholera, Pasteurella pestis, Campylobacter spp., Campylobacter jejuni, Clostridium spp., Clostridium difficile, Corynebacterium diphtheria, Mycobacterium spp.), Mycobacterium tuberculosis, Pseudomonas aeruginosa, Treponema spp.), Leptospira spp., Hemophilus ducreyi, Haemophilus influenzae, Escherichia coli, Shigella spp., Ehrlichia spp., Rickettsia spp., and combinations thereof.
[0186] In certain embodiments, one or more antigens in the provided vaccines are virus-associated antigens. In certain embodiments, the virus-associated antigen is an antigen associated with a virus selected from influenza virus, parainfluenza virus, mumps virus, adenovirus, respiratory syncytial virus, Epstein-Barr virus (Epstein-Barr virus; EBV), rhinovirus, poliovirus, coxsackievirus, echovirus, measles virus, rubella virus, varicella zoster virus, herpes virus, herpes simplex virus, parvovirus, cytomegalovirus, hepatitis virus, human papillomavirus, alphavirus, flavivirus, bunyavirus, rabies virus, arenavirus, filovirus, HIV-1, HIV-2, HTLV-1, HTLV-II, feline leukemia virus (felineleukemia virus, FeLV), bovine leukemia virus (bovine LV), feline immunodefiency virus (feline immunodefiency virus, fe ... virus, FeIV), canine distemper virus, canine contagious hepatitis virus, feline calicivirus, feline rhinotracheitis virus, transmissible gastroenteritis virus (TGEV), foot-and-mouth disease virus, coronavirus, dengue virus and combinations thereof.
[0187] In certain embodiments, one or more antigens in the provided vaccines are tumor-associated antigens. In some embodiments, the tumor-associated antigens are antigens selected from the group consisting of killed tumor cells and their lysates;
[0188] MAGE-1, MAGE-3 and their peptide fragments; human chorionic gonadotropin and its peptide fragments; carcinoembryonic antigen and its peptide fragments; alpha-fetoprotein and its peptide fragments; pancreatic embryonic antigen (POA) and its peptide fragments; prostate-specific antigen and its peptide fragments; MUC-1 and its peptide fragments; CA 125, CA 15-3, CA 19-9, CA 549, CA 195 and their peptide fragments; prostate-specific membrane antigen and its peptide fragments; squamous cell carcinoma-associated antigen and its peptide fragments; ovarian cancer antigen and its peptide fragments; pancreatic cancer-associated antigen and its peptide fragments; Her1 / neu and its peptide fragments; gp-100 and its peptide fragments; mutant K-Ras protein and its peptide fragments; mutant p53 and its peptide fragments; truncated epidermal growth factor receptor, chimeric protein p210 BCR-ABL 、STn、Tn、Lewis x Lewis y , TF, GM1, GM2, GD2, GD3, Gb3, KH-1, Globo-H, SSEA-4; and mixtures thereof.
[0189] As described above, provided compounds can be combined with tumor-associated antigens and used as adjuvants in cancer vaccines. In certain embodiments, vaccines can be used to treat or prevent tumors. In certain embodiments, the tumor is a benign tumor. In other embodiments, the tumor is a malignant tumor. Any cancer can be treated using the compounds of the invention and antigens.
[0190] In another aspect, the present application relates to a method of immunizing an individual using the vaccine composition of the present application.
[0191] preparation
[0192] The present application saponin analogs can be combined with pharmaceutically acceptable excipients to form pharmaceutical compositions. In certain embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable amount of the compounds of the present invention. The amount of active ingredients that can be combined with a carrier material to produce a single dosage form will vary according to the host being treated and a specific mode of administration. The amount of active ingredients that can be combined with a carrier material to produce a single dosage form is generally the amount of the compound that can produce a therapeutic effect. Typically, the amount is about 1% to about 99% of the active ingredient, preferably about 5% to about 70%, and most preferably about 10% to about 30%.
[0193] The composition may also contain wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release controlling agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants.
[0194] The formulations of the present invention include formulations suitable for oral, nasal, topical, rectal, vaginal and / or parenteral administration. The formulations may be conveniently present in unit dosage form and may be prepared by any method well known in the pharmaceutical field. In certain embodiments, the formulations of the present invention comprise an excipient and a compound of the present invention, the excipient being selected from the group consisting of cyclodextrins, liposomes, colloidal particle forming agents (e.g., bile acid) and polymer carriers (e.g., polyesters and polyanhydrides). In certain embodiments, the aforementioned formulations render the compounds of the present invention orally biocompatible.
[0195] Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored base, usually sucrose and gum arabic or tragacanth), powders, granules, or as a solution or suspension in an aqueous or non-aqueous liquid, or an oil-in-water or water-in-oil liquid emulsion, or an elixir or syrup, or pastilles (using an inert base such as gelatin and glycerin, or sucrose and gum arabic), and / or mouthwashes, each containing a predetermined amount of a compound of the invention as the active ingredient. The compounds of the invention may also be administered in the form of a bolus, electuary or paste.
[0196] The preparations of the present application can be administered orally, parenterally, topically or rectally. Of course, they are administered in a form suitable for each route of administration. For example, administration in the form of tablets or capsules; administration by injection, inhalation, eye drops, ointments, suppositories, etc.; administration by injection, infusion or inhalation; topical administration by lotion or ointment; and suppositories for rectal administration.
[0197] Regardless of the route of administration selected, the saponin analogs of the present application can be used in a suitable hydrated form, and / or the pharmaceutical composition of the present invention can be formulated into a pharmaceutically acceptable dosage form by well-known methods known to those skilled in the art. The actual dosage concentration of the active ingredient in the pharmaceutical composition of the present invention can be varied to obtain an amount of active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration without being toxic to the patient.
[0198] The selection of dosage concentration will depend upon a variety of factors, including: the activity of the specific compound of the invention being employed, or its ester, salt or amide; the route of administration; the time of administration; the rate of excretion or metabolism of the specific compound being employed; the duration of the treatment; other drugs, compounds and / or substances used in combination with the specific compound being employed; the age, sex, weight, condition, general health and prior medical history of the patient being treated; and factors well known in the medical art.
[0199] A physician or veterinarian with ordinary skills in the art can easily judge and prescribe the effective amount of the desired pharmaceutical composition. For example, a physician or veterinarian can use a concentration lower than the level required to achieve the desired therapeutic effect as the starting dose of the compound of the present invention used in the pharmaceutical composition, and then gradually increase the dosage until the desired effect is achieved.
[0200] Example
[0201] The following examples are provided to illustrate certain aspects of the present invention and to help those skilled in the art to implement the present invention. These examples are not intended to limit the scope of the present invention.
[0202] Unless otherwise specified, all reagents and solvents were of reagent grade and used without further purification. Molecular sieves were activated at 200°C before use. p-Anisaldehyde, ninhydrin and cerium ammonium molybdate were used as developers on 0.25 mm silica gel 60F 254 Thin layer chromatography was performed on Merck Millipore to monitor the reaction progress. Flash column chromatography was performed using 230-400 mesh silica gel.
[0203] instrument
[0204] NMR mass spectra were obtained using a Bruker-AV-400 (400 MHz) and a Bruker-AV-600 (600 MHz). Chemical shifts (δ) are in ppm relative to CDCl3. 1 H: 7.26ppm, 13 C: 77.0ppm; relative to CD3OD 1 H: 3.31ppm, 13 C: 49.0ppm. The split form is represented by single peak as s, double peak as d, triplet as t, quartet as q, and multiple peak as m. The coupling constant (J) is in Hertz (Hz). Reverse phase HPLC purification and analysis were performed using a HITACHID-2000 Elite HPLC system equipped with an automatic sampler L-2200, a UV detector L-2420, and a pump L-2130, or a SHIMADZU HPLC system equipped with a system controller CBM-20A, a photodiode array detector SPD-M20A, a pump LC-20AT, and an automatic sampler SIL-20AHT. Accurate mass measurements were performed using a VG platform electrospray ionization mass spectrometer or a BioTOF II.
[0205] Synthesis Example I
[0206]
[0207] p-Methylphenyl 2,3,4-tri-O-acetyl-β-D-xylopyranosyl-(1→4)-2-O-acetyl-3-O-fluorenylmethoxycarbonyl-1-thio-α-L-rhamnopyranoside (3)
[0208] At -40 °C and N2 atmosphere, BF3·OEt2 (about 48%, 11 μL, 0.08 mmol) was added to 1 (137 mg, 0.33 mmol), 2 (87 mg, 0.16 mmol) and activated The molecular sieve powder was stirred in anhydrous CH2Cl2 (1.6 mL) in a suspension. After the reaction was complete after 3 hours, saturated NaHCO3 was added to quench the mixture, and then heated to room temperature. The resulting mixture was dried over MgSO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; EtOAc / hexane = 1 / 4 to 1 / 2) to obtain 3 (75 mg, 58%) as a colorless syrup: R f 0.36 (EtOAc / hexane=1 / 2); 1 H NMR(600MHz, CDCl3)δ7.78(d,J=7.5Hz,2H),7.64(dd,J=19.0,7.4Hz,2H),7.45–7.41(m,2H),7.3 9–7.34(m,4H),7.12(d,J=8.0Hz,2H),5.54(dd,J=3.4,1.4Hz,1H,H-2),5.33(d,J=1.4Hz,1H,H-1) ,5.21(t,J=9.4Hz,1H,H-3'),5.08(dd,J=9.6,3.4Hz,1H,H-3),4.99(td,J=9.4,5.4Hz,1H,H-4'), 4.95(dd,J=9.4,7.6Hz,1H,H-2'),4.79(d,J=7.6Hz,1H,H-1'),4.57(dd,J=13.4,10.1Hz,1H,Fmoc C H2 ),4.35–4.31(m,2H,Fmoc C H2 and C H ),4.28–4.25(m,1H,H-5),4.14(dd,J=11.8,5.4Hz,1H,H-5 a '),3.84(t,J=9.5Hz,1H,H-4'),3.40(dd,J=11.8,9.5Hz,1H,H-5 b'),2.33(s,3H),2.16(s,3H),2.05(s,3H),2.03(s,3H),1.91(s,3H),1.35(d,J=6.2Hz,3H,H-6); 13 C NMR (151MHz, CDCl3) δ167.0,169.9,169.8,169.5,154.0,143.4,143.1,141.3,141.2,138.2,132.6,129.9,129.3,128.0,127.3 ,125.2,125.0,120.1,120.0,100.8(C-1'),85.8(C-1),76.1(C-3),75.9(C-4),72.2(C-3'),71.3(C-2'),71.2(C-2),70.6(Fmoc C H2),69.3(C-4'),68.1(C-5),62.5(C-5'),46.6(Fmoc C H),21.1,20.9,20.7,20.7,20.5,17.5(C-6)ppm; C 41 H 44 O 14 SNa[M+Na] + HRMS (ESI-TOF) calculated value: 815.2349, found value: 815.2352.
[0209]
[0210] Benzyl 2,3,4-tri-O-acetyl-β-D-xylopyranosyl-(1→4)-2-O-acetyl-3-O-fluorenylmethyloxycarbonyl-α-L-rhamnopyranosyl-(1→2)-3,4-O-isopropylidene-α-D-fucopyranoside (5)
[0211] NIS (1.12 g, 4.99 mmol) and BF3·OEt2 (0.38 mL, 1.42 mmol) were added to 4α (1.05 g, 3.57 mmol), 3 (3.40 g, 4.28 mmol) and activated carbon at -50 °C under N2 atmosphere. Molecular sieve powder was stirred in anhydrous CH2Cl2 (2 mL) in a suspension. After the reaction was complete after 1 hour, saturated NaHCO3 and 10% Na2S2O3 aqueous solution were added to quench the reaction. The reaction mixture was heated to room temperature, stirred for 1 hour, and then filtered. The filtrate was diluted with CH2Cl2, washed with 10% Na2S2O3 (aq.), saturated NaHCO3, and brine, dried with MgSO4, and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; EtOAc / CH2Cl2 / hexane = 1 / 1 / 6 to 1 / 1 / 4) to obtain 5 (2.00 g, 58%) as a white foam: R f 0.44 (EtOAc / CH2Cl2 / hexane=1 / 1 / 2); 1 H NMR (600MHz, CDCl3) δ7.78(d,J=7.5Hz,2H),7.67(d,J=7.4Hz,1H),7.63(d,J=7.5Hz,1H),7.42(t ,J=7.4Hz,2H),7.42(t,J=7.4Hz,2H),7.39–7.27(m,5H),5.50–5.46(m,1H,H-2'),5.19(t,J=9.2H z,1H,H-3”),5.12–5.10(m,2H,H-1’,H-3’),4.99(td,J=9.2,5.5Hz,1H,H-4”),4.94(dd,J=9.2,7 .6Hz,1H,H-2”),4.82(d,J=3.5Hz,1H,H-1),4.77(d,J=7.5Hz,1H,H-1”),4.71(d,J=12.3Hz,1H,Bn C H2 ),4.60–4.51(m,2H,Bn C H2 ,Fmoc C H2 ),4.37–4.31(m,2H,H-3,Fmoc C H ),4.28(dd,J=10.0,8.1Hz,1H,Fmoc C H2 ),4.17–4.09(m,2H,H-5,H-5 a ”),4.02(dd,J=5.3,2.4Hz,1H,H-4),3.76(dd,J=8.1,3.5Hz,1H,H-2),3.72(t ,J=9.6Hz,1H,H-4'),3.65–3.60(m,1H,H-5'),3.40(dd,J=11.6,9.7Hz,1H,H-5 b”),2.18(s,3H),2.05(s,3H),2.01(s,3H),1.86(s,3H),1.50(s,3H),1.34(d,J=6.7Hz,3H,H-6),1.32(s,3H),1.18(d,J=6.2Hz,3H,H-6'); C 50 H 58 O 19 Na[M+Na] + The HRMS (ESI-TOF) calculated value was 985.3463 and the found value was 985.3476.
[0212]
[0213] Benzyl 2,3,4-tri-O-acetyl-β-D-xylopyranosyl-(1→4)-2,3-di-O-acetyl-α-L-rhamnopyranosyl-(1→2)-3,4-O-isopropylidene-α-D-fucopyranoside (6)
[0214] Morpholine (0.5 mL) was added to a stirred suspension of 5 (100 mg, 0.10 mmol) in CH2Cl2 (5 mL) at room temperature. After the reaction was complete after 1.5 hours, the reaction mixture was diluted with CH2Cl2, washed with saturated NH4Cl, saturated NaHCO3, brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; EtOAc / hexane = 1 / 1 to 3 / 2) to give the fluorenylmethyloxycarbonyl (Fmoc)-deprotected product (72 mg, 95%). Ac2O (91 μL, 0.96 mmol), Et3N (201 μL, 1.4 mmol) and DMAP (6 mg, 0.048 mmol) were added to a stirred solution of the Fmoc-deprotected product (462 mg, 0.48 mmol) in anhydrous CH2Cl2 (10 mL) at room temperature and N2 gas environment. After 2 hours, the reaction was completed, and the reactant was diluted with CH2Cl2, washed with H2O and brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; EtOAc / hexane = 2 / 3) to obtain 6 (391 mg, 96%) as a white foam: R f 0.48 (EtOAc / hexane=1 / 1); 1H NMR (600MHz, CDCl3) δ7.38–7.27(m,5H),5.32(dd,J=3.5,1.6Hz,1H,H-2'),5.26(dd,J=9.3,3.5Hz,1H,H-3'),5.13(t,J=9.3Hz,1H,H-3”),5.05(d, J=1.5Hz,1H,H-1'),4.96(td,J=9.3,5.4Hz,1H,H-4”),4.91–4.87(dd,J=9 .3,7.6Hz,1H,H-2”),4.80(d,J=3.6Hz,1H,H-1),4.71(d,J=12.3Hz,1H,Bn C H2 ),4.63(d,J=7.6Hz,1H,H-1”),4.54(d,J=12.3Hz,1H,Bn C H2 ),4.34(dd,J=8.1,5.4Hz,1H,H-3),4.14(qd,J=6.7,2.5Hz,1H,H-5),4.10(dd,J=11.7,5.4Hz,1H,H-5 a ”),4.02(dd,J=5.4,2.5Hz,1H,H-4),3.74(dd,J=8.1,3.6Hz,1H,H-2),3.62–3.54(m,2H,H-4',H-5'),3.33(dd,J=11.7,9.5Hz,1H,H-5 b ”),2.13(s,3H),2.08(s,3H),2.03(s,3H),2.01(s,6H),1.49(s,3H),1.34(d,J=6.7Hz,3H,H-6),1.32(s,3H),1.14(d,J=5.6Hz,3H,H-6')ppm; C 37 H 50 O 18 Na[M+Na] + HRMS (ESI-TOF) calculated value 805.2889, found value 805.2898.
[0215]
[0216] Trichloroacetimidyl 2,3,4-tri-O-acetyl-β-D-xylopyranosyl-(1→4)-2,3-di-O-acetyl-α-L-rhamnopyranosyl-(1→2)-3,4-O-isopropylidene-α / β-D-fucopyranoside (10)
[0217] A suspension of 6 (1.26 g, 1.6 mmol) and 10% Pd / C (0.2 g) in phosphate buffer (100 mM Na2HPO4 / NaH2PO4 (aq.), pH = 7.0) / THF / MeOH = 1 / 1 / 4 (30 mL) was stirred under H2 (balloon) gas at room temperature. After stirring for 3 days, the mixture was filtered through celite and concentrated under reduced pressure. The residue was diluted with CH2Cl2, washed with H2O, brine, dried over MgSO4, concentrated, and then purified by column chromatography (silica gel; EtOAc / hexane = 1 / 1 to 3 / 2) to give hemiacetal (0.79 g, 71%) as a colorless syrup. Cl3CCN (16 μL, 0.16 mmol) and DBU (3 μL, 0.021 mmol) were added to a stirred solution of hemiacetal (36 mg, 0.48 mmol) in anhydrous CH2Cl2 (1 mL) at room temperature under N2 gas. After stirring for 1.5 hours, TLC analysis confirmed the completion of the reaction and the mixture was concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel; EtOAc / hexane = 1 / 1 to 3 / 2, containing 0.5% Et3N) to give 10 (34 mg, 78%) as a yellow syrup. 10α:R f 0.46 (EtOAc / hexane=1 / 1); 1 H NMR (600MHz, CDCl3) δ8.67 (s, 1H), 6.30 (d, J = 3.5Hz, 1H, H-1), 5.24 (dd, J = 3.3, 1.8Hz ,1H,H-2'),5.14–5.08(m,2H,H-3',H-3”),5.03(d,J=1.8Hz,1H,H-1’),4.93(td,J=9. 4,5.4Hz,1H,H-4”),4.86(dd,J=9.4,7.7Hz,1H,H-2”),4.58(d,J=7.7Hz,1H,H-1”),4. 40(dd,J=7.8,5.4Hz,1H,H-3),4.32(qd,J=6.7,2.5Hz,1H,H-5),4.12–4.07(m,2H,H-5 a ”,H-4),3.91(dd,J=7.8,3.5Hz,1H,H-2),3.81(dq,J=9.6,6.2Hz,1H,H-5'),3.60(t,J=9.6Hz,1H,H-4'),3.31(dd,J=11.7,9.7Hz,1H,H-5 b”),2.13(s,3H),2.03(s,3H),2.02(s,3H),2.00(s,3H),1.95(s,3H),1.52( s,3H),1.38(d,J=6.7Hz,3H,H-6),1.34(s,3H),1.28(d,J=6.2Hz,3H,H-6').
[0218]
[0219] p-Methylphenyl 2,3,4-tri-O-acetyl-β-D-xylopyranosyl-(1→4)-2,3-di-O-acetyl-1-thio-α-L-rhamnopyranoside (9)
[0220] A stirred solution of 8 (4.6 g, 8.1 mmol) in 80% AcOH (100 mL) was heated to 60 °C for 12 h. The resulting mixture was evaporated and then azeotroped twice with toluene (50 mL) under reduced pressure. After drying under high vacuum, the crude slurry was treated with a solution of Ac2O (2.2 mL, 23 mmol), Et3N (5.2 mL, 38 mmol) and DMAP (9 mg, 0.074 mmol) in CH2Cl2 at room temperature under N2 gas. After the reaction was complete after 2 h, the mixture was diluted with CH2Cl2, washed with H2O, brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; EtOAc / hexane = 2 / 3) to give 9 (3.8 g, 76%) as a white solid: R f 0.19 (EtOAc / hexane=1 / 2); 1 H NMR (400MHz, CDCl3) δ7.34(d,J=7.9Hz,2H),7.11(d,J=7.8Hz,2H),5.39(brs,1H ,H-2),5.26(brs,1H,H-1),5.22(dd,J=9.6,3.1Hz,1H,H-3),5.14(t,J=9.2Hz,1H ,H-3'),5.00–4.93(m,1H,H-4'),4.90(dd,J=9.2,7.6Hz,1H,H-2'),4.66(d,J=7. 6Hz,1H,H-1'),4.24(dq,J=9.6,6.1Hz,1H,H-5),4.12(dd,J=11.6,5.3Hz,1H,H-5 a '),3.72(t,J=9.6Hz,1H,H-4),3.39–3.30(m,1H,H-5 b'),2.31(s,3H),2.11(s,3H),2.09(s,3H),2.03(s,3H),2.02(s,6H,Ac×2),1.31(d,J=6.1Hz,3H)ppm; C 28 H 36 O 13 SNa[M+Na] + HRMS (ESI-TOF) calculated value: 635.1769, found value: 635.1774.
[0221]
[0222] Benzyl 2,3,4-tri-O-acetyl-β-D-xylopyranosyl-(1→4)-2,3-di-O-acetyl-α-L-rhamnopyranosyl-(1→2)-3,4-O-isopropylidene-β-L-arabinopyranoside (12)
[0223] At -50 °C under N2 atmosphere, NIS (0.23 g, 1.0 mmol) and TMSOTf (12 μL, 0.066 mmol) were added to 9 (500 mg, 0.82 mmol), 11α (190 mg, 0.68 mmol) and activated Molecular sieve powder was stirred in anhydrous CH2Cl2 (7 mL) in a suspension. After the reaction was complete after 0.5 hours, Et3N, saturated NaHCO3 and 10% Na2S2O3 aqueous solution were added to quench the reaction. After heating and stirring at room temperature for 1 hour, the reaction mixture was filtered, diluted with CH2Cl2, washed with 10% Na2S2O3 aqueous solution, saturated NaHCO3, brine, dried with MgSO4, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; EtOAc / hexane = 2 / 3 to 1 / 1) to obtain 12 (412 mg, 79%) as a white foam: R f 0.25 (EtOAc / hexane=2 / 3); 1 H NMR (600MHz, CDCl3) δ7.38–7.28(m,5H),5.32(dd,J=3.4,1.4Hz,1H,H-2'),5.26(dd,J=9.2,3.4Hz,1H,H-3'),5.13(t,J=9.2Hz,1H,H-3”),5 .05(s,1H,H-1'),4.96(td,J=9.2,5.5Hz,1H,H-4”),4.90(dd,J=9.2,7.7Hz,1H,H-2”),4.82(d,J=3.4Hz,1H,H-1),4.73(d,J=12.3Hz,1H,Bn C H2),4.63(d,J=7.7Hz,1H,H-1”),4.53(d,J=12.3Hz,1H,Bn C H2 ),4.36(dd,J=7.9,5.6Hz,1H,H-3),4.20(d,J=5.6Hz,1H,H-4),4.10(dd,J=11.7,5.5Hz,1H,H-5 a ”),3.98(brs,2H,H-5),3.75(dd,J=7.9,3.4Hz,1H,H-2),3.61–3.54(m,2H,H-4',H-5'), 3.33(dd,J=11.7,9.6Hz,1H),2.14(s,3H),2.08(s,3H),2.03(s,3H),2.02–2.01(m,6H,Ac C H3 ×2),1.50(s,3H),1.32(s,3H),1.14(d,J=5.7Hz,3H)ppm; C 36 H 48 O 18 Na[M+Na] + HRMS (ESI-TOF) calculated value: 791.2733, found value: 791.2735.
[0224]
[0225] Trichloroacetimidyl 2,3,4-tri-O-acetyl-β-D-xylopyranosyl-(1→4)-2,3-di-O-acetyl-α-L-rhamnopyranosyl-(1→2)-3,4-O-isopropylidene-α / β-L-arabinopyranoside (13)
[0226] A suspension of 12 (300 mg, 0.39 mmol) and 10% Pd / C (150 mg) in buffer (100 mM Na2HPO4 / NaH2PO4 (aq.), pH = 7.0) / THF / MeOH = 1 / 1 / 4 (30 mL) was stirred at room temperature under H2 (balloon) gas. After stirring for 3.5 days, the mixture was filtered through celite and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; EtOAc / hexane = 1 / 1 to 3 / 2) to give hemiacetal (166 mg, 63%) as a white foam. Cl3CCN (22 μL, 0.22 mmol) and DBU (4.3 μL, 0.029 mmol) were added to a stirred solution of hemiacetal (50 mg, 0.074 mmol) in anhydrous CH2Cl2 (1.5 mL) at room temperature under N2 gas. After stirring for 16 hours, the mixture was concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel; EtOAc / hexane = 1 / 1, containing 0.5% Et3N) to give 13 (60 mg, 98%) as a colorless syrup. 100α:R f 0.43 (EtOAc / hexane=1 / 1); 1 H NMR(600MHz,CDCl3)δ8.69(s,1H,N H ),6.30(d,J=3.4Hz,1H,H-1),5.24(dd,J=3.2,1.3Hz,1H,H-2'),5.14–5.08(m,2H,H- 3',H-3"),5.02(d,J=1.3Hz,1H,H-1'),4.93(td,J=9.4,5.4Hz,1H,H-4"),4.85(dd,J =9.5,7.7Hz,1H,H-2”),4.58(d,J=7.7Hz,1H,H-1”),4.42(dd,J=7.6,5.7Hz,1H,H-3) ,4.31–4.26(m,1H,H-4),4.12(d,J=1.8Hz,2H,H-5),4.09(dd,J=11.7,5.4Hz,1H,H-5 a ”),3.91(dd,J=7.6,3.4Hz,1H,H-2),3.80(dq,J=9.5,6.2Hz,1H,H-5'),3.60(t,J=9.5Hz,1H,H-4'),3.31(dd,J=11.7,9.4Hz,1H,H-5 b”),2.13(s,3H),2.03(s,3H),2.02(s,3H),2.00(s,3H),1.95(s,3H),1.52(s,3H),1.35(s,3H),1.28(d,J=6.2Hz,3H,H-6')ppm.
[0227]
[0228] p-Methylphenyl 2,3,4,6-tetra-O-acetyl-β-D-pyranoglucopyranosyl-(1→3)-2-O-acetyl-4-O-(p-methoxybenzyl)-1-thio-α-L-rhamnopyranoside (16)
[0229] TMSOTf (10 μL, 0.052 mmol) was added to 15 (130 mg, 0.26 mmol), 14 (114 mg, 0.26 mmol) and activated carbon at -50 °C under N2 atmosphere. The molecular sieve powder was stirred in anhydrous CH2Cl2 (2.5 mL) and suspended. After 0.5 hours, the reaction was complete, and Et3N was added to quench the reaction, heated to room temperature, filtered, and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; EtOAc / hexane = 1 / 2) to give 16 (102 mg, 51%) as a white foam: R f 0.24 (EtOAc / hexane=1 / 2); 1H NMR (600MHz, CDCl3) δ7.29–7.27(m,4H),7.08(d,J=8.0Hz,2H),6.89(d,J=8.7Hz,2H),5.39(dd,J=3.4,1.4Hz,1H,H-2),5.30(d,J=1.4Hz,1H,H-1) ,5.18(t,J=9.7Hz,1H,H-3'),5.06(dd,J=9.7,8.0Hz,1H,H-2'),5.03(t, J=9.7Hz,1H,H-4'),4.79(d,J=8.0Hz,1H,H-1'),4.71(d,J=10.5Hz,1H),4 .46(d,J=10.5Hz,1H),4.19–4.13(m,2H),4.09(dd,J=12.2,2.2Hz,1H'),4.06(dd,J=9.5,3.4Hz,1H),3.79(s,3H,3.70(ddd,J=9.7,5.7,2.2Hz,1H ,H-5'),3.48(t,J=9.5Hz,1H,H-4),2.29(s,3H),2.10(s,3H),2.09(s,3H ),2.01(s,3H),1.98(s,3H),1.83(s,3H),1.25(d,J=6.2Hz,3H,H-6)ppm; C 37 H 46 O 15 SNa[M+Na] + HRMS (ESI-TOF) calculated value: 785.2450, found value: 785.2457.
[0230]
[0231] Trichloroacetimidyl 2,3,4,6-tetra-O-acetyl-β-D-pyranose glucopyranosyl-(1→3)-2-O-acetyl-4-O-(p-methoxybenzyl)-α / β-L-rhamnopyranoside (17)
[0232] NBS (35 mg, 0.19 mmol) was added to a stirred solution of 16 (37 mg, 0.049 mmol) in acetone / H2O (1 mL) at room temperature. After stirring for 2 h, saturated NaHCO3 and 10% Na2S2O were added. 3(aq.) The mixture was quenched with 1% Na2S2O. The resulting mixture was stirred at room temperature for 1 hour, and then the solvent was removed under reduced pressure. The residue was diluted with CH2Cl2 and washed with 10% Na2S2O. 3(aq.), saturated NaHCO3, brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; EtOAc / hexane = 3 / 2) to give hemiacetal (26 mg, 82%) as a colorless syrup. Cl3CCN (12 μL, 0.12 mmol) and DBU (2.4 μL, 0.016 mmol) were added to a stirred solution of hemiacetal (26 mg, 0.040 mmol) in anhydrous CH2Cl2 (1 mL) at room temperature and under N2 gas. After stirring for 1 hour, the mixture was concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel; EtOAc / hexane = 1 / 2, containing 0.5% Et3N) to give 17 (25 mg, 79%) as a white foam. 17: R f 0.44 (EtOAc / hexane=1 / 1); 1 H NMR (400MHz, CDCl3) δ8.68(s,1H),7.29(d,J=8.4Hz,2H),6.91(d,J=8.4Hz,2H),6.15(s,1H,H-1),5.34(s,1H,H-2) ,5.20(t,J=9.4Hz,1H,H-3'),5.12–5.06(m,2H,H-2',H-4'),4.84(d,J=7.9Hz,1H,H-1'),4.72(d,J=10.3Hz,1H,PMB C H2 ),4.49(d,J=10.3Hz,1H,PMB C H2 ),4.21–4.13(m,2H,H-3,H-6 a '),4.09(t,J=11.0Hz,1H,H6 b '),3.89(dq,J=9.6,6.1Hz,1H,H-5),3.81(s,3H,PMB OC H3 ),3.66(d,J=9.7Hz,1H,H-5'),3.52(t,J=9.6Hz,1H,H-4),2.15(s,3H),2.07( s,3H),2.01(s,3H),2.00(s,3H),1.88(s,3H),1.29(d,J=6.1Hz,3H,H-6)ppm.
[0233]
[0234] Benzyl 2,3,4,6-tetra-O-acetyl-β-D-pyranoglucopyranosyl-(1→3)-2-O-acetyl-4-O-(p-methoxybenzyl)-α-L-pyranosyl-rhamnosyl-(1→2)-3,4-O-isopropylidene-α-D-pyranoglucoside (18)
[0235] TMSOTf (1 μL, 0.0062 mmol) was added to 17 (25 mg, 0.31 mmol), 4α (9 mg, 0.31 mmol) and activated carbon at -50 °C under N2 atmosphere. The molecular sieve powder was stirred in anhydrous CH2Cl2 (1.5 mL) and suspended. After 1 hour, the reaction was complete, and Et3N was added to quench the reaction, heated to room temperature, filtered, and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; EtOAc / hexane = 2 / 3) to obtain 18 (24 mg, 82%) as a white foam: R f 0.43 (EtOAc / hexane=1 / 1); 1 H NMR(600MHz, CDCl3)δ7.34(d,J=7.2Hz,2H),7.29(t,J=7.5Hz,2H),7.26–7.24 (m,3H),6.89(d,J=8.7Hz,2H),5.30(dd,J=3.6,1.7Hz,1H,H-2'),5.16(t,J=9 .5Hz,1H,H-3”),5.09–5.04(m,H-2”,H-4”),5.03(d,J=1.7Hz,1H,H-1'),4.85 (d,J=3.6Hz,1H,H-1),4.77(d,J=7.9Hz,1H,H-1”),4.70(d,J=10.8Hz,1H,PMB C H2 ),4.69(d,J=12.2Hz,1H,Bn C H2 ),4.51(d,J=12.2Hz,1H,Bn C H2 ),4.45(d,J=10.8Hz,1H,PMB C H2 ),4.29(dd,J=8.1,5.4Hz,1H,H-3),4.21(dd,J=12.2,4.9Hz,1H,H-6 a ”),4.14–4.09(m,1H,H-5),4.08(dd,J=9.5,3.6Hz,1H,H-3'),4.04–3.99(m,2H,H-4,H-6 b ”),3.81(s,3H,PMBOC H3),3.74(dd,J=8.1,3.6Hz,1H,H-2),3.70–3.61(m,2H,H-5”,H-5’),3.40(t,J=9.5Hz,1H,H-4’),2.10(s,3H),2.07(s,3H), C 46 H 60 O 20 Na[M+Na] + HRMS (ESI-TOF) calculated value: 955.3570, found value: 955.3579.
[0236]
[0237] Benzyl 2,3,4,6-tetra-O-acetyl-β-D-pyranoglucopyranosyl-(1→3)-2-O-acetyl-α-L-pyranosyl-rhamnosyl-(1→2)-3,4-O-isopropylidene-α-D-pyranofucoside (19)
[0238] DDQ (9 mg, 0.039 mmol) was added to a stirred solution of 18 (24 mg, 0.026 mmol) in CH2Cl2 / H2O=18 / 1 (1 mL) at room temperature. The reaction mixture was stirred for 3 hours and then quenched with saturated NaHCO3. The resulting mixture was diluted with CH2Cl2, washed with saturated NaHCO3, brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, EtOAc / hexane=1 / 1) to give 19 (17 mg, 81%) as a colorless syrup: R f 0.30 (EtOAc / hexane=1 / 1); 1 H NMR (600MHz, CDCl3) δ7.37–7.29(m,5H),5.24(dd,J=3.6,1.7Hz,1H,H-2'),5.20(t,J=9.6Hz,1H, H-3”),5.04–4.99(m,3H,H-2”,H-1’,H-4”),4.87(d,J=3.6Hz,1H,H-1),4.72(d,J=12.1Hz,1H,Bn C H2 ),4.70(d,J=7.8Hz,1H,H-1”),4.53(d,J=12.1Hz,1H,BnC H2),4.30(dd,J=8.2,5.3Hz,1H,H-3),4.22(dd,J=12.3,5.0Hz,1H,H-6 a ”),4.12(qd,J=6.7,2.6Hz,1H,H-5),4.05–4.03(m,2H,H-4,H-6 b ”),3.85(dd,J=9.0,3.6Hz,1H,H-3'),3.74(dd,J=8.2,3.6Hz,1H,H-2),3.71(ddd,J =10.1,5.0,2.2Hz,1H,H-5”),3.63–3.56(m,2H,H-4’,H-5’),2.46(d,J=2.2Hz,1H,O H ),2.08(s,3H),2.07(s,3H),2.05(s,3H),2.02(s,3H),2.00(s,3H),1.48(s,3 H),1.33(d,J=6.7Hz,3H,H-6),1.32(s,3H),1.19(d,J=5.7Hz,3H,H-6')ppm; C 38 H 52 O 19 Na[M+Na] + HRMS (ESI-TOF) calculated value 835.2995, found value 835.3000.
[0239]
[0240] Benzyl 2,3,4,6-tetra-O-acetyl-β-D-pyranoglucopyranosyl-(1→3)-(2,3,4-tri-O-acetyl-β-D-pyranoxylanosyl-(1→4))-2-O-acetyl-α-L-pyranosyl-rhamnosyl-(1→2)-3,4-O-isopropylidene-α-D-pyranofucoside (20)
[0241] TMSOTf (0.4 μL, 0.0021 mmol) was added to 1 (13 mg, 0.031 mmol), 19 (17 mg, 0.021 mmol) and activated carbon at -50 °C under N2 atmosphere. The molecular sieve powder was stirred in anhydrous CH2Cl2 (1 mL) to form a suspension. After 0.5 hours, the reaction was completed, and Et3N was added to quench the reaction, heated to room temperature, filtered, and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; EtOAc / hexane = 1 / 1) to obtain 20 (20 mg, 89%) as a colorless syrup: R f 0.27 (EtOAc / hexane=1 / 1); 1H NMR(600MHz, CDCl3)δ7.39–7.30(m,5H),5.30(dd,J=3.6,1.8Hz,1H,H-2'),5.16(t,J=9.5Hz, 1H,H-4”),5.11(t,J=8.2Hz,1H,H-3”’),5.04–4.98(m,2H,H-2”,H-3”),4.96(d,J=1.8Hz,1H,H -1'),4.91(td,J=8.3,4.9Hz,1H,H-4"'),4.86(dd,J=8.2,6.3Hz,1H,H-2"'),4.82(d,J=3.6Hz ,1H,H-1),4.80(d,J=6.3Hz,1H,H-1”'),4.73(d,J=7.7Hz,1H,H-1”),4.69(d,J=12.1Hz,1H,Bn C H2 ),4.50(d,J=12.1Hz,1H,Bn C H2 ),4.25(dd,J=8.2,5.3Hz,1H,H-3),4.16–4.09(m,2H,H-6 a ”,H-5),4.09–4.03(m,2H,H-5 a ”',H-3'),4.03–3.99(m,2H,H-4,H-6 b ”),3.75(t,J=9.5Hz,1H,H-4’),3.71–3.66(m,2H,H-2,H-5”),3.54(dq,J=9.5,6.2Hz,1H,H-5’),3.37(dd,J=11.9,8.3Hz,1H,H-5 b ”'),2.19(s,3H),2.08(s,3H),2.08(s,3H),2.08(s,3H),2.04(s,3H),2.01(s,3H),1.99(s,3H),1 .97(s,3H),1.46(s,3H),1.33(d,J=6.7Hz,3H,H-6),1.29(s,3H),1.10(d,J=6.2Hz,3H,H-6')ppm; C 49 H 66 O 26 Na[M+Na] + The HRMS (ESI-TOF) calculated value was 1093.3735 and the found value was 1093.3734.
[0242]
[0243] N-phenyl-2,2,2-trifluoroacetimidyl 2,3,4,6-tetra-O-acetyl-β-D-pyranoglucopyranosyl-(1→3)-(2,3,4-tri-O-acetyl-β-D-pyranoxylanosyl-(1→4))-2-O-acetyl-α-L-pyranosyl-rhamnosyl-(1→2)-3,4-O-isopropylidene-α / β-D-pyranofucoside (22)
[0244] A suspension of 20 (255 mg, 0.24 mmol) and 20% Pd(OH)2 / C (25 mg) in THF (5 mL) was stirred at room temperature under H2 (balloon) atmosphere. After stirring for 24 h, the mixture was filtered through celite and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; EtOAc / hexane = 3 / 2 to 2 / 1) to give the hemiacetal (180 mg, 77%) as a white foam. N-phenyl-2,2,2-trifluoroacetimidoyl chloride (19 μL, 0.12 mmol) and DBU (3.7 μL, 0.024 mmol) were added to a stirred solution of the hemiacetal (20 mg, 0.020 mmol) in anhydrous CH2Cl2 (1 mL) at room temperature under N2 atmosphere. After stirring for 1.5 h, the mixture was concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel; EtOAc / hexane = 1 / 1 to 3 / 2, containing 0.5% Et3N) to give 22 (16 mg, 68%) as a colorless syrup. 22α: R f 0.61 (EtOAc / hexane=3 / 2); 1H NMR (600MHz, CDCl3) δ7.33(t,J=7.8Hz,2H),7.12(t,J=7.4Hz,1H),6.85(d,J=7. 6Hz,2H),5.58(brs,1H,H-1),5.20(s,1H,H-1'),5.19–5.15(m,2H),5.10(t,J=9 .7Hz,1H),5.06(t,J=7.0Hz,1H),4.99(dd,J=9.3,7.9Hz,1H),4.92(d,J=5.1Hz, 1H,H-1”'),4.86(td,J=6.9,4.2Hz,1H),4.80(dd,J=6.7,5.3Hz,1H),4.72(d,J= 7.9Hz,1H,H-1”),4.23–4.08(m,5H),4.00–3.98(m,2H),3.89(brs,1H),3.84–3. 77(m,2H),3.66–3.63(m,1H),3.45(dd,J=12.1,7.0Hz,1H),2.16(s,3H),2.11(s ,3H),2.09(s,3H),2.06(s,3H),2.04(s,4H),2.02(s,3H),1.99(s,3H),1.99(s, 3H), 1.53 (s, 3H), 1.39 (d, J = 6.3Hz, 3H), 1.32 (s, 3H), 1.27 (d, J = 5.6Hz, 3H) ppm.
[0245]
[0246] 28-O-allyl-3-O-(methyl 2,3,4-tri-O-trimethylacetyl-β-D-pyranosyl glucopyranosyl uronic acid ester) soap acid ester (34)
[0247] At room temperature under N2 atmosphere, B(PhF5)3 (42 mg, 0.083 mmol) was added to 33 (500 mg, 0.83 mmol), 23 (435 mg, 0.83 mmol) and activated The molecular sieve powder was stirred in anhydrous CH2Cl2 (8 mL) to form a suspension. After 0.5 hours, the reaction was completed, and Et3N was added to quench the reaction, filtered, and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; EtOAc / CH2Cl2 / hexane = 1 / 1 / 6) to give 34 (385 mg, 48%) as a white solid: R f 0.57 (EtOAc / hexane=1:2); 1H NMR (600 MHz, CDCl3) δ9.40 (s, 1H, H-23), 5.88–5.81 (m, 1H, allyl internal alkenyl C H ), 5.37 (t, J = 3.3 Hz, 1H, H-12), 5.31–5.27 (m, 2H, H-3', allyl terminal alkenyl C H a ), 5.20–5.16 (m, 2H, H-4', allyl terminal alkenyl C H b ), 4.98 (t, J = 8.0 Hz, H-2'), 4.52–4.44 (m, 4H, H-1', H-16, allyl C H2 ),3.99(d,J=10.0Hz,1H,H-5'),3.84(dd,J=11.8,4.7Hz,1H,H-3),3.72(s,3H,OC H3 ,3.05(dd,J=14.3,4.1Hz,1H,H-18),2.15(t,J=13.6Hz,1H,H-19 a ),1.92–1.85(m,4H),1.80–1.70(m,4H),1.68–1.63(m,3H),,1.50–1.41(m,2H),1.35–1.28(m,4H),1.25–1.17(m,3H),1.14( C 55 H 84 O 14 Na[M+Na] + HRMS (ESI-TOF) calculated value: 991.5753, found value: 991.5758.
[0248]
[0249] 28-O-allyl-3-O-(benzyl 2,3,4-tri-O-triethylsilyl-β-D-glucopyranosyl uronic acid ester)-16-O-triethylsilyl soap ester (37)
[0250] 1.0 N KOH (3 mL) was added to a stirred solution of 34 (358 mg, 0.37 mmol) in THF (15 mL) and heated at reflux at 66 °C. The reaction mixture was stirred for 24 hours and then cooled to room temperature. The reaction mixture was purified by Amberlyst IR-120H +Neutralize, filter, concentrate and dry under reduced pressure. The residue was then treated with benzyl bromide (88 μL, 0.73 mmol) and K2CO3 (102 mg, 0.73 mmol) in DMF (7 mL) at room temperature. After stirring for 2 hours, the reaction mixture was diluted with CH2Cl2, washed with H2O, brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, MeOH / CH2Cl2=1 / 15) to give the benzyl ester as a yellow solid. TESOTf (0.6 mL, 2.7 mmol) and 2,6-dimethylpyridine (0.4 mL, 3.4 mmol) were added to a stirred solution of the benzyl ester (266 mg, 0.34 mmol) in anhydrous CH2Cl2 (5 mL) at room temperature and under N2 gas. The reaction mixture was stirred for 2 hours, and then saturated NaHCO3 was added to quench it. The mixture was diluted with CH2Cl2, washed with saturated NaHCO3, brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, EtOAc / hexane = 1 / 40) to give 37 (310 mg, three-step yield 67%) as a colorless syrup: R f 0.71 (EtOAc / hexane=1 / 10); 1 H NMR (400 MHz, CDCl3) δ9.34 (s, 1H, H-23), 7.39–7.30 (m, 5H), 5.90–5.80 (m, 1H, allyl internal alkenyl C H ),5.35(s,1H,H-12),5.29(d,J=17.2Hz,1H,allyl terminal alkenyl C H a ),5.20(d,J=10.7Hz,1H,terminal alkenyl C H b ),5.17–5.15(m,2H,Bn C H2 ),4.58–4.57(m,2H,H-1',H-16),4.53–4.40(m,2H,allyl C H2),4.27(dd,J=6.2,4.9Hz,1H,H-4'),4.22(d,J=6.2Hz,1H,H-5'),3.81(dd,J=11.4,3.8Hz,1H,H-3), 3.61(d,J=4.9Hz,1H,H-3'),3.57(d,J=3.4Hz,1H,H-2'),3.02(d,J=11.6Hz,1H,H-18),2.23(t,J=13 .5Hz,1H,H-19),1.99(d,J=10.8Hz,1H),1.91–1.79(m,4H),1.75–1.53(m,5H),1.48–1.31(m,5H),1. 30–1.22(m,1H),1.20–1.23(m,3H),1.11–1.06(m,4H),1.03–0.85(m,47H),0.72–0.52(m,27H)ppm; C 70 H 120 O 11 Si4Na[M+Na] + HRMS (ESI-TOF) calculated value: 1271.7800, found value: 1271.7829.
[0251]
[0252] 3-O-(Benzyl 2,3,4-tri-O-triethylsilyl-β-D-glucopyranosyl uronic acid ester)-16-O-triethylsilyl saponin (39)
[0253] Premixed formic acid (0.38 mL, 10 mmol) / Et3N (1.3 mL, 9.6 mmol) in 1,4-dioxane (2.5 mL) and Pd(OAc)2 (54 mg, 0.24 mmol) in 1,4-dioxane (2.5 mL) were added to a stirred solution of 37 (0.60 g, 0.48 mmol) and PPh3 (0.31 g, 1.2 mmol) in 1,4-dioxane (5 mL) at room temperature. The reaction mixture was stirred for 12 hours and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, EtOAc / hexane = 1 / 6) to give 39 (0.48 g, 83%) as a white foam: R f 0.25 (EtOAc / hexane=1 / 6); 1 H NMR (600MHz, CDCl3) δ9.36 (s, 1H, H-23), 7.37–7.30 (m, 5H), 5.34 (t, J = 3.4Hz, 1H, H-12), 5.16 (s, 2H, BnC H2),4.59(d,J=4.4Hz,1H,H-1'),4.53(s,1H,H-16),4.28(dd,J=6.2,5.3Hz,1H,H-4'),4.22(d,J=6.2Hz,1H,H-5'),3.82(dd,J=11.8,4 .6Hz,1H,H-3),3.61(d,J=5.3Hz,1H,H-3'),3.58(d,J=4.4,1H,H-2'),2.95(dd,J=14.3,4.0Hz,1H,H-18),2.21(t,J=13.6Hz,1H,H-19 a ),2.03–1.95(m,1H),1.90–1.80(m,4H),1.78–1.61(m,4H),1.57(d,J=13.4Hz,1H),1.47–1.37(m,2H),1.35(s, C 67 H 116 O 11 Si4Na[M+Na] + The HRMS (ESI-TOF) calculated value was 1231.7487 and the found value was 1231.7507.
[0254]
[0255] 28-O-allyl-3-O-(methyl 2,3,4-tri-O-benzoyl-β-D-glucopyranosyl uronic acid ester) echinocystoate (36)
[0256] At room temperature under N2 atmosphere, B(PhF5)3 (1.5 mg, 0.0030 mmol) was added to 31 (20 mg, 0.030 mmol), 24 (7.7 mg, 0.015 mmol) and activated The molecular sieve powder was stirred in anhydrous CH2Cl2 (0.6 mL) and suspended. After 0.5 hours, the reaction was completed, and Et3N was added to quench the reaction, filtered, and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; EtOAc / CH2Cl2 / hexane = 1 / 1 / 6) to give 36 (11 mg, 72%) as a white solid: R f 0.42 (EtOAc / hexane=1:2); 1H NMR (600 MHz, CDCl3) δ7.95–7.91 (m, 4H), 7.85 (dd, J = 8.4, 1.3 Hz, 2H), 7.53–7.49 (m, 2H), 7.45–7.42 (m, 1H), 7.40–7.35 (m, 4H), 7.31–7.28 (m, 2H), 5.91 (t, J = 9.7 Hz, 1H, H-3'), 5.89–5,82 (m, 1H, allyl internal alkenyl C H ), 5.64 (t, J = 9.7 Hz, 1H, H-4'), 5.59 (dd, J = 9.7, 7.8 Hz, 1H, H-2'), 5.39 (t, J = 3.6 Hz, 1H, H-12), 5.29 (dt, J = 17.2, 1.5 Hz, 1H, allyl terminal alkenyl C H a ),5.20(dt,J=10.5,1.3Hz,1H,allyl terminal alkenyl C H b ), 4.89 (d, J = 7.8 Hz, 1H, H-1'), 4.53–4.45 (m, 3H, H-16, allyl C H2 ),4.30(d,J=9.7Hz,1H,H-5'),3.69(s,3H,OC H3 ),3.16(dd,J=11.7,4.6Hz,1H,H-3),3.06(dd,J=14.4,4.3Hz,1H,H-18),2.14(dd,J=13.7Hz,1H,H-19 a ),1.90–1.85(m,4H,H-2 a ,H-11 ab ,H-22 a ),1.82–1.71(m,4H,H-2 b ,H-15 a ,H-21 a ,H-22 b ),1.65–1.61(m,1H,H-1 a ),1.55–1.52(m,2H,H-9,16-O H ),1.44–1.34(m,2H,H-6 a ,H-7 a ),1.34–1.30(m,4H,H-15 b ,H-27),1.26–1.19(m,3H,H-6 b ,H-7 b ,H-21 b ),1.14–1.10(m,1H,H-19 b),0.97(s,3H,H-30),0.94–0.92(m,1H,H-1 b ),0.90(s,3H,H-29),0.88(s,3H,H-25),0.71(s,3H,H-23),0.70–0.65(m,4H,H-5,H-26),0.62(s,3H,H-24)ppm; C 61 H 74 O 13 Na[M+Na] + HRMS (ESI-TOF) calculated value: 1037.5022, found value: 1037.5026.
[0257]
[0258] 28-O-allyl-3-O-(benzyl 2,3,4-tri-O-triethylsilyl-β-D-glucopyranosyl uronic acid ester)-16-O-triethylsilyl echinocysteate (38)
[0259] 1.0 N KOH (5 mL) was added to a stirred solution of 36 (0.45 g, 0.41 mmol) in THF (25 mL) and heated at 45 °C. The reaction mixture was stirred for 12 hours and then cooled to room temperature. The reaction mixture was concentrated with Amberlyst IR-120H + Neutralize, filter, concentrate, and then dry under reduced pressure. The residue was then treated with benzyl bromide (98 μL, 0.82 mmol) and K2CO3 (113 mg, 0.82 mmol) in DMF (8 mL) at room temperature. After stirring for 12 hours, the reaction mixture was diluted with CH2Cl2, washed with H2O, brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, MeOH / CH2Cl2=1 / 20) to give the benzyl ester. TESOTf (0.74 mL, 3.3 mmol) and 2,6-dimethylpyridine (0.48 mL, 4.1 mmol) were added to a stirred solution of the benzyl ester in anhydrous CH2Cl2 (8 mL) at room temperature and under N2 gas. The reaction mixture was stirred for 2 hours, and then saturated NaHCO3 was added to quench it. The mixture was diluted with CH2Cl2, washed with saturated NaHCO3, brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, EtOAc / hexane = 1 / 40) to give 38 (0.21 g, 41%) as a colorless syrup: f 0.41 (EtOAc / hexane=1 / 20); 1H NMR (400 MHz, CDCl3) δ7.39–7.28 (m, 5H), 5.92–5.82 (m, 1H, allyl internal alkenyl C H ),5.35(s,1H,H-12),5.33–5.27(m,1H,allyl terminal alkenyl C H ), 5.20 (d, J = 10.3 Hz, 1H, allyl terminal alkenyl C H ),5.16(s,2H,Bn C H2 ),4.77(d,J=4.2Hz,1H,H-1'),4.59(s,1H,H-16),4.53–4.43(m,2H,allyl C H2 ),4.34(dd,J=6.1,5.1Hz,1H,H-4'),4.27(d,J=6.1Hz,1H,H-5'),3.73(d,J=4.2Hz,1H,H- 2'),3.65(d,J=5.1Hz,1H,H-3'),3.06–2.98(m,2H,H-3,H-18),2.23(t,J=13.5Hz,1H,H-19 a ),1.96(d,J=10.8Hz,1H),1.89–1.80(m,4H),1.77–1.62(m,3H),1.58–1.40(m,4H),1.34(s,3H),1.31–1.2 3(m,3H),1.16–1.04(m,2H),1.04–0.90(m,42H),0.89–0.84(s,7H),0.78(s,3H),0.72–0.55(m,28H)ppm; 70 H 122 O 10 Si4Na[M+Na] + HRMS (ESI-TOF) calculated value: 1257.8007, found value: 1257.8019.
[0260]
[0261] 3-O-(Benzyl 2,3,4-tri-O-triethylsilyl-β-D-glucopyranosyl uronic acid ester)-16-O-triethylsilyl echinocystic acid (40)
[0262] Premixed formic acid (150 μL, 3.3 mmol) / Et3N (430 μL, 3.1 mmol) in 1,4-dioxane (2 mL) and Pd(OAc)2 (17 mg, 0.078 mmol) in 1,4-dioxane (2 mL) were added to a stirred solution of 38 (194 mg, 0.16 mmol) and PPh3 (1.03 mg, 0.39 mmol) in 1,4-dioxane (4 mL) at room temperature. The reaction mixture was stirred for 12 hours and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, EtOAc / hexane = 1 / 6) to give 40 (168 mg, 89%) as a white foam: R f 0.58 (EtOAc / hexane=1 / 6); 1 H NMR (400MHz, CDCl3) δ7.40–7.28(m,5H),5.34(s,1H,H-12),5.16(s,2H,Bn C H2 ),4.78(d,J=4.3Hz,1H,H-1'),4.55(s,1H,H-16),4.34(t,J=5.5Hz,1H,H-4'),4.27(d,J=5.8Hz,1H,H-5'),3.73(d,J=3.9Hz,1H ,H-2'),3.66(d,J=5.0Hz,1H,H-3'),3.02(dd,J=11.5,3.7Hz,1H,H-3),2.95(d,J=11.3Hz,1H,H-18),2.21(t,J=13.5Hz,1H,H-19 a ),1.96(d,J=11.1Hz,1H),1.92–1.62(m,7H),1.62–1.40(m,4H),1.34(s,3H),1.31–1.23(m,3H), 1.17–1.04(m,2H),1.02–0.91(m,42H),0.90–0.84(s,7H),0.79(s,3H),0.73–0.55(m,28H)ppm; C 67 H 118 O 10 Si4Na[M+Na] + The HRMS (ESI-TOF) calculated value was 1217.7694 and the found value was 1217.7703.
[0263]
[0264] 3-O-(Benzyl 2,3,4-tri-O-triethylsilyl-β-D-glucopyranosyl uronic acid ester)-28-O-(2,3,4-tri-O-acetyl-β-D-xylopyranosyl-(1→4)-2,3-di-O-acetyl-α-L-rhamnopyranosyl-(1→2)-3,4-O-isopropylidene-β / α-D-fucopyranosyl)-16-O-triethylsilyl saponate (41β / α)
[0265] At -75 °C under N2 atmosphere, BF3·OEt2 (about 48%, 12 μL, 0.044 mmol) was added to 10 (276 mg, 0.33 mmol), 39 (266 mg, 0.22 mmol) and activated The molecular sieve powder was stirred in anhydrous CH2Cl2 (11 mL) and suspended. After the reaction was complete after 0.5 hours, Et3N was added to quench the reaction, heated to room temperature, filtered, and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; EtOAc / CH2Cl2 / hexane = 2 / 1 / 5) to obtain 41β (391 mg, 94%) as a colorless syrup. 41β: R f 0.64 (EtOAc / hexane=1:1); 1 H NMR (600MHz, CDCl3) δ9.35 (s, 1H, H-23), 7.40–7.28 (m, 5H), 5.41 (d, J = 7.5Hz, 1H, H-1'), 5.34 (t, J = 3 .5Hz,1H,H-12),5.25(dd,J=3.5,1.6Hz,1H,H-2”),5.21(dd,J=9.8,3.5Hz,1H,H-3”),5.16(s,2H,Bn C H2 ),5.13(t,J=9.2Hz,1H,H-3”'),4.98(d,J=1.6Hz,1H,H-1”),4.96(td,J=9.2,5.5H z,1H,H-4"'),4.85(dd,J=9.2,7.7Hz,1H,H-2"'),4.63(d,J=7.7Hz,1H,H-1"'),4.5 8(d,J=4.3Hz,1H,H-1””),4.49(s,1H,H-16),4.27(t,J=6.3Hz,1H,H-4””),4.22(d ,J=6.3Hz,1H,H-5””),4.18(t,J=6.0Hz,1H,H-3'),4.13(dd,J=11.7,5.4Hz,1H,H-5 a”), 4.01 (dd, J = 6.0, 2.0 Hz, 1H, H-4’), 3.87 (qd, J = 6.5, 2.0 Hz, 1H, H-5’), 3.84–3.79 (m, 2H, H-3, H-5”), 3.66 (dd, J = 7.5, 6.3 Hz, 1H, H-2’), 3.64–3.60 (m, 2H, H-3””, H-4”), 3.57 (dd, J = 4.3, 0.9 Hz, 1H, H-2””), 3.34 (dd, J = 11.7, 9.3 Hz, 1H, H-5 b ”’), 2.94 (dd, J = 14.2, 4.0 Hz, 1H, H-18), 2.23 (t, J = 13.6 Hz, 1H, H-19 a ), 2.13 (s, 3H), 2.06 (s, 3H), 2.03 (s, 3H), 2.00 (s, 3H,), 1.99–1.97 (m, 4H, H-2, Ac C H3 ), 1.88–1.75 (m, 5H, H-11 ab , H-21 a , H-22 ab ), 1.73–1.65 (m, 2H, H-2 a , H-15 a ), 1.63–1.60 (m, 1H, H-9), 1.57–1.55 (m, 1H, H-1 a ), 1.53 (s, 3H, isopropylidene C H3 ), 1.47–1.40 (m, 2H, H-6 a , H-7 a ), 1.35 (s, 3H, H-27), 1.34 (s, 3H, isopropylidene C H3 ), 1.29 (d, J = 6.5 Hz, 4H, H-6’), 1.27–1.24 (m, H-6”, H-15 b ), 1.19–1.16 (m, 2H, H-5, H-6 b ), 1.12 (d, J = 7.8 Hz, 1H, H-21 b ), 1.09 (s, 3H, H-24), 1.05 (dd, J = 12.1, 4.0 Hz, 1H, H-19 b ), 1.01–0.89 (m, 44H, TES C H3 , H-1 b , H-7 b , H-25, H-30), 0.89 (s, 3H, H-29), 0.73 (s, 3H, H-26), 0.69–0.55 (m, 24H, TES CH2 )ppm; C 97 H 158 O 28 Si4Na[M+Na] + The HRMS (ESI-TOF) calculated value was 1906.9937 and the found value was 1906.9959.
[0266] 41α: R f 0.69 (EtOAc / hexane=1:1); 1 H NMR (600MHz, CDCl3) δ9.34 (s, 1H, H-23), 7.37–7.30 (m, 5H), 6.02 (d, J = 3.7Hz, 1H, H- 1"),5.39(t,J=3.6Hz,1H,H-12),5.21(dd,J=3.5,1.7Hz,1H,H-2"'),5.16(s,2H,Bn C- H2 ),5.11(t,J=9.0Hz,1H,H-3””),5.08–5.06(m,2H,H-1”’,H-3”’),4.93(td,J=9.0,5.3 Hz,1H,H-4””),4.80(dd,J=9.0,7.4Hz,1H,H-2””),4.66(d,J=7.4Hz,1H,H-1””),4.58 (d,J=4.4Hz,1H,H-1'),4.56(s,1H,H-16),4.27(t,J=6.3Hz,1H,H-4'),4.21(d,J=6.3 Hz,1H,H-5'),4.19(dd,J=8.0,5.1Hz,1H,H-3”),4.13–4.09(dd,J=11.8,5.2Hz,1H,H-5 a ””),4.06–4.01(m,2H,H-4”,H-5”),3.87(dd,J=8.0,3.7Hz,1H,H-2”),3.81(dd,J=11.8,4.7Hz,1H,H-3),3.70–3.6 4(m,1H,H-5"'),3.63–3.58(m,2H,H-4"',H-3'),3.57(dd,J=4.4,1.1Hz,1H,H-2'),3.35(dd,J=11.8,9.0Hz,1H,H-5 b ""),3.00(dd,J=14.3,4.1Hz,1H,H-18),2.19(t,J=13.2Hz,1H,H-19 a ),2.13(s,3H),2.03(s,3H),2.02(s,3H),2.02(s,3H),2.00–1.97(m,1H,H-2a ),1.96(s,3H),1.95–1.83(m,3H,H-22 a ,H-11 ab ),1.81–1.65(m,3H,H-21 a ,H-22 b ,H-2 b ),1.62–1.52(m,3H,H-9,H-1 a ,H-15 a ),1.51(s,3H,isopropylidene C H3 ),1.48–1.40(m,2H,H-6 a ,H-7 a ),1.35(s,3H,H-27),1.34(s,3H,isopropylidene C H3 ),1.32(d,J=6.5Hz,3H,H-6”),1.29–1.27(m,4H,H-15 b ,H-6”'),1.23–1.11(m,3H,H-21 b ,H-5,H-6 b ),1.09–1.05(m,4H,H-24,H-19 b ),1.01(m,TES C H3 ×3),0.96–0.90(m,35H,H-1 b ,H-7 b ,H-25,H-30,TES C H3 ×9),0.88(s,3H,H-29),0.73(s,3H,H-26),0.67(m,6H,TES C H2 ×3), 0.62–0.54(m,18H,TES C H2 ×9)ppm;C 97 H 158 O 28 Si4Na[M+Na] + The HRMS (ESI-TOF) calculated value was 1906.9937 and the found value was 1906.9967.
[0267]
[0268] 3-O-(Benzyl 2,3,4-tri-O-triethylsilyl-β-D-glucopyranosyl uronic acid ester)-28-O-(2,3,4-tri-O-acetyl-β-D-xylopyranosyl-(1→4)-2,3-di-O-acetyl-α-L-rhamnopyranosyl-(1→2)-3,4-O-isopropylidene-β / α-L-arabinopyranosyl)-16-O-triethylsilyl soap ester (42β / α)
[0269] At -75 °C under N2 gas environment, BF3·OEt2 (about 48%, 1.5 μL, 0.0058 mmol) was added to 13 (67 mg, 0.081 mmol), 39 (65 mg, 0.054 mmol) and activated Molecular sieve powder was stirred in anhydrous CH2Cl2 (6 mL) suspension. After 0.5 hours, the reaction was quenched with Et3N and heated to room temperature. The resulting mixture was diluted with CH2Cl2, washed with saturated NaHCO3, brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; EtOAc / CH2Cl2 / hexane = 2 / 1 / 5) to obtain 101 (101β: 76 mg, 75%, 101α: 15 mg, 16%) as a colorless syrup. 42β: R f 0.24 (EtOAc / CH2Cl2 / hexane=2 / 1 / 5); 1 H NMR (600MHz, CDCl3) δ9.36 (s, 1H, H-23), 7.39–7.29 (m, 5H), 5.76 (d, J = 3.8Hz ,1H,H-1'),5.35(s,1H,H-12),5.21(s,1H,H-2”),5.19–5.15(m,3H,H-3”,Bn C H2 ),5.13(t,J=9.2Hz,1H,H-3”'),4.97–4.92(m,2H,H-1”,H-4”’),4.86(dd,J=9.2, 7.6Hz,1H,H-2”’),4.63(d,J=7.6Hz,1H,H-1”’),4.58(d,J=4.2Hz,1H,H-1””),4.5 5(s,1H,H-16),4.35(q,J=6.2Hz,1H,H-4'),4.27(t,J=5.8Hz,1H,H-4””),4.21(d, J=6.3Hz,1H,H-5""),4.17(t,J=5.4Hz,1H,H-3'),4.12(dd,J=11.5,5.1Hz,1H,H-5 a ”'),3.85–3.76(m,4H,H-3,H-2',H-5 a’,H-5”), 3.71 (dd, J=11.7, 8.2 Hz, 1H, H-5 b ’), 3.64–3.60 (m, 2H, H-4”, H-3””), 3.57 (d, J=4.2 Hz, 1H, H-2””), 3.33 (t, J=10.6 Hz, 1H, H-5 b ”’), 2.98 (d, J=11.8 Hz, 1H, H-18), 2.24 (t, J=13.5 Hz, 1H, H-19 a ), 2.13 (s, 3H), 2.07 (s, 3H), 2.03 (s, 3H), 2.01 (s, 3H), 2.00–1.97 (m, 4H, Ac C H3 , H-2 a ), 1.89–1.65 (m, 7H, H-2 b , H-11 ab , H-15 a , H-21 a , H-22 ab ), 1.63–1.60 (m, 1H, H-9), 1.56 (d, J=13.5 Hz, 1H, H-1 a ), 1.51 (s, 3H, C H3 ) 1.48–1.40 (m, 2H, H-6 a , H-7 a ), 1.35 (s, 6H, H-27, C H3 ), 1.27–1.24 (m, 4H, H-15 b , H-6”), 1.20–1.12 (m, 3H, H-5, H-6 b , H-21 b ), 1.09 (s, 3H, H-24), 1.06 (d, J=13.2 Hz, 1H, H-19 b ), 1.01–0.90 (m, 44H, H-1 b , H-7 b , H-25, H-30, TES C H3 ), 0.89 (s, 3H, H-29), 0.72 (s, 3H, H-26), 0.69–0.53 (m, 24H) ppm; C 96 H 156 O 28 Si4Na[M+Na] + The calculated value of HRMS (ESI-TOF) for C
[0270] 42α: R f0.29 (EtOAc / CH2Cl2 / hexane = 2 / 1 / 5); 1 1H NMR (600 MHz, CDCl3) δ 9.35 (s, 1H, H-23), 7.39–7.30 (m, 5H), 6.07 (d, J = 3.3 Hz, 1H, H-1”), 5.39 (t, J = 3.5 Hz, 1H, H-12), 5.22 (dd, J = 3.5, 1.3 Hz, 1H, H-2”’), 5.16 (s, 2H, Bn C H2 ), 5.11 (t, J = 8.9 Hz, 1H, H-3””), 5.07 (dd, J = 9.7, 3.5 Hz, 1H, H-3”’), 5.05 (d, J = 1.3 Hz, 1H, H-1”’), 4.94 (td, J = 8.9, 5.3 Hz, 1H, H-4””), 4.81 (dd, J = 8.9, 7.4 Hz, 1H, H-2””), 4.67 (d, J = 7.4 Hz, 1H, H-1””), 4.58 (d, J = 4.4 Hz, 1H, H-1’), 4.57 (s, 1H, H-16), 4.27 (t, J = 5.8 Hz, 1H, H-4’), 4.25–4.20 (m, 3H, H-3”, H-4”, H-5’), 4.11 (dd, J = 11.8, 5.3 Hz, 1H, H-5 a ”), 4.05–4.01 (d, J = 13.4 Hz, 1H, H-5 a ”), 3.91–3.84 (m, 2H, H-2”, H-5 b ”), 3.81 (dd, J = 11.8, 4.6 Hz, 1H, H-3), 3.69 (dq, J = 9.5, 6.1 Hz, 1H, H-5”’), 3.64–3.59 (m, 2H, H-4”’, H-3’), 3.57 (d, J = 4.4 Hz, 1H, H-2’), 3.36 (dd, J = 11.8, 9.1 Hz, 1H, H-5 b ”), 2.99 (dd, J = 14.4, 4.0 Hz, 1H, H-18), 2.20 (t, J = 13.6 Hz, 1H, H-19 a ), 2.14 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 2.02 (s, 3H), 2.00–1.99 (m, 1H, H-2 a ), 1.97 (s, 3H), 1.95–1.83 (m, 3H, H-22 a , H-11 ab ), 1.81–1.65 (m, 3H, H-21 a , H-22 b,H2 b ),1.65–1.62(m,1H,H-9),1.58–1.53(m,2H,H-1 a ,H-15 a ),1.51(s,3H,isopropylidene C H3 ),1.45–1.40(m,2H,H-6 a ,H-7 a ),1.36–1.35(m,6H,H-27,isopropylidene C H3 ),1.32(dd,J=14.5,1.6Hz,1H,H-15 b ),1.29(d,J=6.1Hz,3H,H-6”'),1.23–1.15(m,3H,H-5,H-6 b ,H-21 b ),1.10–1.05(m,4H,H-19 b ,H-24),1.04–0.89(m,44H,H-1 b ,H-7 b ,H-25,H-30,TES C H3 ×12),0.88(s,3H,H-29),0.73(s,3H,H-26),0.71–0.54(m,24H,TES C H2 ×12)ppm;C 96 H 156 O 28 Si4Na[M+Na] + The HRMS (ESI-TOF) calculated value was 1892.9793 and the found value was 1892.9780.
[0271]
[0272] 3-O-(Benzyl 2,3,4-tri-O-triethylsilyl-β-D-glucopyranosyl uronic acid ester)-28-O-(2,3,4-tri-O-acetyl-β-D-xylopyranosyl-(1→4)-2,3-di-O-acetyl-α-L-rhamnopyranosyl-(1→2)-3,4-O-isopropylidene-β-D-fucopyranosyl)-16-O-triethylsilyl cystocystate (43β)
[0273] At -75 °C under N2 gas environment, BF3·OEt2 (about 48%, 7.0 μL, 0.026 mmol) was added to 10 (166 mg, 0.20 mmol), 40 (158 mg, 0.13 mmol) and activated Molecular sieve powder was stirred in anhydrous CH2Cl2 (6.5 mL). After 0.5 hours, the reaction was quenched with Et3N and heated to room temperature. The resulting mixture was diluted with CH2Cl2, washed with saturated NaHCO3 and brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; EtOAc / CH2Cl2 / hexane = 2 / 1 / 5) to obtain 43β (237 mg, 96%) as a colorless syrup. 102β: R f 0.23 (EtOAc / CH2Cl2 / hexane=2 / 1 / 5); 1 H NMR (600MHz, CDCl3) δ7.37–7.29(m,5H),5.42(d,J=7.5Hz,1H,H-1'),5.34(s,1H,H-12),5. 26(dd,J=3.4,1.5Hz,1H,H-2”),5.21(dd,J=9.8,3.4Hz,1H,H-3”),5.16(d,J=3.2Hz,2H,Bn C H2 ),5.13(t,J=9.3Hz,1H,H-3”'),4.99(d,J=1.5Hz,1H,H-1”),4.95(td,J=9.3,5.4Hz ,1H,H-4”'),4.85(dd,J=9.3,7.6Hz,1H,H-2”’),4.77(d,J=4.4Hz,1H,H-1””),4.64( d,J=7.6Hz,1H,H-1”’),4.50(s,1H,H-16),4.33(dd,J=6.1,5.8Hz,1H,H-4””),4.26( d,J=6.1Hz,1H,H-5""),4.18(t,J=6.0Hz,1H,H-3'),4.12(dd,J=11.7,5.4Hz,1H,H-5 a ”'),4.01(dd,J=6.0,1.8Hz,1H,H-4'),3.89–3.81(m,2H,H-5',H-5”),3.72(d,J=4.4 Hz,1H,H-2””),3.68–3.61(m,3H,H-2’,H-3””,H-4”),3.34(dd,J=11.9,9.3Hz,1H,H-5 b ”'),3.01(dd,J=11.7,4.3Hz,1H,H-3),2.93(dd,J=14.2,3.7Hz,1H,H-18),2.23(t,J=13.5Hz,1H,H-19 a),2.13(s,3H),2.07(s,3H),2.03(s,3H),2.00(s,3H),1.98(s,3H),1.97–1.93(m,1H,H-2 a ),1.86–1.76(m,6H,H-11 ab ,H-22 a ,H-21 a ,H-22 b ),1.76–1.71(m,1H,H-15 a ),1.67–1.65(m,1H,H-2 b ),1.54(s,3H,isopropylidene C H3 ),1.53–1.42(m,4H,H-9,H-1 a ,H-6 a ,H-7 a ),1.34–1.33(m,6H,H-27,isopropylidene C H3 ),1.31–1.24(m,9H,H-6',H-6”,H-6 b ,H-7 b ,H-15 b ),1.11–1.10(m,1H,H-21 b ),1.07–1.02(m,2H,H-19 b ),1.01–0.91(m,42H,H-23,H-30,TES C H3 ),0.89(s,3H,H-25),0.88(s,5H,H-29),0.79(s,3H,H-24),0.73(s,3H,H-26),0.70–0.55(m,25H,H-5,TES C H2 )ppm; C 97 H 160 O 27 Si4Na[M+Na] + HRMS (ESI-TOF) calculated value: 1893.0144, found value: 1893.0150.
[0274]
[0275] 3-O-(Benzyl 2,3,4-tri-O-triethylsilyl-β-D-glucopyranosyl uronic acid ester)-28-O-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl-(1→3)-(2,3,4-tri-O-acetyl-β-D-xylopyranosyl-(1→4))-2-O-acetyl-α-L-rhamnopyranosyl-(1→2)-3,4-O-isopropylidene-β-D-fucopyranosyl)-16-O-triethylsilyl saponate (44β)
[0276] At -75 °C under N2 atmosphere, BF3·OEt2 (about 48%, 2.0 μL, 0.0076 mmol) was added to 22 (22 mg, 0.019 mmol), 39 (23 mg, 0.019 mmol) and activated The molecular sieve powder was stirred in anhydrous CH2Cl2 (1 mL) and suspended. After the reaction was completed after 0.5 hours, saturated NaHCO3 was added to quench the reaction and heated to room temperature. The resulting mixture was diluted with CH2Cl2, washed with saturated NaHCO3 and brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; EtOAc / CH2Cl2 / hexane = 4 / 1 / 7) to obtain 103 (44β: 19 mg, 46%; 44α: 2 mg, 5%) as a colorless syrup. 44β: R f 0.60 (EtOAc / hexane=1 / 1); 1 H NMR (600MHz, CDCl3) δ9.36 (s, 1H, H-23), 7.38–7.30 (m, 5H), 5.39 (d, J = 7.3Hz, 1H, H-1') ,5.32(t,J=3.6Hz,1H,H-12),5.17(dd,J=3.5,1.8Hz,1H,H-2”),5.16(d,J=1.8Hz,2H,Bn C H2 ),5.15–5.09(m,3H,H-3”’,H-4”’,H-3””),5.02(m,J=7.8Hz,1H,H-2””),4.95(d,J=1.8Hz,1H,H-1”),4.91(td,J=8.0,4.9Hz,1H,H-4””),4. 85–4.81(m,2H,H-2””,H-1””),4.68(d,J=7.8Hz,1H,H-1”’),4.58(d,J =4.4Hz,1H,H-1””’),4.47(s,1H,H-16),4.28–4.25(m,2H,H-4””’,H-6 a”), 4.21 (d, J = 6.3 Hz, 1H, H-5””), 4.16 (t, J = 6.0 Hz, 1H, H-3’), 4.14–4.09 (m, 2H, H-6 b ”’, H-5 a ””), 4.03 (dd, J = 6.0, 1.9 Hz, 1H, H-4’), 3.99 (dd, J = 9.4, 3.5 Hz, 1H, H-3”), 3.86 (qd, J = 6.5, 1.9 Hz, 1H, H-5’), 3.81 (dd, J = 11.8, 4.6 Hz, 1H, H-3), 3.76 (t, J = 9.4 Hz, 1H, H-4”), 3.71–3.62 (m, 3H, H-5”, H-2’, H-5”’), 3.61 (dd, J = 5.4, 1.2 Hz, 1H, H-3””’), 3.57 (dd, J = 4.4, 1.2 Hz, 1H, H-2””’), 3.40 (dd, J = 11.9, 8.1 Hz, 1H, H-5 b ””), 2.91 (dd, J = 14.4, 4.2 Hz, 1H, H-18), 2.22 (t, J = 13.5 Hz, 1H, H-19 a ), 2.18 (s, 3H), 2.11 (s, 3H), 2.09 (s, 6H), 2.04 (s, 3H), 2.03 (s, 3H), 2.01 (s, 3H), 2.00 (s, 3H), 1.99–1.97 (m, 1H, H-2 a ), 1.87–1.84 (m, 2H, H-11 ab ), 1.80 (s, 3H, H-21 a , H-22 ab ), 1.70–1.68 (m, 2H, H-2 b, H-15 a ), 1.59–1.56 (m, 2H, H-9, H-1 a) , 1.54 (s, 3H, isopropylidene C H3 ), 1.45–1.41 (m, 2H, H-6 b , H-7 a ), 1.34 (s, 6H, H-27, isopropylidene C H3 ), 1.28 (d, J = 6.5 Hz, 3H, H-6’), 1.26–1.24 (m, 1H, H-15 b ), 1.22 (d, J = 6.1 Hz, 3H, H-6”), 1.18–1.16 (m, 2H, H-5, H-6 b ), 1.13–1.11 (m, 1H, H-21 b),1.08(s,3H,H-24),1.06–1.02(m,1H,H-19 b ),1.00–0.92(m,44H,H-1 b ,H-7 b ,H-25,H-30,TES C H3 ),0.88(s,3H,H-29),0.74(s,3H,H-26),0.68–0.55(m,24H,TESC H2 )ppm; C 109 H 174 O 36 Si4Na[M+Na] + HRMS (ESI-TOF) calculated value: 2195.0788, found value: 2195.0785.
[0277] General procedure for amide bond formation:
[0278]
[0279] A suspension of the benzyl ester starting material (1 eq.) and 10% Pd / C (10% w / v) in THF (50 mM) was stirred at room temperature under H2 gas environment (balloon). The reaction mixture was stirred for 12 to 24 hours. The resulting mixture was filtered through celite, concentrated, and then dried under reduced pressure to provide a crude acid intermediate. Alkylamine (3 eq.) was added to a stirred solution of the crude acid intermediate, HBTU (3 eq.) and DIPEA (3 eq.) in anhydrous CH2Cl2 (50 mM) at room temperature under N2 gas environment. The reaction mixture was stirred for 4 hours. The resulting mixture was concentrated and then purified by column chromatography (silica gel, EtOAc / CH2Cl2 / hexane=2 / 1 / 5 to 1 / 1 / 2) to give the amide product with a two-step yield of 61-95%.
[0280] In some embodiments, the silyl groups are randomly deprotected under hydrogenolysis conditions, so that the subsequent amide coupling step produces an inseparable mixture. Therefore, after filtering through a short column (silica, EtOAc / CH2Cl2 / hexane=1 / 1 / 2), the mixture is directly subjected to the overall deprotection step without structural characterization.
[0281] General steps for bulk deprotection:
[0282]
[0283] Precooled TFA / H2O=4 / 1 solution (50% v / v relative to CH2Cl2) was added to a CH2Cl2 (10 mM) solution of the raw material at 0°C and stirred for 30 minutes. The solvent was evaporated at 0°C and reduced pressure (<1 torr), and then dried at room temperature and high vacuum for 1 hour. K2CO3 (20 equivalents) was added to a MeOH (10 mM) solution of the residue and stirred at room temperature for 12 hours. The suspension was centrifuged and the liquid was purified by HPLC (HPLC column: SUPELCO Ascentis C18 25 cm×10 mm, 5 μm; mobile phase: gradient from 20% ACN / H2O to 90% ACN / H2O in 20 minutes, then 90% ACN / H2O isocratic for 15 minutes; flow rate: 5 mL / min) to obtain the product in a two-step yield of 30-75%.
[0284]
[0285] 3-O-(N-((Dodecyl)-β-D-pyranosylglucopyranosyluronamide)-28-O-(β-D-pyranosyl-(1→4)-α-L-pyranosyl-rhamnosyl-(1→2)-β-D-pyranosylfucosyl) saponate (46)
[0286] Following the general procedure for global deprotection, 46 was obtained as a white solid in 68% yield: [α] D 20 -68.0 (c 0.15, MeOH); 1 H NMR (600 MHz, MeOD) δ 9.43 (s, 1H, H-23), 8.55 (s, 1H, amide N H ),5.41(d,J=1.7Hz,1H,H-1”),5.31(t,J=3.5Hz,1H,H-12),5.28(d,J=8.2Hz,1H,H-1′),4. 49–4.48(m,2H,H-1”’,H-16),4.26(d,J=7.8Hz,1H,H-1””),3.92–3.79(m,6H,H-2”,H-3,H- 5”',H-3”,H-2’,H-5”),3.69–3.64(m,3H,H-5’,H-3’,H-5””),3.57–3.53(m,2H,H-4’,H-4” ),3.49–3.42(m,2H,H-4”’,H-4””),3.33–3-30(m,2H,H-3”’,H-3””),3.28–3.26(m,1H,–NHC H a –),3.24–3.17(m,3H,–NHC H b –, H-2”’, H-5”’), 3.14 (dd, J = 9.2, 7.8 Hz, 1H, H-2”), 2.94 (dd, J = 14.1, 4.3 Hz, 1H, H-18), 2.30 (t, J = 13.6 Hz, 1H, H-19a), 1.97–1.89 (m, 5H, H-2 a , H-11 ab , H-21 a , H-22 a ), 1.84–1.64 (m, 5H, H-2 b , H-22 b , H-9, H-1 a , H-15 a ), 1.58–1.48 (m, 4H, H-6 a , H-7 a , carbon chain C H2 ), 1.45 (dd, J = 14.8, 2.7 Hz, 1H, H-15 b ), 1.40 (s, 3H, H-27), 1.37–1.27 (m, 23H, H-5, H-6 b , H-6”, carbon chain C H2 ×9), 1.22 (d, J = 6.4 Hz, 3H, H-6’), 1.19–1.16 (m, 1H, H-21 b ), 1.14 (s, 3H, H-24), 1.12–1.09 (m, 1H, H-1 b ), 1.07–1.04 (m, 1H, H-19 b ), 1.02 (s, 3H, H-25), 0.98–0.94 (m, 4H, H-7b, H-30), 0.91 (t, J = 7.0 Hz, 3H, carbon chain C H3 ), 0.88 (s, 3H, H-29), 0.77 (s, 3H, H-26); 13CNMR(151MHz,MeOD)δ209.2(C-23),177.2(C-28),171.5,144.9(C-13),123.1(C-12),107.0(C-1”'),105.1(C-1””),101.1( C-1”),95.2(C-1’),84.0(C-4”),83.5(C-3),78.2(C-3”’),77.6(C-3””),76.7(C-3’),76.6(C-5””),76.1(C-2”’),74.7(C- 2””), 74.6(C-16), 74.0(C-2'), 73.6(C-4'), 73.2(C-4””), 72.7(C-5”), 72.2(C-3”), 71.9(C-2”), 71.1(C-4”'), 68.8(C-5'), 67.3(C-5”'), 56.1(C-4), 50.0(C-17), 49.6(C-5), 48.1(C-9), 48.0(C-19), 42.8(C-14), 42.4(C-18), 41.1(C-8), 40.1(carbon chain C H2), 39.5 (C-1), 37.1 (C-10), 36.5 (C-21), 36.5 (C-15), 33.6 (C-6), 33.4 (C-29), 33.1 (carbon chain C H2), 32.0(C-22), 31.3(C-20), 30.9(carbon chain C H2),30.9(carbon chain C H2),30.8(carbon chain C H2),30.8(carbon chain C H2),30.6(carbon chain C H2),30.5(carbon chain C H2),30.3(carbon chain C H2),28.0(carbon chain C H2), 27.2 (C-27), 26.0 (C-2), 24.8 (C-30), 24.5 (C-11), 23.8 (carbon chain C H2), 21.6 (C-7), 18.3 (C-6”), 17.7 (C-26), 16.5 (C-6'), 16.4 (C-25), 14.5 (carbon chain C H3), 10.6 (C-24) ppm; C 65 H 107 NO 22 Na[M+Na] + The HRMS (ESI-TOF) calculated value was 1276.7177 and the found value was 1276.7209.
[0287]
[0288] 3-O-(N-(methyl)-β-D-pyranosyl glucopyranosyl uronic acid amide)-28-O-(β-D-pyranosyl-(1→4)-α-L-pyranosyl-rhamnosyl-(1→2)-β-D-pyranosyl-fucosyl) saponate (47)
[0289] Following the general procedure for global deprotection, 47 was obtained as a white solid in 36% yield: [α] D 20 -26.8 (c 0.22, MeOH); 1 H NMR (600 MHz, MeOD) δ 9.42 (s, 1H, H-23), 8.52 (s, 1H, amide N H ),5.40(d,J=1.7Hz,1H,H-1”),5.31(t,1H,J=3.5Hz,H-12),5.28(d,J=8.2Hz,1H,H-1′),4.49–4.47(m,2H ,H-1”',H-16),4.24(d,J=7.9Hz,1H,H-1””),3.90(dd,J=3.3,1.7Hz,1H,H-2”),3.89–3.79(m,5H,H-3,H-5 a ”',H-3”,H-2’,H-5”),3.69–3.64(m,3H,H-5’,H-3’,H-5””),3.56–3.53(m,2H,H-4’,H-4”),3.46(ddd,J=10.4,8 .8,5.4Hz,1H,H-4”’),3.41(t,J=9.1Hz.1H,H-4””),3.33–3.30(m,2H,H-3”’,H-3””)3.23–3.17(m,2H,H-2”’,H-5 b ”'),3.13(dd,J=9.2,7.9Hz,1H,H-2””),2.94(dd,J=14.6,4.1Hz,1H,H-18),2.80(s,3H,–NHC H3 ),2.30(t,J=13.7Hz,1H,H-19 a ),1.94–1.91(m,5H,H-2 a ,H-11 ab ,H-21 a ,H-22 a ),1.81–1.66(m,5H,H-2 b ,H-22 b ,H-9,H-1a ,H-15 a ),1.55–1.43(m,3H,H-6 a ,H-7 a ,H-15 b ),1.40(s,3H,H-27),1.35–1.31(m,5H,H-5,H-6 b ,H-6”),1.22(d,J=6.4Hz,3H,H-6’),1.18(d,J=10.3,2.5Hz,1H,H-21 b ),1.13(s,3H,H-24),1.10(dd,J=13.2,4.02Hz,1H,H-1 b ),1.05(dd,J=13.4,3.5Hz,1H,H-19 b ),1.02(s,3H,H-25),0.97–0.95(m,4H,H-7 b ,H-30),0.88(s,3H,H-29),0.77(s,3H,H-26); 13 C NMR(151MHz,MeOD)δ209.3(C-23),177.2(C-28),172.3,144.8(C-13),123.2(C-12),107.0(C-1”’),104.8(C-1””),101.1(C-1”),95.2(C-1’),84.1(C-4”),83.3(C-3),78.2(C-3”’),77.5(C-3””),76.7(C-3’),76.5(C-5””),76.1(C-2”’),74.7(C-2””),74.6(C-16),74.0(C-2’),73.6(C-4’),73.4(C-4””),72.7(C-5’),72.2(C-3”),71.9(C-2”),71.1(C-4”’),68.8(C-5”),67.3(C-5”’),56.1(C-4),50.0(C-17),49.6(C-5),48.0(C-9),48.0(C-19),42.8(C-14),42.4(C-18),41.1(C-8),39.3(C-1),37.1(C-10),36.5(C-21),36.5(C-15),33.6(C-6),33.4(C-29),32.0(C-22),31.3(C-20),27.2(C-27),26.2(–NH CC 54 H 86 NO 22 [M+H] + The HRMS (ESI-TOF) calculated value was 1100.5636 and the found value was 1100.5667.
[0290]
[0291] 3-O-(N-(Hexyl)-β-D-pyranosyl glucopyranosyl uronamide)-28-O-(β-D-pyranosyl-(1→4)-α-L-pyranosyl-rhamnosyl-(1→2)-β-D-pyranosyl-fucosyl) saponate (48)
[0292] Following the general procedure for global deprotection, 48 was obtained as a white solid in 45% yield: [α] D 20 -17.35 (c 0.34, MeOH); 1 H NMR (600 MHz, MeOD) δ 9.42 (s, 1H, H-23), 8.55 (s, 1H, amide N H ),5.40(d,J=1.6Hz,1H,H-1”),5.31(t,J=3.4Hz,1H,H-12),5.28(d,J=8.2Hz,1H,H-1′),4. 49–4.48(m,2H,H-16,H-1”’),4.26(d,J=7.9Hz,1H,H-1””),3.92–3.77(m,6H,H-2”,H-3,H-5 a ”',H-3”,H-2’,H-5”),3.70–3.62(m,3H,H-5’,H-3’,H-5””),3.56–3.53(m,2H,H-4’,H-4”) ,3.49–3.41(m,2H,H-4”’,H-4””),3.33–3.30(m,2H,H-3”’,H-3””),3.29–3.17(m,4H,–NHC H2 –,H-2”’,H-5 b ”'),3.14(dd,J=9.2,7.9Hz,1H,H-2””),2.94(dd,J=14.1,4.0Hz,1H,H-18),2.30(t,J=13.8Hz,1H,H-19 a), 1.96–1.90 (m, 5H, H-2 a , H-11 ab , H-21 a , H-22 a ), 1.84–1.64 (m, 5H, H-2 b , H-22 b , H-9, H-1 a , H-15 a ), 1.55–1.49 (m, 4H, H-6 a , H-7 a , carbon chain C H2 ), 1.45 (dd, J=14.8, 2.7Hz, 1H, H-15 b ), 1.40 (s, 3H, H-27), 1.36–1.29 (m, 13H, H-5, H-6 b , H-6”, carbon chain C H2 ×4), 1.22 (d, J=6.4Hz, 3H, H-6’), 1.18–1.17 (m, 1H, H-21 b ), 1.13 (s, 3H, H-24), 1.12–1.09 (m, 1H, H-1 b ), 1.05 (dd, J=12.6, 3.0Hz, 1H, H-19 b ), 1.01 (s, 3H, H-25), 0.95 (s, 4H, H-7 b , H-30), 0.92 (t, J=7.0Hz, 3H, carbon chain C H3 ), 0.88 (s, 3H, H-29), 0.77 (s, 3H, H-26); 13C NMR(151MHz,MeOD)δ209.3(C-23),177.2(C-28),171.5,144.8(C-13),123.2(C-12),106.9(C-1”'),104.9(C-1””),101.1 (C-1”),95.2(C-1’),84.0(C-4”),83.3(C-3),78.2(C-3”’),77.6(C-3””),76.7(C-3’),76.6(C-5””),76.1(C-2”’),74.7( C-2””), 74.6(C-16), 74.1(C-2'), 73.6(C-4'), 73.2(C-4””), 72.7(C-5'), 72.2(C-3”), 71.9(C-2”), 71.1(C-4”'), 68.8(C-5”), 67.3(C-5”'), 56.1(C-4), 50.0(C-17), 49.6(C-5), 48.0(C-9, C-19), 42.8(C-14), 42.4(C-18), 41.1(C-8), 40.1(carbon chain C H2), 39.4 (C-1), 37.1 (C-10), 36.5 (C-21), 36.5 (C-15), 33.6 (C-6), 33.4 (C-29), 32.8 (carbon chain C H2), 32.0(C-22), 31.3(C-20), 30.3(carbon chain C H2),27.6(carbon chain C H2), 27.2 (C-27), 25.9 (C-2), 24.8 (C-30), 24.5 (C-11), 23.8 (carbon chain C H2), 21.5 (C-7), 18.3 (C-6”), 17.7 (C-26), 16.5 (C-6'), 16.3 (C-25), 14.5 (carbon chain C H3), 10.6 (C-24) ppm; C 59 H 96 NO 22 [M+H] + The HRMS (ESI-TOF) calculated value was 1170.6418, and the found value was 1170.6448.
[0293]
[0294] 3-O-(N-(octadecyl)-β-D-pyranosyl glucopyranosyl uronamide)-28-O-(β-D-pyranosyl-(1→4)-α-L-pyranosyl-rhamnosyl-(1→2)-β-D-pyranosyl-fucosyl) saponate (49)
[0295] Following the general procedure for bulk deprotection (HPLC column: Alltima C8 150 mm×4.6 mm, 5 μm, flow rate: 1 mL / min), 49 was obtained as a white solid in 30% yield: [α] D 20 -27.4 (c 0.27, MeOH); 1 H NMR (600 MHz, MeOD) δ 9.43 (s, 1H, H-23), 8.55 (s, 1H, amide N H ),5.41(d,J=1.6Hz,1H,H-1”),5.31(t,J=3.4Hz,1H,H-12),5.28(d,J=8.2Hz,1H,H-1′),4.49 (d,J=7.6Hz,2H,H-16,H-1”’),4.26(d,J=7.9Hz,1H,H-1””),3.92–3.77(m,6H,H-2”,H-3,H-5 a ”',H-3”,H-2’,H-5”),3.69–3.63(m,3H,H-5’,H-3’,H-5””),3.57–3.53(m,2H,H- 4',H-4”),3.49–3.41(m,2H,H-4”’,H-4””),3.33–3.27(m,3H,H-3”’,H-3””,–NHC H a –),3.24–3.17(m,3H,H-2”’,H-5 b ”',–NHC H b –),3.14(dd,J=9.2,7.9Hz,1H,H-2””),2.94(dd,J=14.3,4.1Hz,1H,H-18),2.30(t,J=13.6Hz,1H,H-19 a ),1.98–1.89(m,5H,H-2 a ,H-11 ab ,H21 a ,H-22 a) ,1.84–1.64(m,5H,H-2 b ,H-9,H-22 b ,H-1 a ,H-15 a ),1.55–1.49(m,4H,H-6 a ,H-7 a ,Carbon chain C H2 ),1.45(dd,J=14.8,2.5Hz,1H,H-15 b),1.40(s,3H,H-27),1.37–1.25(m,35H,H-5,H-6 b ,H-6”,Carbon chain C H2 ×15),1.22(d,J=6.4Hz,3H,H-6'),1.20–1.15(m,1H,H-21 b ),1.14(s,3H,H-24),1.13–1.08(m,1H,H-1 b ),1.06(dd,J=12.6,3.0Hz,1H,H-19 b ),1.02(s,3H,H-25),0.97–0.95(m,4H,H-7 b ,H-30),0.90(t,J=7.0Hz,3H,carbon chain C H3 ),0.88(s,3H,H-29),0.77(s,3H,H-26); 13 C NMR(151MHz,MeOD)δ209.2(C-23),177.2(C-28),171.5,144.9(C-13),123.1(C-12),107.0(C-1”’),105.1(C-1””),101.1(C -1”),95.7(C-1’),84.0(C-4”),83.5(C-3),78.2(C-3”’),77.6(C-3””),76.7(C-3’),76.6(C-5””),76.1(C-2”’),74.7(C-2 ””), 74.6(C-16), 74.0(C-2'), 73.6(C-4'), 73.2(C-4””), 72.7(C-5'), 72.2(C-3”), 71.9(C-2”), 71.1(C-4”'), 68.7(C-5”), 67.3(C-5”'), 56.1(C-4), 50.0(C-17), 49.6(C-5), 48.1(C-9), 48.0(C-19), 42.8(C-14), 42.3(C-18), 41.1(C-8), 40.0(C- H2 ),39.5(C-1),37.1(C-10),36.5(C-21),36.5(C-15),33.6(C-6),33.4(C-29),33.1(carbon chain C H2 ),32.0(C-22),31.4(C-20),30.9(carbon chain C H2 ),30.9(carbon chain C H2 ),30.8(carbon chain C H2 ),30.8(carbon chain C H2),30.6(carbon chain C H2 ),30.5(carbon chain C H2 ),30.3(carbon chain C H2 ),28.0(carbon chain C H2 ),27.2(C-27),26.0(C-2),24.9(C-30),24.5(C-11),23.8(carbon chain C H2 ),21.6(C-7),18.3(C-6”),17.7(C-26),16.5(C-6'),16.4(C-25),14.5(carbon chain C H3 ),10.6(C-24)ppm;C 71 H 120 NO 22 [M+H] + The HRMS (ESI-TOF) calculated value was 1338.8297 and the found value was 1338.3327.
[0296]
[0297] 3-O-(N-(8-(4-methoxyphenyl)octyl)-β-D-pyranosyl glucopyranosyl uronamide)-28-O-(β-D-pyranosyl-(1→4)-α-L-pyranosyl-rhamnosyl-(1→2)-β-D-pyranosyl-fucosyl) saponate (53)
[0298] Following the general procedure for global deprotection, 53 was obtained as a white solid in 54% yield: [α] D 20 -123.3 (c 0.06, MeOH); 1 H NMR (600 MHz, MeOD) δ 9.42 (s, 1H, H-23), 8.55 (s, 1H, amide N H ),7.07(d,J=8.7Hz,2H),6.82(d,J=8.7Hz,2H),5.41(d,J=1.8Hz,1H,H-1”),5.30–5.27(m,2H,H-12,H-1’),4.49–4 .48(m,2H,H-16,H-1”’),4.26(d,J=7.8Hz,1H,H-1””),3.91(dd,J=3.3,1.8Hz,1H,H-2”),3.90–3.79(m,5H,H-3,H-5 a ”',H-3”,H-2’,H-5”),3.76(s,3H,OC H3), 3.69–3.66 (m, 2H, H-5’, H-3’), 3.64 (d, J = 9.7 Hz, 1H, H-5”), 3.58–3.53 (m, 2H, H-4’, H-4”), 3.49–3.42 (m, 2H, H-4”’, H-4”), 3.33–3.30 (m, 2H, H-3”’, H-3”), 3.28–3.25 (m, 1H, –NHC H a –), 3.24–3.17 (m, 3H, H-2”’, H-5 b ”’, –NHC H b –), 3.14 (dd, J = 9.2, 7.8 Hz, 1H, H-2”), 2.94 (dd, J = 14.3, 4.1 Hz, 1H, H-18), 2.54 (t, J = 7.4 Hz 2H, carbon chain C H2 Ph), 2.30 (t, J = 13.6 Hz, 1H, H-19 a ), 1.97–1.88 (m, 5H, H-2 a , H-11 ab , H-21 a , H-22 a ), 1.84–1.72 (m, 3H, H-2 b , H-9, H-22 b ), 1.71–1.66 m, 2H, H-1 a , H-15 a ), 1.62–1.47 (m, 6H, carbon chain C H2 ×2, H-6 a , H-7 a ), 1.47–1.43 (m, 1H, H-15 b ), 1.40 (s, 3H, H-27), 1.37–1.30 (m, 13H, H-5, H-6 b , H-6”, carbon chain C H2 ×4), 1.22 (d, J = 6.4 Hz, 3H, H-6’), 1.18–1.16 (m, 1H, H-21 b ), 1.13 (s, 3H, H-24), 1.10–1.08 (m, 1H, H-1 b ), 1.05 (dd, J = 12.1, 3.6 Hz, 1H, H-19 b ), 1.00 (s, 3H, H-25), 0.97–0.94 (m, 4H, H-7 b , H-30), 0.87 (s, 3H, H-29), 0.77 (s, 3H, H-26); 13C NMR(151MHz,MeOD)δ209.2(C-23),177.2(C-28),171.5,159.2,144.8(C-13),135.9,130.3,123.1(C-12),11 4.8,107.0(C-1”’),105.0(C-1””),101.1(C-1”),95.2(C-1’),84.0(C-4”),83.5(C-3),78.2(C-3”’),77.6( C-3""),76.7(C-3'),76.6(C-5""),76.1(C-2"'),74.7(C-2""),74.6(C-16),74.0(C-2'),73.6(C-4'),73.2 (C-4””),72.7(C-5’),72.2(C-3”),71.9(C-2”),71.1(C-4”’),68.8(C-5”),67.3(C-5”’),56.1(C-4),55.7(O C H3), 50.0(C-17), 49.6(C-5), 48.1(C-19), 48.0(C-9), 42.8(C-14), 42.3(C-18), 41.1(C-8), 40.0(carbon chain C H2), 39.4 (C-1), 37.1 (C-10), 36.5 (C-21), 36.5 (C-15), 36.7 (carbon chain C H2), 33.6 (C-6), 33.4 (C-29), 33.0 (carbon chain C H2), 32.0(C-22), 31.3(C-20), 30.7(carbon chain C H2),30.5(carbon chain C H2),30.3(carbon chain C H2),30.2(carbon chain C H2),27.9(carbon chain C C 68 H 106 NO 23 [M+H] + The HRMS (ESI-TOF) calculated value was 1326.6970 and the found value was 1326.6978.
[0299]
[0300] 3-O-(N-(8-(4-fluorophenyl)octyl)-β-D-pyranosyl glucopyranosyl uronamide)-28-O-(β-D-pyranosyl-(1→4)-α-L-pyranosyl-rhamnosyl-(1→2)-β-D-pyranosyl-fucosyl) saponate (54)
[0301] Following the general procedure for global deprotection, 54 was obtained in 56% yield as a white solid: [α] D 20 -28.3 (c 0.18, MeOH); 1 H NMR (600 MHz, MeOD) δ 9.42 (s, 1H, H-23), 8.55 (s, 1H, amide N H ),7.17(dd,J=8.8,5.4Hz,2H),6.98(t,J=8.8Hz,2H),5.41(d,J=1.7Hz,1H,H-1”),5.29–5.27(m,2H,H-1 2,H-1'),4.49–4.48(m,2H,H-16,H-1”’),4.26(d,J=7.9Hz,1H,H-1””),3.92–3.78(m,6H,H-2”,H-3,H-5 a ”',H-3”,H-2’,H-5”),3.70–3.63(m,3H,H-5’,H-3’,H-5””),3.57–3.52(m,2H,H-4’,H-4”) ,3.48–3.41(m,2H,H-4”’,H-4””),3.33–3.30(m,2H,H-3”’,H-3””),3.28–3.25(m,1H,–NHC H a –),3.24–3.16(m,3H,H-2”’,H-5 b ”',–NHC H b –), 3.13 (dd, J = 9.2, 7.9 Hz, 1H, H-2””), 2.94 (dd, J = 14.3, 4.5 Hz, 1H, H-18), 2.59 (t, J = 7.6 Hz, 2H, carbon chain C H2 Ph), 2.29(t, J=13.6Hz, 1H, H-19 a ),1.96–1.89(m,5H,H-2 a ,H-11 ab ,H-21 a ,H-22 a ),1.83–1.72(m,3H,H-2 b ,H-9,H-22 b ),1.72–1.64(m,2H,H-1a , H-15 a ), 1.63–1.58 (m, 2H, carbon chain C H2 ), 1.56–1.48 (m, 4H, H-6 a , H-7 a ), 1.45 (dd, J=14.9, 2.6 Hz, 1H, H-15 b ), 1.40 (s, 3H, H-27), 1.36–1.31 (m, 13H, H-5, H-6 b , H-6”, carbon chain C H2 ×4), 1.22 (d, J=6.4 Hz, 3H, H-6’), 1.18–1.16 (m, 1H, H-21 b ), 1.13 (s, 3H, H-24), 1.11–1.08 (m, 1H, H-1 b ), 1.05–1.03 (m, 1H, H-19 b ), 1.00 (s, 3H, H-25), 0.96–0.94 (m, 4H, H-7 b , H-30), 0.86 (s, 3H, H-29), 0.77 (s, 3H, H-26); 13 C NMR (151 MHz, MeOD) δ 209.2 (C-23), 177.2 (C-28), 171.5, 162.6 (J=241 Hz), 144.9 (C-13), 139.8, 130.9 (J=8 Hz), 123.1 (C-12), 115.8 (J=21 Hz), 107.0 (C-1”’), 105.0 (C-1””), 101.1 (C-1”), 95.2 (C-1’), 84.0 (C-4”), 83.4 (C-3), 78.2 (C-3”’), 77.6 (C-3””), 76.7 (C-3’), 76.6 (C-5””), 76.1 (C-2”’), 74.7 (C-2””), 74.6 (C-16), 74.0 (C-2’), 73.6 (C-4’), 73.2 (C-4””), 72.7 (C-5’), 72.2 (C-3”), 71.9 (C-2”), 71.1 (C-4”’), 68.8 (C-5”), 67.3 (C-5”’), 56.1 (C-4), 50.0 (C-17), 49.6 (C-5), 48.1 (C-9), 48.0 (C-19), 42.8 (C-14), 42.4 (C-18), 41.1 (C-8), 40.0 (carbon chain CH2), 39.4 (C-1), 37.1 (C-10), 36.5 (C-21), 36.5 (C-15), 36.1 (carbon chain C H2), 33.6 (C-6), 33.4 (C-29), 32.9 (C-), 32.0 (C-22), 31.3 (C-20), 30.7 (carbon chain C H2),30.5(carbon chain C H2),30.3(carbon chain C H2),30.3(carbon chain C H2),30.2(carbon chain C H2),27.9(carbon chain C C 67 H 102 FNO 22 Na[M+Na] + The HRMS (ESI-TOF) calculated value was 1314.6770 and the found value was 1314.6794.
[0302]
[0303] 3-O-(N-(8-(4-fluorophenyl)octyl)-β-D-pyranosyl glucopyranosyl uronamide)-28-O-(β-D-pyranosyl-(1→4)-α-L-pyranosyl-rhamnosyl-(1→2)-β-D-pyranosyl-fucosyl) saponate (55)
[0304] Following the general procedure for global deprotection, 55 was obtained as a white solid in 75% yield: [α] D 20 -32.5 (c 0.24, MeOH); 1 H NMR (600 MHz, MeOD) δ 9.42 (s, 1H, H-23), 8.55 (s, 1H, amide N H), 7.29 (d, J = 8.3 Hz, 2H), 7.08 (d, J = 8.3 Hz, 2H), 5.41 (d, J = 1.7 Hz, 1H, H-1”), 5.31 (t, J = 3.6 Hz, 1H, H-12), 5.29 (d, J = 8.2 Hz, 1H, H-1’), 4.49–4.48 (m, 2H, H-1”’, H-16), 4.26 (d, J = 7.8 Hz, 1H, H-1””), 3.91–3.78 (m, 6H, H-2”, H-3, H-5 a ”’, H-3”, H-2’, H-5”), 3.69–3.63 (m, 3H, H-5’, H-3’, H-5””), 3.57–3.53 (m, 2H, H-4’, H-4”), 3.48–3.42 (m, 2H, H-4”’, H-4””), 3.33–3.30 (m, 2H, H-3”’, H-3””), 3.29–3.25 (m, 1H, –NHC H a –), 3.23–3.17 (m, 3H, H-2”’, H-5 b ”’, –NHC H a –), 3.14 (dd, J = 9.2, 7.8 Hz, 1H, H-2””), 2.94 (dd, J = 14.5, 4.3 Hz, 1H, H-18), 2.57 (m, J = 7.6 Hz, 2H, carbon chain C H2 Ph), 2.30 (t, J = 13.6 Hz, 1H, H-19 a ), 1.97–1.89 (m, 5H, H-2 a , H-11 ab , H-21 a , H-22 a ), 1.83–1.72 (m, 3H, H-2 b , H-9, H-22 b ), 1.72–1.64 (m, 2H, H-1 a , H-15 a ), 1.63–1.57 (m, 2H, carbon chain C H2 ), 1.56–1.47 (m, 4H, H-6 a , H-7 a , carbon chain C H2 ), 1.47–1.43 (m, 1H, H-15 b ), 1.40 (s, 3H, H-27), 1.36–1.28 (m, 22H, H-5, H-6 b , H-6”, carbon chain C H2 ×4, tBu C H3×3),1.22(d,J=6.4Hz,3H,H-6'),1.19–1.15(m,1H,H-21 b ),1.13(s,3H,H-24),1.11–1.08(m,1H,H-1 b ),1.08–1.03(m,1H,H-19 b ),1.00(s,3H,H-25),0.96–0.94(m,4H,H-7 b ,H-30),0.86(s,3H,H-29),0.77(s,3H,H-26); 13 C NMR(151MHz,MeOD)δ209.2(C-23),177.2(C-28),171.5,149.5,144.8(C-13),140.8,129.1,126.1,123.1(C-12),107.0(C-1”'),10 5.0(C-1””),101.1(C-1”),95.2(C-1’),84.1(C-4”),83.5(C-3),78.2(C-3”’),77.6(C-3””),76.7(C-3’),76.6(C-5””),76.1(C-2 ”'), 74.7(C-2””), 74.6(C-16), 74.0(C-2'), 73.6(C-4'), 73.2(C-4””), 72.7(C-5'), 72.2(C-3”), 71.9(C-2”), 71.1(C-4”’), 68.8(C-5”), 67.1(C-5”’), 56.1(C-4), 50.0(C-17), 49.6(C-5), 48.1(C-9), 48.0(C-19), 42.8(C-14), 42.4(C-18), 41.1(C-8), 40.0(carbon chain C H2), 39.4(C-1), 37.1(C-10), 36.4(C-15, C-21, carbon chain C H2), 35.2 (tBu 4℃), 33.6 (C-6), 33.4 (C-29), 32.8 (carbon chain C H2),31.9(C-22,tBu C H3×3), 31.3(C-20), 30.7(carbon chain C H2),30.5(carbon chain C H2),30.4(carbon chain C H2),30.2(carbon chain C H2),27.9(carbon chain CC 71 H 111 NO 22 Na[M+Na] + HRMS (ESI-TOF) calculated value: 1352.7490, found value: 1352.7515.
[0305]
[0306] 3-O-(N-(8-(4-phenoxyphenyl)octyl)-β-D-pyranosyl glucopyranosyl uronamide)-28-O-(β-D-pyranosyl-(1→4)-α-L-pyranosyl-rhamnosyl-(1→2)-β-D-pyranosyl-fucosyl) saponate (56)
[0307] Following the general procedure for global deprotection, 56 was obtained as a white solid in 46% yield: [α] D 20 -71.4 (c 0.07, MeOH); 1 H NMR (600 MHz, MeOD) δ 9.42 (s, 1H, H-23), 8.55 (s, 1H, amide N H ),7.32(dd,J=8.6,7.5Hz,2H),7.17(dd,J=8.6,1.0Hz,2H),7.07(tt,J=7.5 ,1.0Hz,1H),6.95(d,J=8.6Hz,2H),6.91(d,J=8.6Hz,2H),5.41(d,J=1.7Hz, 1H,H-1"),5.30(s,1H,H-12),5.27(d,J=8.2Hz,1H,H-1'),4.49–4.47(m,2H, H-16,H-1”’),4.26(d,J=7.8Hz,1H,H-1””),3.91–3.79(m,6H,H-2”,H-3,H-5 a ”',H-3”,H-2’,H-5”),3.67–3.63(m,3H,H-5’,H-3’,H-5””),3.56–3.53(m,2H,H- 4',H-4”),3.49–3.42(m,2H,H-4”’,H-4””),3.33–3.25(m,3H,H-3”’,H-3””,–NHC H a –), 3.23–3.17 (m, 3H, H-2”’, H-5 b ”’, –NHC H b –), 3.14 (dd, J=9.2, 7.8 Hz, 1H, H-2””), 2.94 (dd, J=14.2, 4.4 Hz, 1H, H-18), 2.60 (t, J=7.5 Hz, 2H, carbon chain C H2 Ph), 2.29 (t, J=13.1 Hz, 1H, H-19 a ), 1.98–1.87 (m, 5H, H-2 a , H-11 ab , H-21 a , H-22 a ), 1.82–1.76 (m, 3H, H-2 b , H-9, H-22 b ), 1.71–1.65 (m, 2H, H-1 a , H-15 a ), 1.64–1.60 (m, 2H, carbon chain C H2 ), 1.56–1.48 (m, 4H, H-6 a , H-7 a ), 1.45 (dd, J=14.9, 2.6 Hz, 1H, H-15 b ), 1.40 (s, 3H, H-27), 1.37–1.31 (m, 13H, H-5, H-6 b , H-6”, carbon chain C H2 ), 1.21 (d, J=6.4 Hz, 3H, H-6’), 1.18–1.15 (m, 1H, H-21 b ), 1.13 (s, 3H, H-24), 1.11–1.08 (m, 1H, H-1 b ), 1.06–1.03 (m, 1H, H-19 b ), 1.00 (s, 3H, H-25), 0.97–0.93 (m, 4H, H-7 b , H-30), 0.85 (s, 3H, H-29), 0.77 (s, 3H, H-26); 13C NMR(151MHz,MeOD)δ209.2(C-23),177.1(C-28),171.5,159.2,156.5,144.9(C-13),139.2,130.8,130.7,124.0,123.1(C-12),120.0,119 .4,107.0(C-1”'),105.0(C-1””),101.1(C-1”),95.2(C-1’),84.1(C -4"),83.5(C-3),78.2(C-3"'),77.6(C-3""),76.7(C-3'),76.6(C-5 ””), 76.1(C-2”'), 74.7(C-2””), 74.6(C-16), 74.0(C-2'), 73.6(C-4'), 73.2(C-4””), 72.7(C-5'), 72.2(C-3”), 71.9(C-2”), 71.1(C-4”’), 68.7(C-5”), 67.3(C-5”’), 56.1(C-4), 50.0(C-17), 49.6(C-5), 48.1(C-9), 48.0(C-19), 42.8(C-14), 42.4(C-18), 41.1(C-8), 40.0(carbon chain C H2), 39.4 (C-1), 37.1 (C-10), 36.5 (C-21), 36.5 (C-15), 36.2 (carbon chain C H2), 33.6 (C-6), 33.4 (C-29), 32.9 (carbon chain C H2), 32.0(C-22), 31.3(C-20), 30.7(carbon chain C H2),30.5(carbon chain C H2),30.4(carbon chain C H2),30.3(carbon chain C H2),27.9(carbon chain C C 73 H 107 NO 23 Na[M+Na] + The HRMS (ESI-TOF) calculated value was 1388.7126 and the found value was 1388.7172.
[0308]
[0309] 3-O-(N-(4-phenoxyphenyl-1-yl)-β-D-pyranosyl glucopyranosyl uronamide)-28-O-(β-D-pyranosyl-(1→4)-α-L-pyranosyl-rhamnosyl-(1→2)-β-D-pyranosyl-fucosyl) saponate (57)
[0310] Following the general procedure for global deprotection, 57 was obtained as a white solid in 23% yield: 1 H NMR (600MHz, CD3OD) δ9.45(s,1H),8.55(s,1H),7.61(d,J=8.9Hz,2H),7.34(t,J=7.7Hz,2H),7.09(t ,J=7.1Hz,1H),7.00–6.95(m,4H),5.41(d,J=1.6Hz,1H),5.30(t,J=3.6Hz,1H),5.28(d,J=8.2Hz,1H ),4.50–4.47(m,2H),4.32(d,J=7.8Hz,1H),3.93(dd,J=11.8,4.6Hz,1H),3.90(dd,J=3.2,1.8Hz,1H ),3.87–3.77(m,5H),3.67–3.65(m,2H),3.60–3.53(m,3H),3.46(ddd,J=10.4,9.0,5.4Hz,1H),3.36 (t,J=9.0Hz,1H),3.33–3.30(m,1H)3.24–3.17(m,3H),2.93(dd,J=14.4,4.3Hz,1H),2.29(t,J=13.6 Hz,1H),2.00–1.90(m,5H),1.86–1.64(m,5H),1.61–1.48(m,2H),1.45(dd,J=14.8,2.6Hz,1H),1.39 (s,3H),1.37–1.33(m,2H),1.31(d,J=6.2Hz,3H),1.21(d,J=6.4Hz,3H),1.20–1.16(m,1H),1.15(s, 3H),1.13–1.08(m,1H),1.06–1.02(m,1H),1.01(s,3H),0.97–0.94(m,4H),0.87(s,3H),0.77(s,3H); 13CNMR(151MHz,CD3OD)δ209.4,177.2,170.3,169.4,159.0,155.2,144.7,134.8,130.9,124.3,123.2 ,120.3,119.5,106.9,105.2,101.1,95.2,84.0,83.4,78.2,77.6,77.6,77.6,76.7,76.1,74.7,74.6 ,74.0,73.6,73.0,72.7,72.2,71.9,71.1,68.7,67.3,56.2,50.0,49.6,48.0,48.0,42.8,42.3,41.1 ,39.3,37.1,36.5,36.5,36.5,33.4,32.0,31.3,27.2,24.8,21.6,18.3,17.7,16.5,16.3,10.6ppm; C 65 H 92 NO 23 [M+H] + HRMS (ESI-TOF) calculated value: 1254.6055, found value: 1254.6060.
[0311]
[0312] 3-O-(N-(2-(4-phenoxyphenyl-1-yl)ethyl)-β-D-pyranosyl glucopyranosyl uronamide)-28-O-(β-D-pyranosyl-(1→4)-α-L-pyranosyl-rhamnosyl-(1→2)-β-D-pyranosyl-fucosyl) saponate (58)
[0313] Following the general procedure for global deprotection, 58 was obtained as a white solid in 58% yield: 1H NMR(600MHz,CD3OD)δ9.40(s,1H),8.55(s,1H),7.33(dd,J=8.5,7.5Hz,2H),7.23(d,J=8.5Hz,2H),7.09(t,J=7.5Hz,1H),6.95(d,J=8.5Hz,2H),6.93(d,J=8.6Hz,2H),5.41(d,J=1.7Hz,1H),5.30–5.27(m,2H),4.50–4.47(m,2H),4.23(d,J=7.9Hz,1H),3.91(dd,J=3.2,1.7Hz,1H),3.87–3.77(m,5H),3.70–3.65(m,2H),3.63(d,J=9.7Hz,1H),3.57–3.50(m,3H),3.50–3.43(m,2H),3.40(t,J=9.3Hz,1H),3.33–3.29(m,2H),3.23–3.17(m,2H),3.11(dd,J=9.2,7.9Hz,1H),2.94(dd,J=14.3,4.1Hz,1H),2.83(t,J=6.8Hz,2H),2.30(t,J=13.6Hz,1H),1.98–p1.79(m,8H),1.77(dd,J=13.8,4.3Hz,1H),1.74–1.64(m,4H),1.58–1.41(m,3H),1.39(s,3H),1.35(d,J=11.7Hz,1H),1.34–1.28(m,5H),1.22(d,J=6.4Hz,3H),1.18(d,J=12.8Hz,1H),1.11(s,3H),1.08–1.02(m,2H),0.97(s,3H),0.96–0.92(m,4H),0.89(s,3H),0.76(s,3H);BBD 13C NMR(151MHz,MeOD)δ209.3,177.2,171.7,159.0,157.0,144.7,135.6,131.3,130.9,124.2,123.2,120.2 ,119.5,106.9,104.9,101.1,95.2,84.0,83.5,78.2,77.5,76.7,76.4,76.1,74.7,74.6,74.0,73.6,73. 4,72.7,72.2,71.9,71.1,68.7,67.3,56.1,50.0,49.6,48.0,48.0,42.8,42.3,41.5,41.1,39.4,37.0,3 6.5,36.5,35.4,33.6,33.4,32.0,31.3,27.2,25.9,24.8,24.6,21.5,18.3,17.7,16.5,16.3,10.6ppm; C 67 H 96 NO 23 [M+H] + The HRMS (ESI-TOF) calculated value was 1282.6368 and the found value was 1282.6370.
[0314]
[0315] 3-O-(N-(16-(4-phenoxyphenyl-1-yl) hexadecyl)-β-D-pyranosyl glucopyranosyl uronamide)-28-O-(β-D-pyranosyl-(1→4)-α-L-pyranosyl-rhamnosyl-(1→2)-β-D-pyranosyl-fucosyl) saponate (59)
[0316] Following the general procedure for bulk deprotection (HPLC column: Alltima C8 150 mm×4.6 mm, 5 μm, flow rate: 1 mL / min), 59 was obtained as a white solid in 34% yield: 1H NMR(600MHz,CD3OD)δ9.42(s,1H),8.55(s,1H),7.32(dd,J=8.5,7.5Hz,2H),7.16(d,J=8.5Hz,2H),7.07(t,J=7.5Hz,1H),6.94(d,J=8.5Hz,2H),6.89(d,J=8.5Hz,2H),5.41(d,J=1.6Hz,1H),5.31(brs,1H),5.28(d,J=8.2Hz,1H),4.50–4.47(m,2H),4.26(d,J=7.8Hz,1H),3.92–3.78(m,6H),3.68–3.63(m,3H),3.57–3.53(m,2H),3.48–3.42(m,2H),3.35–3.27(m,3H),3.24–3.16(m,3H),3.14(dd,J=9.2,7.8Hz,1H),2.97–2.92(m,1H),2.60(t,J=7.7Hz,2H),2.30(t,J=13.6Hz,1H),1.97–1.90(m,5H),1.83–1.65(m,5H),1.63–1.59(m,2H),1.56–1.43(m,5H),1.40(s,3H),1.38–1.27(m,29H),1.21(d,J=6.4Hz,3H),1.17(d,J=12.6Hz,1H),1.13(s,3H),1.09(d,J=13.4Hz,1H),1.07–1.03(m,1H),1.01(s,3H),0.97–0.92(m,4H),0.87(s,3H),0.77(s,3H);BBD 13C NMR (151MHz, CD3OD) δ209.2,177.1,171.5,159.2,156.4,144.9,139.3,130.8,130.7,124.0,123.1,112.0,119.4,106.9,1 05.1,101.1,95.2,84.0,83.5,78.2,77.8,76.7,76.7,76.6,76.1,74.7,74.6,73.9,73.6,73.2,72.7,72.2,71.9,71.2,68 .7,67.3,56.1,50.0,49.6,48.1,48.0,42.8,42.3,41.1,40.0,37.1,36.5,36.5,36.2,33.6,33.4,32.8,31.4,30.9,30.9, C 81 H 124 NO 23 [M+H] + The HRMS (ESI-TOF) calculated value was 1478.8559 and the found value was 1478.8560.
[0317]
[0318] 3-O-(N-(8-(4-(4-fluorophenoxy)phenyl-1-yl)octyl)-β-D-pyranosyl glucopyranosyl uronamide)-28-O-(β-D-pyranosyl-(1→4)-α-L-pyranosyl-rhamnosyl-(1→2)-β-D-pyranosyl-fucosyl) saponate (60)
[0319] Following the general procedure of amide bond formation and global deprotection, 60 was obtained as a white solid in 40% yield: 1HNMR(600MHz,CD3OD)δ9.42(s,1H),7.16(d,J=8.5Hz,2H),7.09–7.04(m,2H),6.99–6.95(m,2H),6.88(d,J=8.5Hz,2H),5.41(d,J=1.6Hz,1H),5.29–5.27(m,2H),4.50–4.48(m,2H),4.26(d,J=7.8Hz,1H),3.92–3.77(m,6H),3.67–3.63(m,3H),3.57–3.52(m,2H),3.48–3.43(m,2H),3.33–3.30(m,2H),3.29–3.26(m,1H),3.23–3.17(m,3H),3.14(dd,J=9.2,7.8Hz,1H),2.93(dd,J=14.3,4.1Hz,1H),2.60(t,J=7.6Hz,2H),2.29(t,J=13.6Hz,1H),1.97–1.88(m,5H),1.83–1.64(m,5H),1.63–1.59(m,2H),1.57–1.48(m,4H),1.45(dd,J=14.7,2.4Hz,1H),1.39(s,3H),1.38–1.30(m,13H),1.21(d,J=6.4Hz,3H),1.19–1.15(m,1H),1.13(s,3H),1.11–1.07(m,1H),1.04(dd,J=13.6,3.7Hz,1H),0.99(s,3H),0.96(d,J=11.6Hz,1H),0.92(s,3H),0.85(s,3H),0.76(s,3H); 13C NMR (151MHz, CD3OD) δ209.2,177.1,171.5,160.8,159.2,156.9,155.1,144.9,139.1,130.8,123.1,121.2,121.2,119. 5,117.3,117.1,106.9,105.1,101.0,95.2,84.0,83.5,78.2,77.6,76.7,76.6,76.1,74.7,74.6,73.9,73.6,73.2,72. 7,72.2,71.9,71.1,68.7,67.3,56.1,50.0,49.6,48.1,48.0,42.8,42.3,41.1,40.0,39.4,37.1,36.5,36.5,36.2,33. 6,33.4,32.9,32.0,31.3,30.7,30.5,30.4,30.2,27.9,27.2,26.0,24.8,24.5,21.5,18.3,17.7,16.5,16.4,10.6ppm; C 73 H 107 FNO 23 [M+H] + The HRMS (ESI-TOF) calculated value was 1384.7212 and the found value was 1384.7224.
[0320]
[0321] 3-O-(N-(8-(4-hydroxyphenyl-1-yl)octyl)-β-D-pyranosyl glucopyranosyl uronamide)-28-O-(β-D-pyranosyl-(1→4)-α-L-pyranosyl-rhamnosyl-(1→2)-β-D-pyranosyl-fucosyl) saponate (61)
[0322] Following the general procedure for global deprotection, 61 was obtained as a white solid in 23% yield: 1H NMR(600MHz,CD3OD)δ9.42(s,1H),8.55(s,1H),6.97(d,J=8.5Hz,2H),6.69(d,J=8.5Hz,2H),5.41(d,J=1.7Hz,1H),5.30(t,J=3.1Hz,1H),5.29(d,J=8.2Hz,1H),4.49(d,J=7.7Hz,2H),4.26(d,J=7.8Hz,1H),3.93–3.77(m,6H),3.69–3.63(m,3H),3.58–3.52(m,2H),3.49–3.41(m,2H),3.33–3.25(m,3H),3.24–3.16(m,3H),3.14(dd,J=9.2,7.8Hz,1H),2.94(dd,J=14.2,4.2Hz,1H),2.50(t,J=7.5Hz,2H),2.30(t,J=13.6Hz,1H),1.98–1.88(m,5H),1.83–1.64(m,5H),1.60–1.48(m,6H),1.47–1.43(m,1H),1.40(s,3H),1.37–1.27(m,13H),1.22(d,J=6.4Hz,3H),1.18–1.16(m,1H),1.13(s,3H),1.11–1.03(m,2H),1.00(s,3H),0.96–0.95(m,4H),0.87(s,3H),0.77(s,3H);BBD 13 C NMR(151MHz,CD3OD)δ209.2,177.2,171.5,156.3,144.8,134.8,130.3,123.2,116.1,106.9,105.0,101.1,95.2,84.0,83.4,78.2,77.6,76.7,76.6,76.1,74.7,74.6,74.0,73.6,73.2,72.7,72.2,71.9,71.1,68.7,67.3,56.1,50.0,49.6,48.0,42.8,42.3,41.1,40.0,39.4,37.1,36.5,36.5,36.1,33.6,33.4,33.1,32.0,31.3,30.7,30.5,30.3,30.3,27.9,27.2,26.0,24.8,24.5,21.5,18.3,17.7,16.5,16.4,10.6ppm;C 67 H 104 NO 23 [M+H] +The HRMS (ESI-TOF) calculated value was 1290.6994 and the found value was 19690.7008.
[0323]
[0324] 3-O-(N-(8-(4-morpholinophenyl-1-yl)octyl)-β-D-pyranosyl glucopyranosyl uronamide)-28-O-(β-D-pyranosyl-(1→4)-α-L-pyranosyl-rhamnosyl-(1→2)-β-D-pyranosyl-fucosyl) saponate (62)
[0325] Following the general procedure for global deprotection, 62 was obtained as a white solid in 43% yield: 1 H NMR(600MHz,MeOD)δ9.42(s,1H),8.55(s,1H),7.07(d,J=8.5Hz,2H),6.90(d,J=8.5Hz, 2H),5.41(d,J=1.1Hz,1H),5.31–5.27(m,2H),4.49(d,J=7.6Hz,1H),4.48(brs,1H)4.26 (d,J=7.8Hz,1H),3.92–3.90(m,1H),3.89–3.77(m,9H),3.69–3.63(m,3H),3.57–3.52( m,2H),3.49–3.42(m,2H),3.33–3.26(m,3H),3.24–3.16(m,3H),3.13(dd,J=9.2,7.8Hz, 1H),3.11–3.08(m,4H),2.94(dd,J=14.3,4.0Hz,1H),2.53(t,J=7.6Hz,2H),2.29(t,J= 13.6Hz,1H),1.98–1.86(m,5H),1.82–1.63(m,5H),1.62–61.47(m,6H),1.47–1.43(m,1H) ),1.40(s,3H),1.37–1.29(m,13H),1.22(d,J=6.4Hz,3H),1.17(d,J=13.4Hz,1H),1.13( s,3H),1.11–1.02(m,2H),0.99(s,3H),0.96–0.94(m,4H),0.87(s,3H),0.76(s,3H); BBD 13C NMR (151MHz, CD3OD) δ209.2,177.1,171.5,150.9,144.8,135.9,130.0,123.1,117.4,106.9,105.1,101.1,95 .1,84.0,83.6,78.2,77.6,76.7,76.6,76.1,74.7,74.6,74.0,73.6,73.2,72.7,72.2,71.9,71.1,68.7,68.0 ,67.3,56.1,51.4,50.0,49.6,48.1,48.0,42.8,42.3,41.1,40.0,39.4,37.1,36.5,36.5,36.1,33.6,33.4,3 3.0,32.0,31.3,30.8,30.5,30.3,30.2,27.9,27.2,26.0,24.9,24.1,21.5,18.3,17.8,16.5,16.4,10.6ppm; C 71 H 111 N2O 23 [M+H] + The HRMS (ESI-TOF) calculated value was 1359.7572 and the found value was 1359.7580.
[0326]
[0327] 3-O-(N-(8-(Furan-2-yl)octyl)-β-D-pyranosyl glucopyranosyl uronamide)-28-O-(β-D-pyranosyl-(1→4)-α-L-pyranosyl-rhamnosyl-(1→2)-β-D-pyranosyl-fucosyl) saponate (66)
[0328] Following the general procedure for global deprotection, 66 was obtained as a white solid in 23% yield: 1H NMR(600MHz,CD3OD)δ9.42(s,1H),8.55(s,1H),7.33(d,J=1.1Hz,1H),6.30–6.26(m,1H),5.99(d,J=3.1Hz,1H),5.41(d,J=1.4Hz,1H),5.30–5.27(m,2H),4.50–4.47(m,2H),4.26(d,J=7.8Hz,1H),3.93–3.76(m,6H),3.71–3.62(m,3H),3.58–3.50(m,2H),3.48–3.42(m,2H),3.33–3.25(m,3H),3.23–3.16(m,3H),3.13(dd,J=9.0,7.8Hz,1H),2.94(dd,J=14.3,4.2Hz,1H),2.62(d,J=7.5Hz,2H),2.31(d,J=13.4Hz,1H),1.99–1.87(m,5H),1.84–1.59(m,7H),1.59–1.48(m,4H),1.45(dd,J=14.8,2.5Hz,1H),1.40(s,3H),1.37–1.30(m,13H),1.22(d,J=6.4Hz,3H),1.18(d,J=11.0Hz,1H),1.13(s,3H),1.12–1.08(m,1H),1.07–1.03(m,1H),1.01(s,3H),0.97–1.94(m,4H),0.87(s,3H),0.77(s,3H);BBD 13 C NMR(151MHz,CD3OD)δ209.2,177.2,171.5,157.5,144.8,141.9,123.2,111.0,106.9,105.7,105.0,101.1,95.2,84.0,83.4,78.2,77.6,76.7,76.6,76.1,74.7,74.6,74.0,73.6,73.2,72.7,72.2,71.9,71.1,68.7,67.3,56.1,50.0,49.8,48.0,42.8,42.3,41.1,40.0,39.4,37.1,36.5,36.5,33.6,33.4,32.0,31.3,30.6,30.5,30.2,29.3,28.9,27.9,27.2,26.0,24.8,24.5,21.5,18.3,17.7,16.5,16.3,10.6ppm;C 65 H 102 NO 23 [M+H]+ The HRMS (ESI-TOF) calculated value was 1264.6837 and the found value was 1264.6846.
[0329]
[0330] 3-O-(N-(8-(pyridin-3-yl)octyl)-β-D-pyranosyl glucopyranosyl uronamide)-28-O-(β-D-pyranosyl-(1→4)-α-L-pyranosyl-rhamnosyl-(1→2)-β-D-pyranosyl-fucosyl) saponate (68)
[0331] Following the general procedure of amide bond formation and global deprotection, 68 was obtained as a white solid in 42% yield: 1 HNMR(600MHz,CD3OD)δ9.42(s,1H),8.55(s,1H),8.38(d,J=1.8Hz,1H),8.36(dd,J=4.8,1.8 Hz,1H),7.70(dt,J=7.8,1.8Hz,1H),7.37(dd,J=7.7,4.8Hz,1H),5.41(d,J=1.6Hz,1H),5.2 9–5.27(m,2H),4.50–4.47(m,2H),4.26(d,J=7.8Hz,1H),3.92–3.77(m,6H),3.69–3.63(m,3 H),3.56–3.53(m,2H),3.49–3.42(m,2H),3.33–3.25(m,3H),3.23–3.17(m,3H),3.14(dd,J=9 .2,7.8Hz,1H),2.93(dd,J=14.3,4.2Hz,1H),2.67(t,J=7.6Hz,2H),2.29(t,J=13.6Hz,1H), 1.98–1.87(m,5H),1.83–1.62(m,7H),1.56–1.48(m,4H),1.45(dd,J=14.7,2.4Hz,1H),1.39 (s,3H),1.38–1.28(m,13H),1.22(d,J=6.4Hz,3H),1.19–1.15(m,1H),1.13(s,3H),1.10(d, J=13.5Hz,1H),1.06–1.01(m,1H),1.00(s,3H),0.96–0.94(m,4H),0.86(s,3H),0.76(s,3H); 13C NMR (151MHz, CD3OD) δ209.2,177.2,171.5,170.3,150.0,147.5,144.8,140.3,138.3,130.9,125.2,123.1,106.9,1 05.0,101.1,95.2,84.08,83.4,78.2,77.6,76.7,76.6,76.1,74.7,74.6,74.0,73.6,73.2,72.7,72.2,71.9,71.2, 68.7,67.3,56.1,50.0,49.6,48.1,48.0,42.8,42.3,41.1,40.0,39.4,37.1,36.5,36.4,33.8,33.6,33.4,32.4,32 .0,31.3,30.8,30.8,30.6,30.4,30.3,30.2,27.9,27.2,26.0,24.8,24.5,21.5,18.3,17.7,16.5,16.4,10.6ppm; C 66 H 103 N2O 22 [M+H] + The HRMS (ESI-TOF) calculated value was 1275.6997 and the found value was 1275.7031.
[0332]
[0333] 3-O-(N-(8-(4-phenoxyphenyl)octyl)-β-D-pyranosyl glucopyranosyl uronamide)-28-O-(β-D-pyranosyl-(1→4)-α-L-pyranosyl-rhamnosyl-(1→2)-α-D-pyranosyl-fucosyl) saponate (56α)
[0334] Following the general procedure for global deprotection, 56α was obtained as a white solid in 47% yield: 1 H NMR (600 MHz, MeOD) δ 9.41 (s, 1H, H-23), 8.55 (s, 1H, amide N H), 7.32 (dd, J = 8.6, 7.5 Hz, 2H), 7.16 (d, J = 8.6 Hz, 2H), 7.07 (t, J = 7.4 Hz, 1H), 6.95 (d, J = 8.5 Hz, 2H), 6.90 (d, J = 8.5 Hz, 2H), 6.06 (d, J = 3.7 Hz, 1H, H-1’), 5.33 (t, J = 3.4 Hz, 1H, H-12), 4.87 (d, J = 1.7 Hz, 1H, H-1”), 4.49 (s, 1H, H-16), 4.42 (d, J = 7.7 Hz, 1H, H-1”’), 4.26 (d, J = 7.8 Hz, 1H, H-1””), 3.97 (dd, J = 3.2, 1.7 Hz, 1H, H-2”), 3.92–3.86 (m, 3H, H-3, H-2’, H-5’), 3.85–3.80 (m, 2H, H-3’, H-5 a ”’), 3.77 (dd, J = 9.4, 3.2 Hz, 1H, H-3”), 3.72 (d, J = 3.0 Hz, 1H, H-4’), 3.65 (d, J = 9.7 Hz, 1H, H-5”), 3.53 (dq, J = 9.4, 6.0 Hz, 1H, H-5”), 3.49 (t, J = 9.4 Hz, 1H, H-4”), 3.45–3.41 (m, 2H, H-4”’, H-4”), 3.33–3.25 (m, 3H, H-3”’, H-3””, –NHC H a –), 3.23–3.16 (m, 3H, H-2”’, H-5 b ”’, –NHC H b –), 3.14 (dd, J = 9.2, 7.8 Hz, 1H, H-2””), 2.98 (dd, J = 14.3, 4.1 Hz, 1H, H-18), 2.60 (t, J = 7.7 Hz, 2H, carbon chain C H2 Ph), 2.26 (t, J = 13.7 Hz, 1H), 2.01–1.88 (m, 5H, H-2 a , H-11 ab , H-21 a , H-22 a ), 1.83–1.74 (m, 3H, H-2 b , H-22 b , H-9), 1.70 (d, J = 13.4 Hz, 1H, H-1 a ), 1.65–1.59 (m, 3H, H-15 a , carbon chain C H2 ), 1.58–1.47 (m, 4H, H-6 a , H-7 a, carbon chain C H2 ), 1.41–1.38 (m, 4H, H-15 b , H-27), 1.37–1.31 (m, 9H, H-5, carbon chain C H2 ×4), 1.24 (d, J=6.0Hz, 3H, H-6”), 1.23–1.19 (m, 2H, H-6 b , H-21 b ), 1.17 (d, J=6.5Hz, 3H, H-6’), 1.12 (s, 3H, H-24), 1.11–1.08 (m, H-1 b ), 1.05 (dd, J=11.7, 4.3Hz, 1H, H-19 b ), 1.01 (s, 3H, H-25), 0.95–0.91 (m, 4H, H-7 b , H-30), 0.87 (s, 3H, H-29), 0.79 (s, 3H, H-26); 13C NMR(151MHz,MeOD)δ209.1(C-23),176.8(C-28),171.5,159.2,156.5,144.7(C-13),139.1,130.8,130 .7,124.0,123.4(C-12),120.0,119.4,107.1(C-1”’),105.0(C-1””),104.5(C-1”),93.0(C-1’),84.5 (C-4”),83.3(C-3),78.4(C-3”’),77.6(C-3””),76.9(C-2’),76.6(C-5””),76.1(C-2”’),75.0(C-16) ,74.7(C-2””),73.5(C-4’),73.2(C-4””),72.5(C-3”),71.6(C-2”),71.0(C-4”’),71.0(C-3’),70.5( C-5'),68.8(C-5”),67.2(C-5”’),56.1(C-4),50.6(C-17),49.6(C-5),48.0(C-9),48.0(C-19),42.8( C-14),42.1(C-18),41.0(C-8),40.0,39.4(C-1),37.1(C-10),36.3(C-21,C-15),36.2,33.6(C-6),33 .4(C-29),32.9,32.4(C-22),31.4(C-20),30.7,30.4,30.3,30.2,27.9,27.2(C-27),26.0(C-2),25.3 (C-30),24.5(C-11),21.4(C-7),18.0(C-26),17.9(C-6”),16.8(C-6’),16.3(C-25),10.5(C-29)ppm; C 73 H 108 NO 23 [M+H] + The HRMS (ESI-TOF) calculated value was 1366.7307 and the found value was 1366.7318.
[0335]
[0336] 3-O-(N-(8-(4-phenoxyphenyl)octyl)-β-D-pyranosyl glucopyranosyl uronamide)-28-O-(β-D-pyranosyl-(1→4)-α-L-pyranosyl-rhamnosyl-(1→2)-β-L-pyranosylarabinosyl) saponate (77β)
[0337] Following the general procedure for global deprotection, 77β was obtained as a white solid in 67% yield: 1 H NMR (600 MHz, MeOD) δ 9.42 (s, 1H, H-23), 8.55 (s, 1H, amide N H ),7.32(dd,J=8.5,7.4Hz,2H),7.16(dd,J=8.5,1.0Hz,2H),7.07(tt,J=7.6,1 .0Hz,1H),6.95(d,J=8.5Hz,2H),6.90(d,J=8.5Hz,2H),5.61(d,J=3.7Hz,1H, H-1'),5.35(t,J=3.5Hz,1H,H-12),5.02(s,1H,H-1”),4.51(d,J=7.7Hz,1H,H -1”'),4.49(s,1H,H-16),4.26(d,J=7.8Hz,1H,H-1””),3.92–3.79(m,7H,H-5 a ',H-3,H-3',H-2”,H-3”,H-5 a ”',H-4'),3.77(dd,J=5.2,3.7Hz,1H,H-2'),3.73–3.67(m,1H,H-5”),3.65 (d,J=9.7Hz,1H,H-5””),3.57(t,J=9.1Hz,1H,H-4”),3.50–3.41(m,3H,H-5 b ',H-4”’,H-4””),3.33–3.26(m,3H,H-3”’,H-3””,–NHC H a –),3.23–3.16(m,3H,H-2”’,H-5 b ”',–NHC H b –), 3.14 (dd, J = 9.2, 7.8 Hz, 1H, H-2””), 3.05 (dd, J = 14.3, 4.2 Hz, 1H, H-18), 2.60 (t, J = 7.6 Hz, 2H, carbon chain C H2 Ph), 2.28(t, J=13.6Hz, 1H, H-19 a ),1.97–1.87(m,5H,H-2 a ,H-11 ab ,H-21 a ,H-22 a ),1.84–1.66(m,5H,H-2 a ,H-22 b ,H-9,H-15 a ,H-1 a),1.66–1.59(m,2H,carbon chain C H2 ),1.59–1.50(m,3H,H-6a,carbon chain C H2 ),1.42–1.37(m,4H,H-15 b ,H-27),1.36–1.32(m,9H,H-5,carbon chain C H2 ×4),1.31–1.27(m,5H,H-6 b ,H-7 a ,H-6”),1.17–1.12(m,4H,H-21 b ,H-24),1.12–1.07(m,1H,H-1 b ),1.04(dd,J=12.7,3.1Hz,1H,H-19 b ),1.00(s,3H,H-25),0.97–0.92(m,4H,H-30,H-7 b ),0.86(s,3H,H-29),0.77(s,3H,H-26); 13 C NMR(151MHz,MeOD)δ209.1(C-23),176.9(C-28),171.5,159.2,156.5,144.9(C-13),139.1,130.8,130.7,124.0,123.4(C-12),120.0,1 19.4,106.6(C-1”’),105.0(C-1””),101.3(C-1”),94.0(C-1’),83.4(C-3),83.3(C-4”),78.1(C-3”’),77.6(C-3””),76.6(C-5””),76.0 (C-2”’),75.5(C-2’),74.7(C-2””),74.6(C-16),73.2(C-4””),72.3(C-3”),72.1(C-2”),71.1(C-3’,C-4”’),69.0(C-5”),67.2(C-5”’ ),67.0(C-4'),63.7(C-5'),56.1(C-4),50.2(C-17),49.6(C-5),48.1(C-9),47.7(C-19),42.8(C-14),42.1(C-18),41.1(C-8),40.0(carbon chain C H2), 39.4 (C-1), 37.1 (C-10), 36.4 (C-21), 36.3 (C-15), 36.2 (carbon chain C H2), 33.5(C-6), 33.4(C-29), 32.9(carbon chainC H2), 32.0(C-22), 31.4(C-20), 30.7(carbon chain C H2),30.5(carbon chain C H2),30.3(carbon chain C H2),30.3(carbon chain C H2),27.9(carbon chain C C 72 H 105 NO 23 [M+H] + HRMS (ESI-TOF) calculated value: 1352.7150, found value: 1352.7167.
[0338]
[0339] 3-O-(N-(8-(4-phenoxyphenyl)octyl)-β-D-pyranosyl glucopyranosyl uronamide)-28-O-(β-D-pyranosyl-(1→4)-α-L-pyranosyl-rhamnosyl-(1→2)-α-L-pyranosyl-arabinosyl) saponate (77α)
[0340] Following the general procedure for global deprotection, 77α was obtained as a white solid in 35% yield: 1 H NMR (600 MHz, MeOD) δ 9.41 (s, 1H, H-23), 8.55 (s, 1H, amide N H), 7.32 (dd, J = 8.6, 7.4 Hz, 2H), 7.16 (d, J = 8.6 Hz, 2H), 7.07 (t, J = 7.4 Hz, 1H), 6.95 (d, J = 8.6 Hz, 2H), 6.90 (d, J = 8.6 Hz, 2H), 6.09 (d, J = 3.6 Hz, 1H, H-1’), 5.34 (t, J = 3.5 Hz, 1H, H-12), 4.89 (d, J = 1.7 Hz, H-1”), 4.49 (s, 1H, H-16), 4.43 (d, J = 7.7 Hz, 1H, H-1”’), 4.26 (d, J = 7.8 Hz, 1H, H-1””), 3.96 (dd, J = 3.1, 1.7 Hz, 1H, H-2”), 3.94 (dd, J = 10.1, 3.6 Hz, 1H, H-2’), 3.92–3.90 (m, H-4’), 3.89 (dd, J = 11.8, 4.7 Hz, 1H, H-3), 3.85 (dd, J = 10.1, 3.3 Hz, 1H, H-3’), 3.83 (dd, J = 11.4, 5.4 Hz, 1H, H-5 a ”’), 3.80–3.76 (m, 2H, H-5 a ’, H-3”), 3.67 (dd, J = 12.4, 1.8 Hz, 1H, H-5 b ’), 3.65 (d, J = 9.7 Hz, 1H, H-5””), 3.58–3.53 (m, 1H, H-5”), 3.49 (t, J = 9.4 Hz, 1H, H-4”), 3.46–3.41 (m, 2H, H-4”’, H-4””), 3.33–3.26 (m, 3H, H-3”’, H-3””, –NHC H a –), 3.23–3.12 (m, 4H, H-2”’, H-5 b ”’, H-2””, –NHC H b –), 2.98 (dd, J = 14.4, 4.2 Hz, 1H, H-18), 2.60 (t, J = 7.6 Hz, 2H, carbon chain C H2 Ph), 2.26 (t, J = 13.6 Hz, 1H, H-19 a ), 2.00–1.87 (m, 5H, H-2 a , H-11 ab , H-21 a , H-22 a ), 1.83–1.78 (m, 2H, H-2 b , H-22 b ), 1.75 (dd, J = 10.9, 6.7 Hz, 1H, H-9), 1.73–1.65 (m, 2H, H-1a , H-15 a ), 1.65–1.60 (m, 2H, carbon chain CH 2 ), 1.60–1.46 (m, 4H, H-6 a , H-7 a , carbon chain C H2 ), 1.43–1.38 (m, 4H, H-15 b , H-27), 1.37–1.32 (m, 9H, H-5, carbon chain C H2 ×4), 1.26–1.24 (m, 4H, H-6 b , H-6”), 1.21 (d, J=12.5 Hz, 1H, H-21 b ), 1.12 (s, 3H, H-24), 1.10 (dd, J=13.7, 3.6 Hz, 1H, H-1 b ), 1.05 (dd, J=12.4, 3.7 Hz, 1H, H-19 b ), 1.01 (s, 3H, H-25), 0.95–0.91 (m, 4H, H-7 b , H-30), 0.87 (s, 3H, H-29), 0.77 (s, 3H, H-26); 13 C NMR (151 MHz, MeOD) δ 209.0 (C-23), 176.8 (C-28), 171.5, 170.3, 159.2, 156.5, 144.5 (C-13), 139.2, 130.8, 130.7, 124.0, 123.5 (C-12), 120.0, 119.4, 107.1 (C-1”’), 105.0 (C-1””), 104.3 (C-1”), 93.5 (C-1’), 84.4 (C-4”), 83.3 (C-3), 78.4 (C-3”’), 77.6 (C-3””), 77.0 (C-2’), 76.6 (C-5””), 76.1 (C-2”’), 74.9 (C-16), 74.7 (C-2””), 73.2 (C-4””), 72.5 (C-3”), 71.6 (C-2”), 71.0 (C-4”’), 70.7 (C-4’), 70.1 (C-3’), 68.8 (C-5”), 67.2 (C-5”’), 66.5 (C-5’), 56.1 (C-4), 50.7 (C-17), 49.6 (C-5), 48.0 (C-9), 47.9 (C-19), 42.8 (C-14), 42.2 (C-18), 41.1 (C-8), 40.0 (carbon chain C H2),39.4(C-1),37.1(C-10),36.4(C-21),36.3(C-15),36.2(carbon chain C H2 ),33.7(C-6),33.3(C-29),32.9(carbon chain C H2 ),32.3(C-22),31.4(C-20),30.7(carbon chain C H2 ),30.4(carbon chain C H2 ),30.3(carbon chain C H2 ),30.2(carbon chain C H2 ),27.9(carbon chain C H2 ),27.2(C-27),26.0(C-2),25.3(C-30),24.5(C-11),21.4(C-7),17.9(C-6”),17.9(C-26),16.3(C-25),10.5(C-24)ppm; C 72 H 106 NO 23 [M+H] + HRMS (ESI-TOF) calculated value: 1352.7150, found value: 1352.7159.
[0341]
[0342] 3-O-(N-(8-(4-phenoxyphenyl)octyl)-β-D-pyranosyl glucopyranosyl uronamide)-28-O-(β-D-pyranosyl-(1→4)-α-L-pyranosyl-rhamnosyl-(1→2)-β-D-pyranosyl-fucosyl) spiny cystocystate (78)
[0343] Following the general procedure for global deprotection, 78 was obtained as a white solid in 69% yield: 1 H NMR (600 MHz, MeOD) δ 8.55 (s, 1H, amide N H ),7.32(dd,J=8.6,7.4Hz,2H),7.16(dd,J=8.6,1.0Hz,2H),7.06(tt,J=7.4,1 .0Hz,1H),6.95(d,J=8.6Hz,2H),6.90(d,J=8.6Hz,2H),5.41(d,J=1.7Hz,1H, H-1”),5.30–5.27(m,2H,H-12,H-1’),4.51–4.48(m,2H,H-1”’,H-16),4.40(d ,J=7.8Hz,1H,H-1””),3.92(dd,J=3.3,1.7Hz,1H,H-2”),3.88–3.79(m,4H,H-5 a”’, H-3”, H-2’, H-5”), 3.69–3.62 (m, 3H, H-5””, H-3’, H-5’), 3.58–3.53 (m, 2H, H-4”, H-4’), 3.50–3.45 (m, 2H, H-4”’, H-4””), 3.38 (t, J = 9.1 Hz, 1H, H-3””), 3.35–3.28 (m, 2H, H-3”’, –NHC H a –), 3.27–3.24 (m, 2H, H-2”’, H-2””), 3.23–3.17 (m, 3H, H-3, H-5 b ”’, –NHC H b –), 2.93 (dd, J = 14.3, 4.2 Hz, 1H, H-18), 2.60 (m, J = 7.5 Hz, 2H, carbon chain C H2 Ph), 2.29 (t, J = 13.6 Hz, 1H, H-19 a ), 1.96–1.82 (m, 5H, H-2 a , H-11 ab , H-21 a , H-22 a ), 1.80–1.66 (m, 3H, H-22 b , H-2 b , H-15 a ), 1.66–1.55 (m, 5H, H-1 a , H-7 a , H-9, carbon chain C H2 ), 1.55–1.49 (m, 3H, H-6 a , carbon chain C H2 ), 1.48–1.41 (m, 2H, H-15 b , H-6 b ), 1.40–1.36 (m, 4H, H-7b, H-27), 1.36–1.32 (m, 11H, H-6”, carbon chain C H2 ×4), 1.21 (d, J = 6.4 Hz, 3H, H-6’), 1.16 (dd, J = 10.8, 3.8 Hz, 1H, H-21 b ), 1.06 (s, 3H, H-23), 1.03 (dd, J = 12.1, 8.9 Hz, 1H, H-19 b ), 0.98 (dd, J = 13.4, 3.5 Hz, 1H, H-1 b),0.95(s,3H,H-25),0.92(s,3H,H-30),0.86(s,3H,H-24),0.85(s,3H,H-29),0.78(d,J=12.0Hz,1H,H-5),0.76(s,3H,H-26); 13 C NMR(151MHz,MeOD)δ177.1(C-28),171.7,159.2,156.5,144.8(C-13),139.1,130.8,130.7,124.0,123 .4(C-12),120.1,119.4,107.0(C-1”’),106.8(C-1””),101.1(C-1”),95.2(C-1’),91.0(C-3),84.1(C- 4”),78.1(C-3”’),77.8(C-3””),76.7(C-3’),76.5(C-5””),76.1(C-2”’),75.2(C-2””),74.7(C-16),7 4.0(C-2'),73.6(C-4'),73.4(C-4””),72.7(C-5’),72.2(C-3”),71.9(C-2”),71.1(C-4”’),68.7(C-5” ),67.3(C-5”'),57.2(C-5),50.0(C-17),48.1(C-9),48.1(C-19),42.7(C-14),42.3(C-18),40.8(C-8 ),40.2(C-4),40.0(C-1),39.9,37.9(C-10),36.5(C-21),36.5(C-15),36.4,34.3(C-6),33.4(C-29),3 2.9,32.0(C-22),31.3(C-20),30.7,30.6,30.4,30.3,28.5(C-23),27.9,27.3(C-2),27.2(C-27),24.8 (C-30),24.6(C-11),19.4(C-7),18.3(C-6”),17.8(C-26),17.0(C-24),16.5(C-6’),16.3(C-25)ppm; C 73 H 110 NO 22 [M+H] + The HRMS (ESI-TOF) calculated value was 1352.7514 and the found value was 1352.7532.
[0344]
[0345] 3-O-(N-(8-(4-phenoxyphenyl)octyl)-β-D-pyranosyl glucopyranosyl uronamide)-28-O-(β-D-pyranosyl-(1→3)-(β-D-pyranosyl-(1→4))-α-L-pyranosyl-rhamnosyl-(1→2)-β-D-pyranosyl-fucosyl) saponate (79)
[0346] Following the general procedure for bulk deprotection, 79 was obtained as a white solid in 33% yield: 1H NMR (600 MHz, MeOD) δ 9.42 (s, 1H, H-23), 8.55 (s, 1H, amide N H ),7.32(dd,J=8.5,7.5Hz,2H),7.17(d,J=8.5Hz,2H),7.07(t,J=7.5Hz,1H),6.95(d,J=8.5H z,2H),6.90(d,J=8.5Hz,2H),5.29(s,1H,H-12),5.26(d,J=8.1Hz,1H,H-1'),5.23(s,1H,H- 1”), 4.70 (d, J=7.9Hz, 1H, H-1””), 4.53 (d, J=7.3Hz, 1H, H-1”’), 4.46 (s, 1H, H-16), 4.27–4. 25(m,2H,H-2”,H-1””’),3.95(dd,J=9.5,3.0Hz,1H,H-3”),3.90–3.81(m,4H,H-5”,H-3,H-6 a ”',H-5 a ””),3.74(dd,J=10.2,8.1Hz,1H,H-2'),3.71–3.60(m,5H,H-4”,H-6 b ”',H-5””’,H-5’,H-3’),3.55(d,J=2.6Hz,1H,H-4’),3.49–3.41(m,2H,H-4”” ,H-4””’),3.33–3.25(m,7H,H-2”’,H-3”’,H-4”’,H-5”’,H-3””,H-3””’,–NHC H a –),3.23–3.08(m,4H,H-2””,H-5 b ””,H-2””'),2.95–2.88(m,1H,H-18),2.60(t,J=7.6Hz,2H,carbon chain C H2 Ph), 2.28(t, J=13.6Hz, 1H, H-19 a ),1.98–1.86(m,5H,H-2 a ,H-21 a ,H-22 a,H-11 ab ),1.86–1.77(m,2H,H-22 b ,H-2 b ),1.76–1.67(m,3H,H-9,H-15 a ,H-1 a ),1.65–1.59(m,2H,carbon chain C H2 ),1.58–1.48(m,4H,H-6 a ,H-7 a ,Carbon chain C H2 ),1.41–1.38(m,4H,H-15 b ,H-27),1.37–1.31(m,9H,H-5,carbon chain C H2 ×4),1.30–1.26(m,4H,H-6 b ,H-6"),1.21(d,J=6.3Hz,3H,H-6'),1.16(d,J=11.2Hz,1H,H-21 b ),1.14(s,3H,H-24),1.10(d,J=16.7Hz,2H,H-1 b ),1.04(d,J=10.1Hz,1H,H-19 b ),1.00(s,3H,H-25),0.96–0.94(m,1H,H-7 b ),0.93(s,3H,H-30),0.85(s,3H,H-29),0.79(s,3H,H-26); 13C NMR(151MHz,MeOD)δ209.4(C-23),177.2(C-28),171.5,159.2,156.5,144.8(C-13),139.2,130.8,130.7,124.0, 123.1(C-12),120.0,119.4,105.4(C-1”'),105.1(C-1””’),105.0(C-1””),101.5(C-1”),95.4(C-1’),83.5(C-3) ,83.0(C-3”),78.7(C-4”),78.6(C-3”’),78.3(C-3””),77.8(C-2”’),77.6(C-3””’),76.6(C-5””’),75.9(C-3’) ,75.7(C-2””),75.3(C-4”’),74.9(C-2’),74.8(C-16),74.7(C-2””’),73.5(C-4’),73.2(C-4””’),72.7(C-5’),7 1.5(C-4””),71.3(C-2”),71.1(C-5”’),69.1(C-5”),67.0(C-5””),62.4(C-6”’),56.1(C-4),49.9(C-17),49.5( C-5),48.1(C-19),48.0(C-9),42.8(C-14),42.4(C-18),41.1(C-8),40.0,39.4(C-1),37.1(C-10),36.5(C-15,C- 21),36.2,33.8(C-6),33.4(C-29),32.9,31.8(C-22),31.3(C-20),30.7,30.5,30.4,30.3,27.9,27.3(C-27),26 C 79 H 118 NO 28 [M+H] + The HRMS (ESI-TOF) calculated value was 1528.7835 and the found value was 1528.7847.
[0347] Synthesis Example II
[0348] The protosapogenin is coupled to the trisaccharide.
[0349] Considering the long process of glucuronic acid ester conjugation with saponin acid ester, we further applied semi-synthetic method to obtain saponin core. The starting material Quillaja Ultra Dry100-Q (Desert King, batch: QDU-100-121213-2) was hydrolyzed under alkaline conditions to connect the oligosaccharide of C-28. After triethyl silylation and selective benzylation, the original sapogenin core (flow 7) was provided in three steps.
[0350] Scheme 7 - Isolation and selective protection of branched trisaccharide-triterpenoid saponins.
[0351]
[0352] Diversified linkers are formed by amide bonds on the protosapogenins.
[0353] The coupling of trisaccharides to protosapogenins can be easily achieved to provide saponin cores. After deprotection and amide bond formation, target saponins with diversified carbon chains are provided.
[0354] Scheme 8 - Demonstrates the preparation of saponin analogs according to embodiments of the present invention.
[0355]
[0356] Experimental details
[0357]
[0358] 3-O-(2,3,4,6-Tetra-O-triethylsilyl-β-D-galactopyranosyl-(1→2)-(2,3,4-tri-O-triethylsilyl-β-D-xylopyranosyl-(1→3))-3-O-triethylsilyl-β-D-pyranoglucuronic acid))-16-O-triethylsilyl saponin (81)
[0359] TESOTf (5.0 mL, 22.1 mmol) was added to a stirred suspension of protosapogenin (1.72 g) in anhydrous pyridine (25 mL) at room temperature and under N2 gas. The reaction mixture was stirred for 2 days, then TESOTf (1.3 mL, 5.8 mmol) was added, and then 1 more time (1.0 mL, 4.4 mmol) was added after 24 hours. The reaction mixture was stirred for a total of 5 days. The resulting mixture was concentrated and passed through a silica gel column, eluted with hexane / EtOAc (2: 1). The eluate was concentrated and dried under reduced pressure to give a yellow oil. The resulting yellow oil was dissolved in MeOH / THF (1: 1) (80 mL), and the solution was stirred at room temperature for 3 days. The reaction mixture was concentrated under reduced pressure and then purified by column chromatography (silica gel, EtOAc / hexane = 1 / 6 to 1 / 4) to give 81 (0.66 g, ~19%) as a white solid foam. R f 0.47 (EtOAc / benzene=1 / 4); 1 H NMR (600MHz, CDCl3) δ9.68(s,1H),5.35(br.s,1H,H-12),4.56(br.s,1H,H-16),4.54(d,J=7.4Hz,1H,H-1"'),4.42( d,J=7.4Hz,1H,H-1”),4.41(d,J=6.4Hz,1H,H-1’),3.96-3.88(m,4H,H-4”,H-3’,H-5’,H-3”),3.84-3.82(m,2H,H-5 a ”',H-2'),3.77(t,J=9.2Hz,1H,H-6 a ”),3.65-3.61(m,3H,H-3,H-2”,H-6 b ”),3.52-3.49(m,1H,H-4”’),3.53-3.51(m,1H,H-4’),3.42-3.35(m,2 H,H-3”',H-5”),3.27(t,J=7.8Hz,1H,H-2”’),3.12(t,J=10.7Hz,1H,H -5"'),2.96(dd,J=13.3Hz,J=3.1Hz,1H,H-18),2.22(t,J=13.8Hz,1H,H-19),1.92-1.86(m,4H),1.84-1.71(m,4H),1.68(t,J=8.9Hz,1H,H-19 a),1.63-1.31(m,1H,H-1),1.57-1.50(m,1H),1.49-1.41(m,2H,H-6),1.39-1.36(m,5H,H-5,H-27),1.29-1.25(m,5H,H-15 C 101 H 199 O 20 Si9[M+H] + The HRMS (ESI-TOF) calculated value was 1986.2504 and the found value was 1986.3361.
[0360]
[0361] 3-O-(Benzyl 2,3,4,6-tetra-O-triethylsilyl-β-D-galactopyranosyl-(1→2)-(2,3,4-tri-O-triethylsilyl-β-D-xylopyranosyl-(1→3))-3-O-triethylsilyl-β-D-glucopyranosyl uronic acid ester))-16-O-triethylsilyl saponin (82)
[0362] CBzCl (47 μL, 0.33 mmol) was added to a stirred suspension of 81 (253 mg, 127 μmol), TBP (319 mg, 1.29 mmol) and anhydrous pyridine (94 μL, 1.2 mmol) in CH2Cl2 (2.2 mL) under N2 gas. After 14 hours, the reaction was complete and the reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; EtOAc / hexane = 1 / 20 to 1 / 10) to give 82 (207 mg, 65%) as a white solid foam. f 0.74 (EtOAc / benzene=1 / 9); 1 H NMR (400MHz, CDCl3) δ9.68 (s, 1H), 7.33-7.29 (m, 5H), 5.31 (br.s, 1H, H-12), 5.23 (d, J=12.4Hz, 1H Bn C H 2),5.07(d,J=12.0Hz,1H Bn C H2),4.53(d,J=7.6Hz,1H,H-1”'),4.51(br.s,1H,H-16),4.40(d,J=7.2Hz,1H,H-1”),4.12 (d,J=7.2Hz,1H,H-1'),3.93-3.79(m,4H,H-4”,H-3’,H-5’,H-3”),3.878-3.74(m,2H,H-5 a ”',H-2'),3.72(t,J=9.1Hz,1H,H-6 a ”),3.61-3.52(m,3H,H-3,H-2”,H-6 b ”),3.49-3.42(m,1H,H-4”’),3.40-3.35(m,1H,H-4’),3.39-3.29(m,2H ,H-3”',H-5”),3.23(t,J=7.7Hz,1H,H-2”’),3.11(t,J=11.0Hz,1H,H-5 b ”'),2.91(dd,J=13.8Hz,J=3.6Hz,1H,H-18),2.19(t,J=13.6Hz,1H,H-1 9),1.89-1.79(m,4H),1.55-1.45(m,4H),1.42-1.30(m,5H,H-5,H-27), 1.30-1.23(m,5H,H-15,H-24),1.16-1.09(m,2H,H-21),1.08-1.01(m,1 H,H-9),1.00-0.90(m,94H),0.88(s,3H,H-29),0.73-0.57(m,54H)ppm; C 108 H 204 O 20 Si9Na[M+Na] + The HRMS (ESI-TOF) calculated value was 2099.2803 and the found value was 2099.3005.
[0363]
[0364] 3-O-(N-(8-(4-phenoxyphenyl)octyl)-β-D-galactopyranosyl-(1→2)-(β-D-xylopyranosyl-(1→3))-β-D-pyranosylglucopyranosyluronamide)-saponin (83)
[0365] DIPEA (5 μL, 25 μmol), 8-(4-phenoxyphenyl)octane-1-amine (4 mg, 14 μmol) were sequentially added to a stirred suspension of saponin diacid (26 mg, 13 μmol) and HBTU (7 mg, 25 μmol) in anhydrous THF (1 mL) under N2 gas environment. After the reaction was completed after 1 hour, the reaction mixture was concentrated under reduced pressure, diluted with CH2Cl2, washed twice with H2O, washed with brine, dried with MgSO4, and then concentrated under pressure. The residue was then purified by flash column (silica gel, EtOAc / hexane=1 / 20 to 1 / 10). The crude product was then dissolved in 1 mL THF and stirred for 6 hours under pH 1 acidic conditions. After neutralization with NaHCO, the mixture was filtered through a 0.22 μm filter plate, the filtrate was concentrated, and then purified by HPLC (HPLC column: SUPELCO Ascentis C18 25 cm×10 mm, 5 μm; mobile phase: gradient from 20% ACN / H2O to 90% ACN / H2O in 20 min, then 90% ACN / H2O isocratic for 15 min; flow rate: 4 mL / min) to provide the product 83 (2 mg) as a white solid in 80% yield: 1 H NMR(600MHz,CD3OD)δ9.44(s,1H,H-23),7.32(t,J=7.7Hz,2H),7.16(d,J=8.3Hz,2H),7 .07(t,J=7.2Hz,1H),6.95(d,J=8.2Hz,2H),6.90(d,J=8.2Hz,1H),5.28(br.s,1H,H-12 ),4.79(d,J=7.1Hz,1H,H-1”),4.45(s,1H,H-16),4.57(d,J=7.7Hz,1H,H-1”’),4.43(d ,J=7.4Hz,1H,H-1'),3.89(dd,J=11.5&5.5Hz,1H,H-3),3.85(dd,J=11.8&4.4Hz,1H,H-5 a ”'),3.81(d,J=2.5Hz,1H,H-4”)3.75(d,J=6.2Hz,2H,H-6”),3.70-3,63(m,4H,H-2”’,H-2’, H-5',H-3'),3.56-3.41(m,5H,H-2”,H-3',H-4',H-5”,H-4”’),3.26-3.19(m,4H,H-3”’,H-5 b ”',-NHC H2 -), 3.00 (dd, J = 14.1 Hz & 4.1 Hz, 1H, H-18), 2.60 (t, J = 7.6 Hz, 2H, carbon chain CH2 Ph), 2.29(t, J = 13.4 Hz, 1H, H-19 a ),1.99-1.87(m,5H),1.80-1.72(m,3H),1.71-1.66(m,1H),1.65-1.60(m,2H),1.55-1.49(m,3H),1.38(s,1H,H-27),1.36-1. C 67 H 97 NO 20 Na[M+Na] + HRMS + (ESI-TOF) calculated value: 1258.6496, found value: 1258.6510.
[0366]
[0367] 3-O-(Benzyl 2,3,4,6-tetra-O-triethylsilyl-β-D-galactopyranosyl-(1→2)-(2,3,4-tri-O-triethylsilyl-β-D-xylopyranosyl-(1→3))-(3-O-triethylsilyl-β-D-glucopyranosyl uronic acid ester))-28-O-(2,3,4-tri-O-acetyl-β-D-xylopyranosyl-(1→4)-2,3-di-O-acetyl-α-L-rhamnopyranosyl-(1→2)-3,4-O-isopropylidene-β-D-fucopyranosyl)-16-O-triethylsilyl saponate (84)
[0368] At -75 °C under N2 gas environment, BF3·OEt2 (about 48%, 4 μL, 24 μmol) was added to 10 (68.8 mg, 83.6 μmol), 82 (130 mg, 62.3 μmol) and activated The molecular sieve powder was stirred in anhydrous CH2Cl2 (3.0 mL). After 0.5 hours, the reaction was quenched with Et3N and heated to room temperature. The resulting mixture was diluted with CH2Cl2 and filtered through a 5 μm filter paper. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; EtOAc / CH2Cl2 / hexane = 1 / 1 / 6 to 1 / 1 / 4) to give 84 (160 mg, 93%) as a white solid foam. f 0.63 (EtOAc / hexane=1 / 1); 1H NMR(600MHz,CDCl3)δ9.67(s,1H),7.32-7.29(m,5H),5.38(d,J=7.4Hz,1H,H-1””),5.30(t,J=3.7 1H,H-12),5.26(d,J=12.0Hz,1H Bn C H 2),5.23-5.21(m,1H,H-2””'),5.19(dd,J=9.8Hz,J=3.5Hz,1H,H-3””'),5.07(d,J=12.4Hz,1H Bn C H 2),4.97(d,J=0.8Hz,1H,H-1””'),4.93(dt,J=9.2Hz,J=5.5Hz,1H,H-4”””),4.83(dd,J=9.2Hz,J=5.5Hz,1H,H-2”””),4.61(d,J=7.8Hz,1H,H-1”””),4.53(d,J=7.8Hz,1H,H-1”'),4.46(s,1H,H-16),4.39(d,J=7.2Hz,1H,H-1”),4.17-4.14(m,2H,H-1',H-3””),4.12-4.07(m,2H,H-3',H-5 a ”””),3.99(dd,J=5.8Hz,J=1.9Hz,1H,H-4””),3.91-3.88(m,2H,H-4',H-5'),3.86-3.81(m,3H,H-4”,H-5””,H-3”),3.81-3.75(m,3H,H-5”',H-5 a ”',H-2'),3.72(t,J=9.2Hz,1H,H-6 a ”),3.66-3.60(m,2H,H-2””,H-5””'),3.59-3.53(m,3H,H-2”,H-6 b ”,H-3),3.47-3.42(m,1H,H-4”'),3.36(dd,J=9.4Hz,J=2.2Hz,1H,H-4””),3.34-3.29(m,3H,H-3”',H-5”,H-5 b ”””),3.22(t,J=7.4Hz,1H,H-2”'),3.10,(t,J=11.0Hz,1H,H-5 b”'),2.90(dd,J=14.1Hz,J=3.7Hz,1H,H-18),2.21(t,J=13.7Hz,1H,H-19),2.11(s,3H),2.04(s,3H),2.01(s,3H),1.99(s,3H),1.95(s,3H),1 .83-1.77(m,4H,H-11,H-22),1.76-1.62(m,4H),1.62-1.55(m,3H),1. 52(s,3H,H-27),1.50-1.47(m,1H),1.33(s,1H,H-5),1.31(s,6H,isopropylidene C H 3),1.27(s,3H,H-24),1.26-1.25(m,3H,H-6””),1.25-1.24(d,3H,H-6””’),1.24-1.22(m, 4H),0.98-0.91(m,94H),0.91-0.89(m,10H,H-1,H-7,H-15,H-20),0.69-0.56(m,54H)ppm; C 138 H 246 O 37 Si9Na[M+Na] + The HRMS (ESI-TOF) calculated value was 2772.5224 and the found value was 2772.5586.
[0369]
[0370] 3-O-{β-D-galactopyranosyl-(1→2)-[β-D-xylopyranosyl-(1→3)]-[N-(8-(4-methoxyphenyl)octyl)-β-D-pyranoglucopyranosyl uronamide]}-28-O-[β-D-pyranoglucopyranosyl-(1→4)-α-L-rhamnopyranosyl-(1→2)-β-D-fucopyranosyl] saponate (92)
[0371] DIPEA (10 μL, 58 μmol) was added to a stirred suspension of 50 (8 mg, 6 μmol), 8-(4-methoxyphenyl)octan-1-amine (13 mg, 58 μmol) and HBTU (22 mg, 58 μmol) in anhydrous DMA (0.5 mL) under N2 atmosphere. After 24 h of reaction completion, the reaction mixture was concentrated under reduced pressure, diluted with MeOH, and then filtered through a 5 μm filter paper. The filtrate was concentrated and then purified by HPLC (HPLC column: SUPELCO Ascentis C18 25 cm×10 mm, 5 μm; mobile phase: gradient from 30% ACN / H2O to 80% ACN / H2O in 20 min, then 90% ACN / H2O isocratic for 15 min; flow rate: 5 mL / min) to provide the product 51b (2 mg) as a white solid in 30% yield; C 79 H 123 NO 32 Na[M+Na] + HRMS (ESI-TOF) calculated value: 1620.7920, found value: 1620.7920.
[0372]
[0373] 3-O-{β-D-galactopyranosyl-(1→2)-[β-D-xylopyranosyl-(1→3)]-[N-(8-(4-phenoxyphenyl)octyl)-β-D-pyranoglucopyranosyluronamide]}-28-O-[β-D-pyranoglucopyranosyl-(1→4)-α-L-rhamnopyranosyl-(1→2)-β-D-fucopyranosyl] saponate (95)
[0374] DIPEA (6 μL, 40 μmol) was added to a stirred suspension of 50 (5 mg, 4 μmol), 8-(4-phenoxyphenyl)octan-1-amine (10 mg, 40 μmol) and HBTU (12 mg, 40 μmol) in anhydrous DMA (0.5 mL) under N2 atmosphere. After 24 h when the reaction was complete, the reaction mixture was concentrated under reduced pressure, diluted with MeOH, and then filtered through a 5 μm filter paper. The filtrate was concentrated and then purified by HPLC (HPLC column: SUPELCO Ascentis C18 25 cm×10 mm, 5 μm; mobile phase: gradient from 20% ACN / H2O to 90% ACN / H2O in 20 min, then 90% ACN / H2O isocratic for 15 min; flow rate: 2.4 mL / min) to provide the product 51a (2 mg) as a white solid in 80% yield: 11H NMR (600 MHz, CD3OD) δ 9.45 (s, 1H, H-23), 8.54 (s, 1H, amide N H ), 7.33 (dd, J = 8.5 Hz & 7.6 Hz, 2H), 7.18 (d, J = 8.5 Hz, 2H), 7.08 (t, J = 7.4 Hz, 1H), 6.95 (d, J = 7.8 Hz, 2H), 6.91 (d, J = 8.5 Hz, 1H), 5.37 (d, J = 1.5 Hz, 1H, H-1””'), 5.28 (t, J = 3.4 Hz, 1H, H-12), 5.27 (d, J = 8.2 Hz, 1H, H-1””), 4.79 (d, J = 7.1 Hz, 1H, H-1”), 4.62 (s, 1H, H-16), 4.57 (d, J = 7.7 Hz, 1H, H-1”'), 4.47 (d, J = 7.7 Hz, 1H, H-1”””), 4.43 (d, J = 7.4 Hz, 1H, H-1'), 3.93 (m, 1H, H-2””'), 3.89 (m, 1H, H-5 a ”'), 3.82 (m, 6H, H-4”, H-2”, H-3”, H-3””, H-5””, H-5 a ”””), 3.75 (m, 2H, H-6”), 3.69 (m, 1H, H-2”'), 3.65 (m, 5H, H-2', H-5', H-3”, H-4””, H-5””), 3.49 (m, 9H, H-3, H-3', H-4', H-5”, H-4”', H-3””', H-4””', H-2”””, H-4”””), 3.22 (m, 6H, H-2”, H-3”', H-5 b ”', H-3”””, H-5 b ”””, -NHC H a -), 2.95 (m, 2H, H-18, -NHC H b -), 2.60 (t, J = 7.6 Hz, 2H, carbon chain C H2 Ph), 2.29 (t, J = 13.4 Hz, 1H, H-19 a),1.95(m,2H),1.90(m,4H),1.76(m,3H),1.69(m,2H),1.63(m,4H),1.53(m, 3H),1.46(m,3H),1.38(s,1H,H-27),1.34(m,13H),1.30(m,11H),1.20(d,J=6 .4Hz,3H,H-6””'),1.16(s,3H,H-23),1.15(m,1H),1.08(m,3H),0.98(s,3H,H -25),0.92(s,3H,H-30),0.90(m,2H),0.86(s,3H,H-24),0.74(s,3H,H-26); C 84 H 125 NO 32 Na[M+Na] + The HRMS (ESI-TOF) calculated value was 1682.8077 and the found value was 1682.8079.
[0375] 6-N-Glycosyl saponate
[0376] Conjugation of saponate with azidoglucose successfully gave product 117 in 70% yield. Interestingly, this result indicated the selectivity of 3-O glycosylation at the 16-O position.
[0377]
[0378] With glycoside 117 in hand, further modifications were made to unmask the C-28 carboxylic acid. First, the benzoyl group was hydrolyzed under alkaline conditions at elevated temperatures. Surprisingly, the 28-O-allyl ester was not affected under this harsh environment of strong base. After triethylsilylation of the resulting azido glycoside, the azide group was reduced to the amine, and then the amide was formed by coupling with a lipophilic long-chain acid to give the fully protected saccharide ester 119a / b / c. The O-allyl ester 119a / b / c was hydrolyzed with Pd(OAc)2 under low acidic conditions to give the glycoside acceptor 120a / b. The monoacid 120a / b / c was conjugated with the trisaccharide 10 at -78°C with Lewis acid catalysis to afford 121a / b / c in 56% yield. The fully protected saponin 121a / b / c was suspended in THF / MeOH with Pd(OH)2 under H2 gas atmosphere to hydrolyze the benzyl groups on 3-O and 4-O of glucose. After acidic hydrolysis and alkaline methanolysis, HPLC purification was performed to obtain 122a / b / c in yields of 13%, 16%, and 30%.
[0379]
[0380] 3-O-(6-azido-2-O-benzoyl-3,4-di-O-benzyl-6-deoxy-β-D-glucopyranosyl)-28-O-allyl-soap acid ester (117):
[0381] 1 H NMR (600 MHz, CDCl3) δ9.17 (s, 1H, H-23), 8.04-8.01 (m, 2H, Bz), 7.61-7.56 (m, 1H, Bz), 7.48-7.44 (m, 2H, Bz), 7.36-7.24 (m, 5H, Bn), 7.14-7.09 (m, 5H, Bn), 5.88–5.80 (m, 1H, allyl internal alkenyl C H ), 5.33 (t, J = 3.5 Hz, 1H, H-12), 5.28 (d, J = 17.6 Hz, 1H, allyl terminal alkenyl C H a ),5.21-15(m,2H,H-2',allyl terminal alkenyl C H b ),4.85(d,J=11.2Hz,1H,Bn C H a ),4.68(d,J=11.1Hz,1H,Bn C H b ),4.62(d,J=11.1Hz,1H,Bn C H a ),4.57(d,J=11.2Hz,1H,BnC H b ),4.52–4.45(m,3H,H-16,allyl C H2 ),4.43(d,J=7.9Hz 1H,H-1'),3.80-3.73(m,2H,H-3,H-3'),3.53-3.50(m,2H,H-4',H-5'),3.41-3.38(m,1H,H-6 a '),3.32-3.28(m,1H,H-6 b '),3.05(dd,J=14.4,4.4Hz,1H,H-18),2.13(t,J=13.4Hz,1H,H-19),1.93–1 .82(m,4H),1.80–1.69(m,4H),1.66-1.60(m,3H),1.59(br.s,3H),1.43–1.3 3(m,2H),1.31(s,3H),1.30–1.26(m,1H),1.21–1.14(m,3H),1.10(dd,J=12. 8,3.6Hz,1H),1.03-0.99(m,1H),0.97–0.94(m,6H),0.90–0.88(m,6H)ppm; C 60 H 75 N3O10 Na[M+Na] + HRMS (ESI-TOF) calculated value: 1020.5345, found value: 1020.5350.
[0382]
[0383] 3-O-(6-azido-3,4-di-O-benzyl-6-deoxy-2-O-triethylsilyl-β-D-glucopyranosyl)-16-O-triethylsilyl-28-O-allyl-soap acid ester (118):
[0384] 1 H NMR (400 MHz, CDCl3) δ9.45 (s, 1H, H-23), 7.61-7.56 (m, 1H, Bz), 7.48-7.44 (m, 2H, Bz), 7.36-7.26 (m, 8H, Bn), 7.18-7.12 (m, 2H, Bn), 5.92–5.80 (m, 1H, allyl internal alkenyl C H ),5.40-5.26(m,2H,H-12,allyl terminal alkenyl C H a ), 5.21 (d, J = 10.4 Hz, 1H, allyl terminal alkenyl C H b ),4.85(br.s,2H,Bn C H2 ),4.73(d,J=11.0Hz,1H,Bn C H b ),4.59(br.s,1H,Bn C H a ),4.55–4.41(m,3H,H-16,allyl C H2 ),4.14(d,J=6.2Hz 1H,H-1'),3.99(dd,J=11.1,4.6Hz,1H,H-3),3.50-3.34(m,5H,H-2',H-3',H-4',H-5',H-6 a '),3.32-3.23(m,1H,H-6 b '),3.07-2.99(m,1H,H-18),2.23(t,J=13.3Hz,1H,H-19),1.93–1.80(m,5H),1.78–1.59(m,6H),1.54-1.4 0(m,2H),1.37(br.s,3H),1.32–1.18(m,4H),1.15(br.s,5H),1.06–0.88(m,30H),0.73–0.59(m,15H)ppm; C 65 H 100 N3O9Si2[M+H] +The HRMS (ESI-TOF) calculated value was 1233.6993 and the found value was 1122.7010.
[0385]
[0386] 3-O-(3,4-di-O-benzyl-6-deoxy-6-(11-(4-(4-fluorophenoxy)phenyl)undecanoyl)-2-O-triethylsilyl-β-D-glucopyranosyl)-16-O-triethylsilyl-28-O-allyl-soap acid ester (119a)
[0387] PPh3 (200 mg, 0.76 mmol) was added to a stirred solution of 118 (282 mg, 0.25 mmol) in THF (15 mL). After the mixture was stirred for 12 hours, 0.5 mL of H2O was added and THF was removed at 35°C under reduced pressure. The resulting residue was diluted with CH2Cl2, then washed with H2O, brine, dried over MgSO4, and then concentrated under pressure. A stirred solution of the resulting mixture in THF (7 mL) was treated with a premixed suspension of 11-(4-(4-fluorophenoxy)phenyl)undecanoic acid (187 mg, 0.50 mmol), HBTU (286 mg, 0.75 mmol), DIPEA (132 μL, 0.75 mmol) and THF (7 mL). After the reaction was complete after stirring at 30°C for 2 hours, the residue was concentrated under reduced pressure to remove THF. The residue was diluted with CH2Cl2, washed with H2O, brine, dried over MgSO4, and then concentrated under pressure. The residue was purified by column chromatography (silica gel, EtOAc / hexane = 1 / 8) to give 119a (349 mg, 96%) as a white foamy solid: R f 0.29 (EtOAc / hexane=1 / 5); 1 H NMR (600 MHz, CDCl3) δ9.45 (s, 1H, H-23), 7.33-7.26 (m, 4H), 7.22-7.17 (m, 2H), 7.10 (d, J = 8.5 Hz, 2H), 7.01-6.96 (m, 2H), 6.95-6.91 (m, 2H), 6.86 (d, J = 8.5 Hz, 2H), 5.87–5.81 (m, 1H, internal alkenyl C H ),5.32(t,J=3.7Hz,1H,H-12),5.28(dq,J=17.0Hz&1.2Hz,1H,terminal olefin C H a ),5.18(dt,J=10.6Hz&1.2Hz,1H,terminal olefin C H b ),4.83(q,J=10.5Hz,2H,Bn CH2 ),4.67(d,J=10.5Hz,1H,Bn C H a ),4.56(br.s,1H,H-16),4.51(d,J=10.6Hz,1H,Bn C H b ),4.45(dt,J=19.9Hz&1.4Hz,2H,allyl C H2 ),4.02(d,J=6.8Hz,1H,H-1'),3.93(dd,J=11.2Hz&5,2Hz,1H,H-3),3.59(dt,J=13.9Hz&5.9Hz,1H,H-6 a '),3.47(dt,J=13.9Hz&5.9Hz,1H,H-6 b '),3.43-3.37(m,2H,H-2',H-4'),3.36-3.22(m,2H,H-3',H-5'),3.00(dd,J=14.3Hz&4.0Hz,1H,H-18),2.54(t,J=6.7Hz,2H,C H2 PhOPhF),2.32(t,J=7.6Hz,1H,NHC H a ),2.20(m,1H,H-19 a ),2.15(td,J=13.6Hz&3.1Hz,1H,H-19 b ),1.90–1.85(m,2H),1.84–1.76(m,3H),1.72-1.65(m,3H),1.64-1.53(m,9H),1.48- 1.40(m,2H),1.34(s,2H),1.31-1.23(m,22H),1.16(s,2H),1.13-1.08(m,2H),1.06-1 .02(m,2H),1.00-0.95(m,10H),0.95-0.92(m,4H),0.92-0.91(m,2H),0.91-0.90(m, 3H),0.89-0.88(m,2H),0.87-0.85(m,4H),0.69-0.63(m,8H),0.63-0.57(m,6H)ppm; C 88 H 129 FNO 11 Si2[M+Na] + HRMS + (ESI-TOF) calculated value: 1451.9113, found value: 1451.9095.
[0388]
[0389] 3-O-(3,4-di-O-benzyl-6-decanoyl-6-deoxy-2-O-triethylsilyl-β-D-glucopyranosyl)-16-O-triethylsilyl-28-O-allyl soap acid ester (119b)
[0390] Following the azide reduction and amide formation procedures as described above, 119b was obtained as a white solid in 56% yield: 1 H NMR (600 MHz, CDCl3) δ9.40 (s, 1H, H-23), 7.33-7.24 (m, 5H), 7.24-7.15 (m, 5H), 5.87–5.80 (m, 1H, internal alkenyl C H ), 5.31(t, J=3.4Hz,1H,H-12), 5.30-5.25(m,2H, terminal alkenyl C H a ,N H CH2), 5.18 (dd, J = 10.5 Hz & 1.1 Hz, 1H, terminal alkenyl C H b ),4.87-4.80(m,2H,Bn C H2 ),4.65(d,J=10.4Hz,1H,Bn C H a ),4.58-4.52(m,2H,H-16,Bn C H b ),4.46(qd,J=13.6Hz&1.1Hz,2H,allyl C H2 ),4.07(d,J=6.8Hz,1H,H-1'),3.98-3.91(m,1H,H-3),3.65-3.54(m,1H,H-4'),3.50-3.30(m,4H,H-2' ,H-5',H-6'),3.29-3.22(m,1H,H-3'),3.00(dd,J=14.2Hz&3.8Hz,1H,H-18),2.31(t,J=7.4Hz,1H,NHC H a ),2.20(t,J=12.8Hz,1H,H-19 a),1.90–1.75(m,7H),1.72–1.63(m,4H),1.63-1.58(m,3H),1.45-1.40(m,2H),1.39( s,3H),1.31-1.21(m,16H),1.78-1.15(m,1H),1.12(s,3H),1.06-1.02(m,2H),0.98( t,J=3.7Hz,3H),0.97(s,3H),0.96(br.s,2H),0.95-0.92(m,6H),0.91(br.s,2H),0. 90(s,3H),0.89(s,3H),0.87-0.84(m,6H),0.67-0.62(m,9H),0.62-0.56(m,6H)ppm; C 75 H 120 NO 10 Si2[M+H] + HRMS + (ESI-TOF) calculated value: 1251.8475, found value: 1251.8426.
[0391]
[0392] 3-O-{2-O-triethylsilyl-3,4-di-O-benzyl-6-[9-(4-phenoxy-phenyl)nonylamide]-6-deoxy-β-D-glucopyranosyl}-16-O-triethylsilyl-28-O-allyl soap acid ester (119c)
[0393] Following the azide reduction and amide formation procedures as described above, 119b was obtained as a white solid in 56% yield: 1 H NMR (400MHz, CDCl3) δ9.45 (s, 1H, H-23), 7.31-7.21 (m, 2H), 7.10 (d, J = 8.4Hz, 2H), 7.04 (t ,J=7.4Hz,2H),6.96(dd,J=8.7Hz&1.0Hz,2H),6.90(d,J=8.5Hz,2H),5.89–5.80(m,2H,amide N H , internal alkenyl C H ),5.32(t,J=3.7Hz,1H,H-12),5.28(d,J=18.2Hz,1H,terminal alkenyl C H a ),5.17(dd,J=10.4Hz&1.3Hz,1H,terminal olefin C H b ),4.83(q,J=11.7Hz,2H,Bn C H2 ),4.67(d,J=10.4Hz,1H,Bn CH a ),4.57(br.s,1H,H-16),4.51(d,J=10.4Hz,1H,Bn C H b ),4.45(ddt,J=11.4Hz&5.6Hz&1.1Hz,2H,allyl C H2 ),4.02(d,J=6.8Hz,1H,H-1'),3.94(dd,J=10.2Hz&5.8Hz,1H,H-3),3.63-3.56(m,1H),3.51- 3.39(m,3H),3.32-3.21(m,2H),3.00(dd,J=14.2Hz&3.9Hz,1H,H-18),2.55(t,J=7.5Hz,2H,C H2 PhOPh), 2.33-2.13(m,3H,H-19 a ,NHCOC H2 ),1.91-1.83(m,3H),1.83–1.76(m,3H),1.75-1.52(m,11H),1.49-1.40(m,2H),1.34(s,3H),1.29(b r.s,11H),1.23(s,3H),1.15(s,3H),1.14-1.00(m,4H),0.98-0.86(m,31H),0.69-0.57(m,16H); BBD 13 C NMR(100MHz, CDCl3)δ207.5(C-23),176.4(C-28),173.1(NH C O), 157.7, 154.8, 143.5 (C-13), 138.5, 137.8, 137.5, 132.2, 129.6 129.4, 128.4, 128.2, 128.1, 127.9, 127.2, 126.8, 122.7, 121.7 (C-12), 118.9, 118.4, 117.8 (allyl terminal olefinic C H2),101.0(C-1'),85.5(C-3),79.3,79.0,75.2(Bn C H2),75.0,75.0(Bn CH2),74.9(C-16),73.1,65.0(C-6'),54.5,48.9,48.8,46.6,46.3,41.3,40.4,40.0,39.5,38.1,36.7,36.0,35.2,35.1,34.5,33.8,32.7 C 86 H 125 NO 11 Si2[M+H] + HRMS + (ESI-TOF) calculated value: 140.8894, found value: 1405.8984.
[0394]
[0395] 3-O-(3,4-di-O-benzyl-6-deoxy-6-(11-(4-(4-fluorophenoxy)phenyl)undecanoyl)-2-O-triethylsilyl-β-D-glucopyranosyl)-16-O-triethylsilyl-saponic acid (120a)
[0396] Premixed formic acid (129 μL, 3.4 mmol) / Et3N (456 μL, 3.2 mmol) in 1,4-dioxane (2 mL) and Pd(OAc)2 (18 mg, 0.08 mmol) in 1,4-dioxane (2 mL) were added to a stirred solution of 119a (237 mg, 0.16 mmol) and PPh3 (107 mg, 0.41 mmol) in 1,4-dioxane (4 mL) at room temperature. The reaction mixture was stirred for 12 hours and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, EtOAc / hexane = 1 / 4 to 1 / 2) to give 120a (186 mg, 81%) as a white solid: R f 0.36 (EtOAc / hexane=1 / 2); 1 H NMR(600MHz, CDCl3)δ9.41(s,1H,H-23),7.27-7.26(m,1H),7.25(br.s,1H),7.34-7.25(m, 6H),7.06(d,J=8.4Hz,1H),6.98-6.64(m,6H),6.82(d,J=8.4Hz,1H),5.82(t,J=5.2Hz,amide N H),5.30(br.s,1H,H-12),4.83-4.76(m,2H,Bn C H2 ),4.63(d,J=10.3Hz,1H,Bn C H a ),4.50-4.53(m,2H,H-16,Bn C H b ),3.98(d,J=6.6Hz,1H,H-1'),3.90(dd,J=11.2Hz&4.9Hz,1H,H-3),3.60-3.53(m,1H,H-6 a '),3.48-3.41(m,1H,H-6 b '),3.41-3.34(m,2H,H-2',H-4'),3.27-3.19(m,2H,H-3',H-5'),2.90(dd,J=14.1Hz&3.6Hz,1H,H-18),2.50(t,J=7.6Hz,2H,C H2 PhOPhF),2.31(t,J=7.4Hz,1H,NHC H a ),2.19-2.09(m,3H),1.87–1.68(m,7H),1.68-1.59(m,3H),1.59-1.49(m,4H), 1.44-1.36(m,2H),1.30(s,3H,H-27),1.28-1.16(m,17H),1.11(s,3H,H-29),1. 09-1.08(m,1H),1.03-0.97(m,2H),0.94(s,2H),0.93(s,3H),0.92(s,3H),0.8 9-0.87(m,5H),0.87(s,3H),0.85(s,2H),0.82(s,3H),0.66-0.53(m,17H)ppm; C 85 H 125 FNO 11 Si2[M+H] + HRMS + (ESI-TOF) calculated value: 1411.8800, found value: 1411.8742.
[0397]
[0398] 3-O-(2-O-triethylsilyl-3,4-di-O-benzyl-6-decylamino-6-deoxy-β-D-glucopyranosyl)-16-O-triethylsilyl-28-O-allyl-soap acid (120b)
[0399] Premixed formic acid (129 μL, 3.4 mmol) / Et3N (456 μL, 3.2 mmol) in 1,4-dioxane (2 mL) and Pd(OAc)2 (18 mg, 0.08 mmol) in 1,4-dioxane (2 mL) were added to a stirred solution of 119b (200 mg, 0.16 mmol) and PPh3 (107 mg, 0.41 mmol) in 1,4-dioxane (4 mL) at room temperature. The reaction mixture was stirred for 12 hours and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, EtOAc / hexane = 1 / 4 to 1 / 2) to give 120b (154 mg, 80%) as a white solid: R f 0.36 (EtOAc / hexane=1 / 2); 1 H NMR (600 MHz, CDCl3) δ9.45 (s, 1H, H-23), 7.32-7.24 (m, 6H), 7.24-7.19 (m, 4H), 5.85 (t, J = 5.0 Hz, amide N H ),5.30(t,J=3.7Hz 1H,H-12),4.86-4.80(m,2H,Bn C H2 ),4.66(d,J=10.4Hz,1H,Bn C H a ),4.54-4.49(m,2H,H-16,Bn C H b ),4.03(d,J=6.8Hz,1H,H-1'),3.94(dd,J=11.2Hz&4.9Hz,1H,H-3),3.59-3.55(m,1H),3.52-3.46(m,1H ),3.44-3.38(m,2H),3.31-3.24(m,2H),2.94(dd,J=14.2Hz&4.0Hz,1H,H-18),2.31(t,J=7.5Hz,1H,NHC H a ),2.19-2.09(m,3H),1.87–1.68(m,7H),1.68-1.59(m,3H),1.59-1.49(m,4H) ,1.44-1.36(m,2H),1.30(s,3H,H-27),1.28-1.16(m,17H),1.11(s,3H),1.09 -1.08(m,1H),1.03-0.97(m,2H),0.94(s,2H),0.93(s,3H),0.92(s,3H),0.89 -0.87(m,5H),0.87(s,3H),0.85(s,2H),0.82(s,3H),0.66-0.53(m,17H); BBD 13C NMR(150MHz,CDCl3)δ207.4(C-23),182.7(C-28),173.3(NH C O),143.3(C-13),138.6,137.6,128.4,128.2,126.9,121.8(C-12),101.1(C-1'),85.5,79.5,79.2(C-3),75.2(Bn C H2),75.0(Bn C H2),74.9,74.8(C-16),73.2,54.5,49.0,48.6,46.6,46.3,41.3,40.1(C-6'),39.5(C-8),38.2,36.8(-NHCO C H2-),36.1,35.1,34.6,34.0,32.6,32.,31.8,31.6,30.5,29.5,29.4,29.3,29.2,29.0 ,26.4,25.8,24.7,24.2,23.2,22.7,20.1,16.9,15.5,14.1,10.4,7.1,7.0,5.1,5.0ppm ppm; C 72 H 116 NO 10 Si2[M+H] + HRMS + (ESI-TOF) calculated value: 1210.8132, found value: 1210.8108.
[0400]
[0401] 3-O-{2-O-triethylsilyl-3,4-di-O-benzyl-6-[9-(4-phenoxy-phenyl)nonylamide]-6-deoxy-β-D-glucopyranosyl}-16-O-triethylsilyl-28-glucose acid (120c)
[0402] Premixed formic acid (129 μL, 3.4 mmol) / Et3N (456 μL, 3.2 mmol) in 1,4-dioxane (2 mL) and Pd(OAc)2 (18 mg, 0.08 mmol) in 1,4-dioxane (2 mL) were added to a stirred solution of 119c (224 mg, 0.16 mmol) and PPh3 (107 mg, 0.41 mmol) in 1,4-dioxane (4 mL) at room temperature. The reaction mixture was stirred for 12 hours and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, EtOAc / hexane = 1 / 4 to 1 / 2) to give 120c (154 mg, 80%) as a white solid: Rf 0.36 (EtOAc / hexane=1 / 2); 1 H NMR (400MHz, CDCl3) δ9.45 (s, 1H, H-23), 7.31-7.21 (m, 2H), 7.10 (d, J = 8.4Hz, 2H), 7.04 (t ,J=7.4Hz,2H),6.96(dd,J=8.7Hz&1.0Hz,2H),6.90(d,J=8.5Hz,2H),5.89–5.80(m,2H,amide N H , internal alkenyl C H ),5.32(t,J=3.7Hz,1H,H-12),4.83(q,J=11.7Hz,2H,Bn C H2 ),4.67(d,J=10.4Hz,1H,Bn C H a ),4.57(br.s,1H,H-16),4.51(d,J=10.4Hz,1H,Bn C H b ),4.02(d,J=6.8Hz,1H,H-1'),3.94(dd,J=10.2Hz&5.8Hz,1H,H-3),3.63-3.56(m,1H),3.51- 3.39(m,3H),3.32-3.21(m,2H),3.00(dd,J=14.2Hz&3.9Hz,1H,H-18),2.55(t,J=7.5Hz,2H,C H2 PhOPh), 2.33-2.13(m,3H,H-19 a ,NHCOC H2 ),1.91-1.83(m,3H),1.83–1.76(m,3H),1.75-1.52(m,11H),1.49-1.40(m,2H),1.34(s,3H),1.29(b r.s,11H),1.23(s,3H),1.15(s,3H),1.14-1.00(m,4H),0.98-0.86(m,31H),0.69-0.57(m,16H); BBD 13 C NMR(100MHz,CDCl3)δ207.5(C-23),182.0(C-28),173.2(NH CO),157.7,154.8,143.5(C-13),138.5,137.5,132.2,129.6 129.4,128.4,128.2,128.1,127.9,127.2,126.8,122.7,121.7(C-12),118.9,118.4,101.0(C-1'),85.5(C-3),79.3,79.0,75.2(Bn C H2),75.0,75.0(Bn C H2),74.9(C-16),73.1,65.0(C-6'),54.5,48.9,48.8,46.6,46.3,41.3,40.4,40.0,39.5,38.1,36.7,36.0,35.2,35.1,34.5,33.8,32.7 C 83 H 122 NO 11 Si2[M+H] + HRMS + (ESI-TOF) calculated value: 1364.8551, found value: 1364.8567.
[0403]
[0404] 3-O-(3,4-di-O-benzyl-6-deoxy-6-(11-(4-(4-fluorophenoxy)phenyl)undecanoyl)-2-O-triethylsilyl-β-D-glucopyranosyl)-28-O-(2,3,4-tri-O-acetyl-β-D-xylopyranosyl-(1→4)-2,3-di-O-acetyl-α-L-rhamnopyranosyl-(1→2)-3,4-O-isopropylidene-β-D-fucopyranosyl)-16-O-triethylsilyl soap ester (121a)
[0405] At -75 °C under N2 gas environment, BF3·OEt2 (about 48%, 4 μL, 24 μmol) was added to 10 (40 mg, 48 μmol), 120a (50 mg, 35 μmol) and activated The molecular sieve powder was stirred in anhydrous CH2Cl2 (0.5 mL). After 0.5 hours, the reaction was quenched with Et3N and heated to room temperature. The resulting mixture was diluted with CH2Cl2 and filtered through a 5 μm filter paper. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; EtOAc / hexane = 1 / 5 to 1 / 2) to give 121a (37 mg, 50%) as a white solid foam. f 0.56 (EtOAc / hexane=1 / 1); 1 HNMR (600MHz, CDCl3) δ9.49 (s, 1H, H-23), 7.33-7.26 (m, 6H), 7.26-7.21 (m, 4H), 7.12 (d, J = 8.4Hz, 1H), 7 .02-7.00(m,2H),6.96-6.93(m,2H),6.88(d,J=8.6Hz,1H),6.82(d,J=8.4Hz,1H),5.86(t,J=5.1Hz,amide N H ),5.41(d,J=7.6Hz,1H,H-1”),5.33(t,J=3.4Hz,1H,H-12),5.25(dd,J=3.4Hz&1.3Hz,1H,H-2”’),5.20(dd,J=9.8Hz&3.5Hz, 1H,H-3”’),5.13(t,J=9.4Hz,1H,H-3””),4.98(d,J=1.3Hz,1H,H-1””),4.97-4.94(m,1H,H-4””),4.88-4.82(m,3H,H-2””,Bn C H2 ),5.68(d,J=10.4Hz,1H,Bn C H a ),4.63(d,J=7.7Hz,1H,H-1””),4.53(d,J=10.4Hz,1H,Bn C H b ),4.50(br.s,1H,H-16),4.17(t,J=6.0Hz,1H,H-3”),4.12-4.10(m,1H,H-5 a ””),4.04-4.00(m,2H,H-1',H-4”),3.98-3.94(m,1H,H-3),3.89-3.84(m,1H,H -5”),3.84-3.79(m,1H,H-5”’),3.68-3,64(m,1H,H-2”),3.64-3.59(m,2H,H-6 a ',H-4'),3.49(dt,J=13.9Hz,&3.8Hz,1H H-6 b'),3.45-3.39(m,2H,H-2',H-4'),3.36-3.24(m,3H,H-3',H-5',H-5 b ""),2.93(dd,J=14.2Hz&3.8Hz,1H,H-18),2.56(t,J=7.6Hz,2H,C H2 PhOPhF), 2.22(m,1H,H-19 a ),2.17(td,J=7.5Hz&3.4Hz,2H,-NHCOC H2 -), 2.13(s, 3H), 2.06(s, 3H), 2.03(s, 3H), 2.01(s, 3H), 1.98(s, 3H), 1.90-1.86(m, 2H), 1.86-1.82(m, 1H), 1.83-1.76(m, 3H), 1.74-1.67(m, 4H), 1.67-1.56(m, 5H), 1.52(s, 3H, isopropylidene C H3 ),1.52-1.49(m,1H),1.34(s,3H,H-27),1.33(s,3H,isopropylidene C H3 ),1.30-1.25(m,24H),1.23-1.32(m,1H),1.19(s,3H,H-24),1.13-1.10( m,1H),1.05-1.03(m,1H),1.03-1.01(m,1H),1.01-0.96(m,15H,H-25,TES C 115 H 167 FNO 28 Si2[M+H] + HRMS + (ESI-TOF) calculated value 2086.1223, found value 2086.1222.
[0406]
[0407] 3-O-(3,4-di-O-benzyl-6-decanoyl-6-deoxy-β-D-glucopyranosyl)-28-O-(2,3,4-tri-O-acetyl-β-D-xylopyranosyl-(1→4)-2,3-di-O-acetyl-α-L-rhamnopyranosyl-(1→2)-3,4-O-isopropylidene-β-D-fucopyranosyl)-16-O-triethylsilyl saponate (121b)
[0408] BF3·OEt2 (about 48%, 4 μL, 24 μmol) was added to 10 (40 mg, 48 μmol), 120b (42 mg, 35 μmol) and activated carbon at -75 °C under N2 gas environment. Molecular sieve powder was stirred in anhydrous CH2Cl2 (0.5 mL). After 0.5 hours, the reaction was quenched with Et3N and heated to room temperature. The resulting mixture was diluted with CH2Cl2 and filtered through a 5 μm filter paper. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; EtOAc / hexane = 1 / 5 to 1 / 2) to give 121b (37 mg, 50%) as a white solid foam. f 0.56 (EtOAc / hexane = 1 / 1); 121b α / β mixture was obtained as a white solid foam.
[0409]
[0410] 3-O-(2-O-triethylsilyl-3,4-di-O-benzyl-6-[9-(4-phenoxy-phenyl)nonanamido}-28-O-(2,3,4-tri-O-acetyl-β-D-xylopyranosyl-(1→4)-2,3-di-O-acetyl-α-L-rhamnopyranosyl-(1→2)-3,4-O-isopropylidene-β-D-fucopyranosyl)-16-O-triethylsilyl soap ester (121c)
[0411] At -75 °C under N2 gas environment, BF3·OEt2 (about 48%, 4 μL, 24 μmol) was added to 10 (40 mg, 48 μmol), 120c (42 mg, 35 μmol) and activated Molecular sieve powder was stirred in anhydrous CH2Cl2 (0.5 mL). After 0.5 hours, the reaction was quenched with Et3N and heated to room temperature. The resulting mixture was diluted with CH2Cl2 and filtered through a 5 μm filter paper. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; EtOAc / hexane = 1 / 5 to 1 / 2) to give 121c (37 mg, 50%) as a white solid foam. f0.56 (EtOAc / hexane = 1 / 1); 121c α / β mixture was obtained as a white solid foam.
[0412]
[0413] 3-O-(6-deoxy-6-(11-(4-(4-fluorophenoxy)phenyl)undecanoyl)-β-D-glucopyranosyl)-28-O-(β-D-xylopyranosyl-(1→4)-α-L-rhamnopyranosyl-(1→2)-β-D-fucopyranosyl) saponate (122a)
[0414] A suspension of 121a (32 mg, 15 μmol) and 10% Pd(OH)2 / C (5 mg, 4 μmol) in THF / MeOH=4 / 1 (1.5 mL) was stirred at room temperature and 1 atm H2 gas environment. The reaction mixture was stirred for 12 hours. Precooled TFA / H2O=4 / 1 (0.5 mL) was added to a stirred solution of crude tetrasaccharide saponin in CH2Cl2 (0.5 mL) at 0°C and stirred for 30 minutes. The solvent was evaporated at 0°C and reduced pressure (<1 Torr), and then dried at room temperature and high vacuum for 1 hour. K2CO3 (40 mg, 300 μmol) was added to a stirred solution of the residue in MeOH (1 mL) and stirred for 12 hours. The suspension was filtered, concentrated, and then purified by HPLC (HPLC column: SUPELCO Ascentis C18 25 cm×10 mm, 5 μm; mobile phase: gradient from 20% ACN / H2O to 90% ACN / H2O in 25 min, then 90% ACN / H2O isocratic for 15 min; flow rate: 5 mL / min) to afford the product 122a (3.6 mg) as a white solid in 16% yield: 1 H NMR (600MHz, CD3OD) δ9.41 (s, 1H, H-23), 7.16 (d, J = 8.4Hz, 2H), 7.07 (t, J = 8.8Hz, 2H) ,6.98-6.95(m,4H),6.87(d,J=8.6Hz,2H),5.40(d,J=1.4Hz,1H,H-1”'),5.31(br.s,1 H,H-12),5.29(d,J=8.2Hz,1H,H-1”),4.50-4.47(m,2H,H-16,H-1””),4.14(d,J=7.7H z,1H,H-1'),3.91-3.89(m,1H,H-2"'),3.86-3.78(m,5H,H-3,H-2",H-3"',H-5"',H-5 a”), 3.68 - 3.64 (m, 2H, H - 3”, H - 5”), 3.60 - 3.56 (m, 1H, H - 6 a ’), 3.56 - 3.53 (m, 2H, H - 4”, H - 4”’), 3.49 - 3.42 (m, 2H, H - 5’, H - 4””), 3.29 - 3.25 (m, 3H, H - 3’, H - 6 b ’, H - 3””), 3.23 - 3.16 (m, 2H, H - 2””, H - 5 b ””), 3.09 - 3.05 (m, 2H, H - 2’, H - 4’), 2.45 (dd, J = 13.4Hz & 3.2Hz, H - 18), 2.60 (t, J = 7.6Hz, 2H, C H2 PhOPhF), 2.30 (m, 1H, H - 19 a ), 2.21 (t, J = 7.6Hz, 2H, - NHCOC H2 -), 1.99 - 1.95 (m, 1H), 1.95 - 1.91 (m, 1H), 1.80 - 1.71 (m, 4H), 1.70 - 1.65 (m, 1H), 1.64 - 1.59 (m, 4H), 1.55 - 1.50 (m, 2H) 1.49 - 1.44 (m, 1H), 1.40 (s, 3H, H - 27), 1.36 - 1.29 (m, 19H, H - 6”’, carbon chain C H2 ×8), 1.20 (d, J = 6.5Hz, 3H, H - 6”), 1.12 (s, 3H, H - 24), 1.10 - 1.06 (m, 1H), 1.01 (s, 3H, 25), 0.99 - 0.96 (m, 1H), 0.93 (s, 3H, H - 30), 0.92 - 0.89 (m, 1H), 0.87 (s, 3H, H - 29), 0.77 (s, 3H, H - 26); BBD 13 C NMR (150MHz, CD3OD) δ 209.3 (C - 23), 177.1 (C - 28), 176.7 (amide NH CO),160(d,J=240Hz),156.8,155.1,144.9(C-13),139.2,130.8,123.1(C-12),121.2(d,J=8Hz),119.5,117.2(d,J=23Hz),107.0,(C-1””) ,105.0(C-1'),101.1(C-1”'),95.2(C-1”),84.0(C-4”’),83.4(C-3) ,78.2(C-3””),77.6(C-3’),76.7(C-3”),76.1(C-2””),75.6(C-2’),7 5.2(C-5'),74.6(C-16),74.0(C-2”),73.6(C-4”),73.3(C-4’),72.7 (C-5”),72.2(C-3”’),71.9(C-2”’),71.1(C-4””),68.7(C-5”’),67.3 (C-5""),56.1(C-5),50.0(C-17),48.1(C-19,C-9),42.8(C-14),42.4(C-18),41.9(C-6'),41.1(C-8),39.6(C-1),37.3(C-1),36.8(-NHCO C H2-),37.1(C-10),,36.5(C-21),36.2(- C H2PhOPhF),33.6(C-16),3.4(C-29),32.9(C-6),32.0(C-22),31.4(C-20),30.8,30.7,30.6,30.4,27.3(C-2),20.2(C-27),26 C 76 H 112 FNO 23 Si2Na[M+H] + HRMS + (ESI-TOF) calculated value: 1448.7501, found value: 1448.7558.
[0415]
[0416] 3-O-{6-decanoyl-6-deoxy-β-D-glucopyranosyl}-28-O-[β-D-xylopyranosyl-(1→4)-α-L-rhamnopyranosyl-(1→2)-β-D-fucopyranosyl] saponate (122b)
[0417] A suspension of 121b (28 mg, 15 μmol) and 10% Pd(OH)2 / C (5 mg, 4 μmol) in THF / MeOH=4 / 1 (1.5 mL) was stirred at room temperature and 1 atm H2 gas environment. The reaction mixture was stirred for 12 hours. Precooled TFA / H2O=4 / 1 (0.5 mL) was added to a stirred solution of crude tetrasaccharide saponin in CH2Cl2 (0.5 mL) at 0°C and stirred for 30 minutes. The solvent was evaporated at 0°C and reduced pressure (<1 Torr), and then dried at room temperature and high vacuum for 1 hour. K2CO3 (40 mg, 300 μmol) was added to a stirred solution of the residue in MeOH (1 mL) and stirred for 12 hours. The suspension was filtered, concentrated, and then purified by HPLC (HPLC column: SUPELCO Ascentis C18 25 cm×10 mm, 5 μm; mobile phase: gradient from 20% ACN / H2O to 90% ACN / H2O in 25 min, then 90% ACN / H2O isocratic for 15 min; flow rate: 5 mL / min) to afford the product 122b (2.3 mg) as a white solid in 13% yield: 1H NMR(600MHz,CD3OD)δ9.42(s,1H,H-23),5.40(s,1H,H-1”'),5.31(br.s,1H,H-12),5.29(d,J=8.2H z,1H,H-1”),4.51-4.46(m,2H,H-16,H-1””),4.15(d,J=7.7Hz,1H,H-1'),3.93-3.90(m,1H),3.87-3 .78(m,5H),3.71-3.66(m,2H,),3.60-3.53(m,3H),3.49-3.41(m,2H),3.29-3.25(m,3H),3.24-3.1 7(m,2H),3.09-3.04(m,2H),2.95(d,J=14.1Hz,1H,H-18),2.30(m,1H,H-19a),2.21(t,J=7.6Hz,2H,
[0418] -NHCOCH2-),2.04-1.88(m,3H),1.69-1.60(m,3H),1.55-1.44(m,4H),1.40(s,3H,H-27),1.35-1.29(m,18H),1.20(d,J=6.5Hz,3H,H -6"),1.12(s,3H),1.10-1.06(m,1H),1.01(s,3H),0.99-0.96(m,1H),0.95(s,3H),0.93-0.89(m,3H),0.88(s,3H),0.77(s,3H); BBD 13C NMR (150MHz, CD3OD) δ209.4 (C-23), 177.2 (C-28), 176.7 (amide NHCO), 144.9 (C-13), 123.1 (C-12), 106.9, (C-1"), 105.0 (C-1'), 101.1 (C-1"), 95.2 (C-1"), 84.0 (C-4"), 83.3 (C-3), 78.1 (C-3"), 77.6, 76.6, 76.1, 75.6, 75., 74.6 (C-16), 74.0, 73.6, 73.3, 72.7, 72.2, 71.9, 71.0, 68.7, 67.3, 56.1, 50.0, 48.1, 42.8, 42.3 (C-18), 41.8 (C-6'), 41.1, 39.6, 37.3, 37.1, 36.8 (-NHCOCH2-), 36.5, 36.4, 33.6, 33.4, 33.1, 32.0, 31.3, 30.8, 30.7, 30.6, 30.5, 27.3, 27.2, 26.0, 24.8, 24.5, 23.8, 21.6, 18.3 (C-6"'), 17.7, 16.5 (C-6"), 16.3, 14.6 (carbon chain end -CH3), 10.6 ppm; C 63 H 104 NO 22 [M+H] + HRMS + (ESI-TOF) calculated value: 1226.7059, found value: 1226.7059.
[0419]
[0420] 3-O-{[9-(4-phenoxy-phenyl)nonanamido]-6-deoxy-β-D-glucopyranosyl}-28-O-[β-D-xylopyranosyl-(1→4)-α-L-rhamnopyranosyl-(1→2)-β-D-fucopyranosyl] saponate (122c)
[0421] A suspension of 121c (20 mg, 15 μmol) and 10% Pd(OH)2 / C (5 mg, 4 μmol) in THF / MeOH=4 / 1 (1.5 mL) was stirred at room temperature and 1 atm H2 gas environment. The reaction mixture was stirred for 12 hours. Precooled TFA / H2O=4 / 1 (0.5 mL) was added to a stirred solution of crude tetrasaccharide saponin in CH2Cl2 (0.5 mL) at 0°C and stirred for 30 minutes. The solvent was evaporated at 0°C and reduced pressure (<1 Torr), and then dried at room temperature and high vacuum for 1 hour. K2CO3 (40 mg, 300 μmol) was added to a stirred solution of the residue in MeOH (1 mL) and stirred for 12 hours. The suspension was filtered, concentrated, and then purified by HPLC (HPLC column: SUPELCO Ascentis C18 25 cm×10 mm, 5 μm; mobile phase: gradient from 20% ACN / H2O to 90% ACN / H2O in 25 min, then 90% ACN / H2O isocratic for 15 min; flow rate: 5 mL / min) to afford the product 122c (6.2 mg) as a white solid in 30% yield: 1 H NMR (600MHz, CD3OD) δ9.41(s,1H,H-23),7.32(t,J=8.2Hz,2H),7.17(d,J=8.4Hz,2H),7.06(t ,J=7.5Hz,1H),6.94(d,J=8.2Hz,2H),6.90(d,J=8.2Hz,2H),5.40(br.s,1H,H-1”'),5.31(br. s,1H,H-12),5.28(d,J=8.2Hz,1H,H-1”),4.50-4.46(m,2H,H-16,H-1””),4.15(d,J=7.8Hz,1H ,H-1'),3.92-3.90(m,1H,H-2”'),3.87-3.79(m,5H),3.67-3.64(m,2H),3.60-3.56(m,1H,H-6 a '),3.56-3.53(m,2H),3.49-3.42(m,1H,H-4””),3.36-3.33(m,1H),3.30-3. 16(m,5H),3.09-3.05(m,2H),2.97-2.92(m,1H,H-18),2.61(t,J=7.8Hz,2H,C H2 PhOPh), 2.30(m,1H,H-19 a ),2.21(t,J=7.7Hz,2H,-NHCOC H2-),1.98-1.88(m,5H),1.80-1.69(m,4H),1.67-1.59(m,4H),1.55-1.43(m ,3H),1.40(s,3H,H-27),1.39-1.33(m,10H),1.31(d,J=6.2Hz,3H,H-6”',) ,1.29(s,1H),1.20(d,J=6.4Hz,3H,H-6”),1.13(s,3H),1.10-1.03(m,2H), 1.00(s,3H),0.98-0.94(m,1H),0.92(s,3H),0.85(s,3H),0.77(s,3H); BBD 13 C NMR (150 MHz, CD3OD) δ 209.4 (C-23), 177.2 (C-28), 176.7 (amide NH C O),159.3,156.5,155.1,144.9(C-13),139.2,130.8,124.0,123.1(C-12),120.0,119.4,1 07.0,(C-1””),104.9(C-1’),101.1(C-1”’),95.2(C-1”),84.2,83.3(C-3),78.2,77.7(C- 3'),76.6,76.2,75.6,75.3,74.6(C-16),74.0,73.6,73.3,72.7,72.3,71.9,71.1,68.8,6 7.2,56.1,50.1,48.1,42.8,42.4(C-18),41.9(C-6'),41.2,39.6,37.1,37.3,36.5(-NHCO C H2-),36.5,36.2(- C H2PhOPh),33.6,33.4,32.8,31.9,31.3,30.7,30.5,30.3,27.3,27.2,26 .0,25.0,24.6,21.6,,18.3(C-6”'),17.8,16.5(C-6”),16.4,10.6ppm; C 74 H 110 NO 23 [M+H] + HRMS + (ESI-TOF) calculated value: 1380.7463, found value: 1380.7476.
[0422] Experimental Example I - Immunological Evaluation of Saponins
[0423] Materials and methods
[0424] Adjuvant stock solution
[0425] The sample powder was dissolved in DMSO to 20 mg / mL. Before administration, the stock solution with 0.5% (w / w) Tween 20 was diluted to 0.5 mg / mL and filtered through PTFE (0.1 μm). PEK lyophilized cake (1 mg / mL PEK and 0.5 mg / mL adjuvant) or OVA (100 mg) was dissolved back, and the placebo was PBS.
[0426] Animals and vaccinations
[0427] C57BL / 6 mice were obtained from the Taiwan Experimental Animal Center, Taiwan Research Institute, Taiwan Province, China. 100 μL of vaccine was inoculated subcutaneously into mice aged 4 to 8 weeks, once a week for three weeks. Mice were sacrificed one week after the third vaccination, and serum and spleen cells were collected.
[0428] Splenocyte sample preparation and flow cytometric analysis
[0429] Spleen tissue was isolated from mice and processed into a single cell suspension using a PP microcentrifuge pestle. 7 / 2mL of spleen cells were inoculated in 6-well plates with or without HPV 16 E7-peptide stimulation and cultured in a CO2 incubator for 2 hours. After 2 hours, cells were treated with protein transport inhibitors monensin (Invitrogen, catalog number 00-4505-51) and brefeldin (Invitrogen, catalog number 00-4506-51) for 4 hours at 37°C. Afterwards, cells were collected, washed twice with PBS, and then stained for surface CD3 (BioLegend, catalog number 100290), CD4 (Invitrogen, catalog number 56-0041-82), CD8 (Invitrogen, catalog number 12-0081-82) at 4°C for 30 minutes. After washing, cells were fixed for 30 minutes at room temperature using IC fixation buffer (Invitrogen, catalog number 00-8222-49), then washed in permeabilization buffer (Invitrogen, catalog number 00-8333-56) and stained with IFNγ antibody (Invitrogen, catalog number 53-7311-82). 20 million cell events were acquired on a flow cytometer (BackmanCoulter Gallions). Flow data were analyzed using Kaluza software version 1.2. Populations were first circled on CD3 + T cells, and then selected on live monocytes using forward and side scatter. Subsequently, a sub-selection was performed on CD4+ / IFNγ + Double positive cells or CD8 + / IFNγ + Double positive cells.
[0430] Enzyme-Linked ImmunoSpot (ELISpot)
[0431] MabTech Mouse IFNγ ELISpot PLUS Kit (3321-4HPW-2) and IL2 ELISpot PLUS Kit (3441-4HPW-2) were used to assess IFNγ and IL2 production. Cells were pre-plated overnight with capture antibodies according to the manufacturer's instructions. Splenocytes were isolated from vaccinated animals and erythrocytes were lysed. 2 x 10 6 / mL resuspend the cells and combine 100 μL of cells with 100 μL of stimulation master mix. The mixture includes 10 μg / mL HPV16E7-pET32a, 2 μg / mL HPV16E7-peptide. The cells were cultured in ELISPOT plates at 37°C for 24 hours and ELISpot analysis was performed according to the manufacturer's instructions. The microplates were analyzed using AIDvSpot Spectrum. The values were calculated as the average of three replicates.
[0432] Enzyme-linked immunosorbent assay (ELISA)
[0433] PEK plates were incubated overnight in 96-well plates (1 μg / well, Nunc Maxisorb) at 4°C with 100 mM carbonate buffer. Plates were blocked with blocking buffer (5% milk in PBS) for at least 1 hour at 37°C and then washed with PBS + 0.05% Tween 20. Serum samples were added to the plates in 2-fold serial dilutions. After 1 hour, the plates were washed with PBS + 0.05% Tween 20 and secondary antibodies were added. Peroxide-labeled goat anti-mouse IgG1 (Southernbiotech, catalog number 1070-05) and goat anti-mouse IgG2b (Southernbiotech, catalog number 1090-05) diluted 1:4000 in 1% milk-PBS were added for 1 hour. The plates were washed with PBS + 0.05% Tween 20 and developed with TMB chromogen solution (Invitrogen, catalog number 00-2023) for 15 minutes, followed by treatment with stop solution (0.2 NH2SO4). The absorbance at 405 nm was recorded.
[0434] Splenocyte sample preparation and flow cytometric analysis (memory T cells)
[0435] Spleen tissue was isolated from mice and processed into a single cell suspension using a PP microcentrifuge pestle. 7 / 2mL spleen cells were seeded on a 6-well plate and cultured in a CO2 incubator for 2 hours. After 2 hours, the cells were stimulated with or without E7 peptide at 37°C for 2 hours, and then treated with protein transport inhibitors monensin (Invitrogen, catalog number 00-4505-51) and brefeldin (Invitrogen, catalog number 00-4506-51) for 4 hours at 37°C. Afterwards, the cells were collected, washed twice with PBS, and then stained for surface CD3 (BioLegend, catalog number 100222), CD4 (BioLegend, catalog number 100540), CD8 (Invitrogen, catalog number 11-0081-86), CD44 (BioLegend, catalog number 103008), CD62L (BioLegend, catalog number 104412) at 4°C for 30 minutes. After washing, cells were fixed for 30 minutes at room temperature using IC fixation buffer (Invitrogen, catalog number 00-8222-49), then washed in permeabilization buffer (Invitrogen, catalog number 00-8333-56), and stained with IFNγ antibody (Invitrogen, catalog number 48-7311-82), IL-2 antibody (Invitrogen, catalog number 25-7021-82), and TNFα antibody (Invitrogen, catalog number 48-7321-82). 1.5 million cell events were acquired on a flow cytometer (Backman Coulter Gallions). Flow data were analyzed using Kaluza software version 1.2. Populations were first gated on live monocytes using forward and side scattered light, and then on CD3 + / CD4 + or CD3 + / CD8 + Next, select CD62L - / CD44 + Memory T cells. + / IFNγ + 、CD8 + / IFNγ + CD4 + / IL-2 + 、CD8 + / IL-2 + 、CD4 + / TNFα + and CD8 + / TNFα + Double positive cells were selected.
[0436] result
[0437] The mouse vaccination model uses the antigen PE-E7-K3 (PEK), a fusion protein composed of Pseudomonas exotoxin, human papillomavirus protein E7 (HPV16E7) and KDEL3 peptide sequence, to evaluate the effect of adjuvants. Five mice per group were immunized three times with 50 μg of saponin and PEK (100 μg) every three weeks. The ability of the saponins of the present invention and GPI-0100 (as a positive control) to regulate immune responses was then analyzed by flow cytometry, ELISpot and ELISA.
[0438] Specific T cell activation
[0439] One week after the third administration, spleen cells of mice were collected and the effects of these saponin adjuvants with PEK antigen on the production of cytokines (IFNγ and IL-2) were measured by ELISpot ( Figure 1 Saponin adjuvants 56, 63, and 79 significantly increased the secretion of the cytokine IFNγ, three to four times that of GPI-0100, and were also moderate in inducing IL-2 ( Figure 1 ).
[0440] T cell activation
[0441] Antigen-specific T cell activation was analyzed by flow cytometry. One week after the third administration, spleen cells of mice were collected and 20 million cell events were acquired on a flow cytometer (Backman Coulter Gallions). + T cells, and then selected on live monocytes using forward and side scatter apertures. + / IFNγ + (or TNFα) double positive cells or CD8 + / IFNγ + (or TNFα) double positive cells were selected.
[0442] According to the results of flow cytometry analysis ( Figures 2 to 4 ), compared with GPI-0100, saponins modified with aliphatic chains resulted in PEK-specific CD4 + and CD8 + Compared with GPI-0100, terminal aromatic-substituted saponins 56, 62, and 79 induced PEK-specific IFN-γ secretion and CD8 + and TNF-α secretion by CD8 + T cell proliferation was 4 to 8 times higher. However, saponins had no significant effect on CD4 + The induction of T cells was not significant. These results show that the saponins of the present invention mainly mediate CD8 + T cell immunity.
[0443] Memory T cell stimulation
[0444] It is known that naive and activated T cells express different adhesion molecules, and they are thought to exhibit different migration patterns due to the expression of distinct adhesion molecules. Two adhesion molecules associated with the differentiation of naive and activated / memory T cells are CD62L (L-selectin) and CD44 (H-CAM). It has been demonstrated that naive T cells express a high CD62L and low CD44 phenotype, while memory T cells express a low CD62L and high CD44 phenotype. + or CD4 + The frequency of splenocytes expressing IFN-γ, TNF-α, or IL-2 was analyzed by flow cytometry for T cells (individual mice). Cytokine positivity was determined. Flow cytometric analysis confirmed that saponins 56, 62, and 79 showed higher CD8 + The frequency of T cells, which are positive for IFN-γ or TNF-α ( Figure 5 and Figure 6 ). Obviously, no cytokine-positive CD4 + These results suggest that 56, 62, and 79 can provide long-lasting cellular immune protection against the E7 antigen.
[0445] Antibody production assay
[0446] After each administration, serum PEK (coated with E7)-specific IgG antibody titers were measured using ELISA. Figure 7 As shown, PEK / GPI-0100 induced the highest level of antibody production in C57BL / 6 mice. Among them, compounds 53-56 were able to induce moderate levels of E7-specific antibody production. Since cellular immunity and humoral immunity inhibit each other, it is reasonable that the compounds induce higher cytotoxic T cell immunity and reduce antibody production.
[0447] Vaccination after immunoassay of the compounds of the present invention showed that compounds 46-62, 64, 66, 77-79, 83, 92, 95 are effective saponin-based adjuvants that can enhance host cellular immunity. Adjuvants with these properties can be used in conjunction with therapeutic vaccines for cancer, bacteria (tuberculosis), viruses (HIV, herpes), protozoa (malaria), etc.
[0448] toxicity
[0449] Acute toxicity was tested with increasing doses of 100 μg to 1000 μg of saponin 56. The results are presented as the number of mice that survived for 7 days in each group of 5 mice (female BALB / c mice, 9 weeks old). After the test, all mice survived and there were no obvious abnormalities in their activity and eating behavior. Figure 8 )
[0450] Table 1. Acute toxicity of saponin 56.
[0451]
[0452] result
[0453] The results are as follows Figure 8 As shown. The median percentage change in body weight of mice receiving increasing doses of saponin adjuvant 56 was less than 5%. There was no change in spleen somatic index and liver somatic index in all experimental groups compared with the control group. These data indicate that saponin 56 is an effective and safe candidate as a vaccine adjuvant.
[0454] Experimental Example II: OVA Peptide Vaccine Challenges Tumors
[0455] Materials and methods
[0456] Adjuvant stock solution
[0457] The sample powder was dissolved in DMSO to 20 mg / mL.
[0458] Animals and vaccinations
[0459] Female C57BL / 6 mice aged 6-8 weeks were obtained from the Taiwan Laboratory Animal Center, Taiwan Research Institutes, Taiwan Province, China. 200 μL of 1.5 × 10 6 E. G7-OVA (EL4 lymphoma expressing OVA) cells in PBS were injected subcutaneously into mice. Tumor volume was measured at regular intervals using a vernier caliper and calculated using the following formula: Tumor volume (mm 3 ) = (longer diameter) x (shorter diameter) 2 x0.52. When the average tumor volume reaches about 100mm 3 On day 7, 100 mL of PBS solution containing 100 μg OVA (with or without 50 μg compound 56), alum, QS-21 and GPI-0100 were subcutaneously injected around the tumor. PBS (200 μL) served as the control group.
[0460] result
[0461] The mouse vaccination model was combined with the antigen OVA to evaluate the antitumor efficacy. Five mice per group were immunized twice with 50 μg saponin and 100 μg OVA every three weeks. The antitumor efficacy of compound 56 and the positive control group (alum, QS-21 and GPI-0100) was analyzed using a vernier caliper.
[0462] Anti-tumor effect
[0463] Different formulations were intradermally inoculated into mice bearing E.G7-OVA tumors twice, on days 7 and 14. Compared with the control group (PBS), mice treated with OVA and OVA+alum initially showed a slight tumor growth inhibition, but the treatment effect was poor, and then the tumor resumed growth rapidly. In contrast, mice treated with OVA+compound 56, OVA+QS-21, and OVA+GPI-0100 showed a significant tumor growth inhibition. In addition, OVA+compound 56 achieved the highest survival rate ( Fig. 9 ).
[0464] Experimental Example III - Challenge of OVA Peptide Vaccine to Influenza
[0465] Materials and methods
[0466] Adjuvant stock solution
[0467] The sample powder was dissolved in DMSO to 20 mg / mL.
[0468] Animals and vaccinations
[0469] Female C57BL / 6 mice aged 6-8 weeks were immunized by subcutaneous injection of 100 μL of vaccine or intranasal administration of 30 μL of vaccine. All vaccine liquids were freshly prepared and diluted in 0.5% Tween 20 PBS. The vaccine for subcutaneous injection contained the immunogenic NP alone or in combination with compound 56 (50 μg) 366–374 / NP 311–325 Peptide. The vaccine for the intranasal route contained the immunogen alone or in combination with compound 56 (30 μg). After two vaccinations, mice were infected intranasally with 110 plaque forming units (PFU) of live PR8 virus.
[0470] result
[0471] The mouse vaccination model was used in combination with the antigen OVA to evaluate the anti-influenza efficacy. Five mice per group were given compound 56 and NP I / II Immunization twice. After two vaccinations, mice were intranasally infected with 110 plaque-forming units (PFU) of live PR8 virus. I and NP II (NP I / II ) peptide-immunized mice, using NP I / II Mice immunized with compound 56 had a higher survival rate after PR8 infection ( Fig.10 ).
[0472] Experimental Example IV - Immunological Evaluation of Combining SARS-CoV-2 Antigen with Compound 56 Immunoadjuvant
[0473] Materials and methods
[0474] Adjuvant stock solution
[0475] The sample powder was dissolved in DMSO to 20 mg / mL. Before administration, the stock solution was diluted to 0.5 mg / mL with 0.5% (w / w) Tween 20 and filtered through PTFE (0.1 μm).
[0476] Animals and vaccinations
[0477] Female C57BL / 6 mice aged 6 to 8 weeks were inoculated with SARS-CoV-2 spike protein without alum or compound 56 via subcutaneous route and injected three times at six-week intervals. To determine IgG levels, blood was collected from mice via the tail artery 10 days after each immunization.
[0478] ELISA
[0479] Maxisorp microtiter plates (Nunc International, Roskilde, Denmark) coated with SARS-CoV-2 spike RBD His protein (0.5 μg / well) were subjected to ELISA in borate buffer (BBS; 100 mM NaCl, 50 mM boric acid, 1.2 mM Na2B4O7, pH 8.2) at 4°C overnight to determine the level of specific serum IgG against SARS-CoV-2 spike protein in each group. The microtiter plates were blocked with blocking buffer (PBS containing 5% milk) at 37°C for at least 1 hour and then washed with PBS + 0.05% Tween 20. Serum samples were added to the microtiter plates in 5-fold serial dilutions. After 1 hour, the microtiter plates were washed with PBS + 0.05% Tween 20. Peroxide-labeled goat anti-mouse IgG (Invitrogen, catalog number 81-6520) diluted 1:3000 was added in 1% BSA-PBS for 1 hour. The microtiter plate was washed with PBS + 0.05% Tween 20 and developed with TMB chromogen solution (Invitrogen, catalog number 00-2023) for 15 minutes, followed by treatment with stop solution (0.2N H2SO4). The absorbance at 450nm was recorded.
[0480] result
[0481] A mouse vaccination model was used in combination with the antigen SARS-CoV-2 spike RBD His protein to evaluate the efficacy against COVID-19. The mice were divided into three groups: compound 56 (50 μg), SARS-CoV-2 (2 μg) + compound 56 (50 μg), SARS-CoV-2 (10 μg) + alum (10 μg).
[0482] Antibody production assay
[0483] After each administration, serum SARS-CoV-2 specific IgG antibody titers were measured using ELISA. Fig.11 As shown, the SARS-CoV-2+Compound 56 group induced the highest level of antibody production in C57BL / 6 mice. Among them, the SARS-CoV-2 / Compound 56 group increased the antibody titer by 1000 times with only 20% of the antigen.
Claims
1. A saponin conjugate of formula (I) or a pharmaceutically acceptable salt thereof, in: is a double bond; ●W is Me or -CHO; ●V is OH; ●Y is —O—; ●Q is C=O; ●X is —NH—; R is: ●R 1 are independently hydrogen or a carbohydrate having a monosaccharide structure; and ● Z is a linear tetrasaccharide or a linear trisaccharide, wherein the first sugar residue is directly attached to Y.
2. The saponin conjugate or a pharmaceutically acceptable salt thereof according to claim 1, wherein the saponin conjugate has the following structure:
3. A vaccine composition comprising an antigen and the saponin conjugate according to claim 1 or a pharmaceutically acceptable salt thereof. The vaccine composition according to claim 3 , further comprising an additional adjuvant. The vaccine composition according to claim 3 , further comprising a pharmaceutically acceptable carrier.
6. A pharmaceutical composition comprising one or more saponin conjugates according to claim 1 or pharmaceutically acceptable salts thereof.
7. The pharmaceutical composition according to claim 6, further comprising a pharmaceutically acceptable excipient.
8. A saponin conjugate intermediate of formula (II) or a pharmaceutically acceptable salt thereof: in: ● is a double bond; ●W is Me or -CHO; ●V is —OH; ●Y is an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates and carbonates; ●Q is C=O; ●X is —NH—; ●R 1 are independently hydrogen or an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates and carbonates, or a carbohydrate having the structure in: ■a, b and c are independently 0 or 1 each time they appear; ■ R0 is independently hydrogen or an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates and carbonates; ■R a , R b , R c and R d Each occurrence is independently hydrogen, halogen, OH, OR, OR x ; R x Each occurrence is independently hydrogen or an oxygen protecting group selected from the group consisting of alkyl ethers, benzyl ethers, silyl ethers, acetals, ketals, esters, carbamates, and carbonates; and R is:
